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Abstract 
 
Tuberculosis has been a deadly human pathogen for thousands of years and is as prevalent 
and lethal now as it was in the pre-antimicrobials era. With new challenges continually being 
presented in the form of multidrug resistant strains evolving and the implications of the HIV 
epidemic, it is imperative that every effort is made to understand the causative agent, 
Mycobacterium tuberculosis, and develop new effective and affordable drugs to treat the 
disease. 
 
With this in mind, the first part of this project tests novel drugs that have been identified 
using different approaches. The desired targets for all the compounds were the fatty acid and 
mycolic acid biosynthesis systems in M. tuberculosis, Mycobacterium bovis BCG and 
Mycobacterium smegmatis. Some promising compounds were identified, which inhibited 
enzymes of the prokaryotic FAS-II system, whilst not affecting the mammalian FAS-I 
system. 
 
As well as identifying new drugs, it is equally important to recognise the essential genes of 
M. tuberculosis, which could be novel drug targets. Whilst the fatty acid biosynthesis 
pathway has been well studied, a lot less is known about fatty acid degradation. M. 
tuberculosis has an abundance of fad genes, yet it is only recently that they have started to be 
explored. Here, the functions and roles of the fadB genes in M. tuberculosis, M. bovis BCG 
and M. smegmatis have been explored. By producing purified recombinant protein and 
generating gene deletion mutants, it has been possible to fully characterise Mt-FadB2 and 
provide preliminary information regarding fadB3, fadB4 and fadB5. 
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1.1. Mycobacterium tuberculosis and Mycobacteriaceae 
Tuberculosis (TB) is one of the world’s most lethal diseases caused by a single infectious 
agent (Kremer et al. 2002a). The vast majority of cases are due to infection by the species 
Mycobacterium tuberculosis, a highly aerobic, non-motile, rod-shaped bacterium of 
approximately 2 µm in length, with no known host other than man (Glickman & Jacobs 
2001). The disease is highly contagious due to the air-borne nature of bacterial transmission 
and as such is estimated to affect one third of the world’s population. The World Health 
Organisation (WHO) has stated that someone in the world is newly infected with M. 
tuberculosis every second (WHO 2010). 
 
M. tuberculosis belongs to the family Mycobacteriaceae. The prefix “myco” in Latin can 
mean “fungus” or “waxy” and here it refers to the waxy nature of the cell wall. 
 
Kingdom: Bacteria 
Phylum: Actinobacteria 
Order: Actinomycetales 
Suborder: Corynebacterineae 
Family: Mycobacteriaceae 
Genus: Mycobacterium 
Species: M. tuberculosis 
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FIGURE 1-1. Images of Mycobacterium tuberculosis. Left: Scanning electron micrograph 
of M. tuberculosis cells (Tuberculosis Research Section). Right: Colonies of M. tuberculosis 
on Lowenstein-Jensen medium (Kubica 1976). 
 
All mycobacteria share similar cell wall characteristics, which classes them separately as 
acid-fast Gram-positive bacilli. Acid-fast, or acid-resistant, refers to the inability of certain 
biological structures to decolourise upon acid treatment once stain, such as Ziehl-Neelsen 
carbol fuschin, has been taken up (Pommerville 2007). Nocardia, endospores, the head of 
sperm and all mycobacteria are acid-fast due to the high lipid content and waxy nature of 
their cell walls (Gaud & Gupta 2008). The species that cause disease are described as the M. 
tuberculosis complex, and include M. tuberculosis, Mycobacterium bovis, Mycobacterium 
microti, Mycobacterium africanum, Mycobacterium pinnipedii and Mycobacterium caprae. 
Between these species there is only 0.01–0.03 % nucleotide variation, a remarkably low 
percentage compared with most bacterial species, which show much less genetic 
homogeneity of 1 % or more (Gutierrez et al. 2006). 
 
1.1.1. Using surrogates to study M. tuberculosis. 
The rate at which species within the Mycobacteriaceae family grow differs greatly; some are 
fast-growing while others are slow-growing and fastidious to culture. M. tuberculosis and 
! !
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Mycobacterium leprae fall into the latter category: M. tuberculosis has a doubling time of 
15–20 hours. To-date it has not been possible to culture M. leprae, the bacillus that causes 
leprosy, in vitro at all. Similarly, another species, Mycobacterium genavense, has only been 
identified by molecular means (Colston & Cox 1999). Due to the slow growth rate of M. 
tuberculosis and its highly infectious nature (M. tuberculosis is a Category 3 human 
pathogen), other species of the family are often used to study shared elements. 
 
The most closely related surrogate used is M. bovis strain Bacille Calmette-Guérin (BCG). 
Although also slow growing, it is an attenuated form of M. bovis, classed as Category 2, and 
is thus non-infective. M. bovis causes active tuberculosis in cattle (bovine TB) but is also 
well known to cause tuberculosis in humans (De la Rua-Domenech 2006). Zoonotic 
transmission is usually through ingestion or inhalation and is indistinguishable from disease 
caused by M. tuberculosis. Wild-type M. bovis BCG colonies can be seen following 3 weeks 
of incubation at 37 °C, and in liquid medium a film of cells appears after 5–7 days. 
 
Another species used to replace M. tuberculosis is Mycobacterium smegmatis, a soil-dwelling 
saprophyte (Shiloh & DiGiuseppe Champion 2009). Approximately 30 % of M. tuberculosis 
genes lack conserved orthologues in M. smegmatis, compared to only 3 % in M. bovis, but, 
although a much more distant relative, M. smegmatis has been a major tool in the 
development of plasmid transformation in mycobacteria (Altaf et al. 2010, Shiloh & 
DiGiuseppe Champion 2009, Snapper et al. 1990). The doubling time is roughly 3 hours, 
visible colonies can be seen after 3–4 days of incubation and it is considered generally non-
pathogenic. 
 
One final model species is Mycobacterium marinum, which was first isolated from fish in 
1926 (Aronson 1926). It is an opportunistic human pathogen that has been seen to infect via 
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swimming pools and fish tanks (Beran et al. 2006, Linell & Norden 1954). Infection mainly 
affects the cooler extremities (hands, arms and feet) because incubation at 37 °C inhibits M. 
marinum cell growth. M. marinum can be cultured at 30 °C and has a doubling time of 6–10 
hours. The genome is larger than that of M. tuberculosis by 2.2 Mb, reflecting the greater 
number of environmental niches M. marinum can occupy (Tobin & Ramakrishnan 2008). For 
example, M. marinum has a gene encoding !-carotene, crtB, which protects the bacilli from 
photo-oxidative damage when living outside a host. This gene has been lost in M. 
tuberculosis (Ramakrishnan et al. 1997). Despite this and the fact that orthologous regions of 
the two genomes share only 85 % identity, the granulomas resulting from infection of either 
species are often indistinguishable, making this a good surrogate for studying infection 
(Tobin & Ramakrishnan 2008). 
 
 
 
 
 
 
 
FIGURE 1-2. Surrogate mycobacterial species used in the laboratory. Left: M. smegmatis 
colonies on trypticase soy agar (Bryan MacDonald, Christopher Adams, and Kyle Smith, 
Brigham Young University, Provo, UT). Right: M. marinum colonies on 7H11 agar with 
oleic acid-albumin-dextrose-catalase enrichment (Richard A. Robison, Gable Moffitt, Neal 
Thomson, and Marissa Cohen, Brigham Young University, Provo, UT). 
 
1.2. Evolutionary history of tuberculosis and its discovery 
The most ancient evidence of tuberculosis has come from fossil remains of an estimated 
500,000-year-old Homo erectus skeleton in Turkey (Kappelman et al. 2008). The skull 
!
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revealed small lesions that are distinctive to the Leptomeningitis tuberculosa form of TB. 
During the migration out of Africa, early dark-skinned hominins were experiencing new 
conditions, including reduced UV exposure. The group who made the discovery hypothesised 
that these human ancestors would have been immunocompromised from vitamin D 
deficiency and thus more likely to succumb to disease. 
 
It has been widely suggested that tuberculosis was transmitted to humans from cattle infected 
with M. bovis during the time of animal domestication roughly 15,000 years ago. Indeed, 
there is much evidence of TB infection in mummies from Egypt, China and South America. 
One such study of ancient Egyptian mummies, however, suggests that modern M. 
tuberculosis may have originated from a M. africanum-like species (Zink et al. 2003). The 
ancient DNA was extracted and analysed by spoligotyping, a method that compares 
polymorphisms in the direct repeat locus of mycobacterial chromosomes. None of the 
spoligotypes found reflected those of M. bovis; mummies dating from 2050–1650 BC 
showed a M. africanum-like pattern and later mummies (circa 500 BC) showed typical M. 
tuberculosis patterns. 
 
Due to the lack of genetic variation between M. tuberculosis species, it has previously been 
estimated that the modern-day M. tuberculosis originated around 35,000 years ago after 
clonal expansion following an evolutionary bottleneck (Hughes et al. 2002). A more recent 
report from 2005, however, has pushed the date of the progenitor species from which M. 
tuberculosis evolved back much further by studying the DNA of current tubercle bacilli from 
East Africa (Gutierrez et al. 2006). Knowing how closely related the M. tuberculosis 
complex species are and using phylogenetic analysis, the group estimated that the common 
ancestor is 3 million years old. It is therefore likely to have infected early Homo species and 
undergone genetic diversification as early hominins moved out of Africa. 
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Although TB had been mentioned in literature of Hippocrates and Aristotle dating from as 
early as 400 BC, the first accurate description of the disease came from the Roman doctor, 
Caelius Aurelianus in the 5th century AD, making detailed observations of his patients. It was 
not until the early 18th century when the English physician Benjamin Marten (c.1690–1756) 
correlated the consumptive ‘phthisis’ as it was then called with small ‘animalcules’ that lived 
in the lungs and caused lesions. Writing in his book “A New Theory of Consumptions” of 
1720, he also recognised the highly contagious nature of the disease, opposing the theory that 
it was hereditary (Doetsch 1978). He stated that eating, drinking or conversing with an 
infected person so that expired air of the diseased may enter the lungs of the healthy person 
may produce disease. 
 
In 1834, the term ‘tuberculosis’ was coined by Johann Lukas Schönlein (1793–1864) as a 
disease associated with tubercles. He did not, however, see it as the same disease as phthisis 
or scrofula: TB was thought of as tumerous, like cancer. The contagiousness of TB was first 
demonstrated experimentally by Philipp Klencke (1813–1881) in 1843, whereby a rabbit 
injected with material from a tubercle contracted the same disease and subsequently died. 
Marten’s animalcule remained anonymous until 1882, when Robert Koch (1843–1910) 
identified a single bacterium within tubercles. He also extracted tuberculin from dead M. 
tuberculosis cells and went on to develop the tuberculin skin test for identifying people with 
the disease, work for which he was awarded the Nobel Prize in 1905 (Herzog 1998). 
 
1.3. TB epidemiology 
In 2009, the World Health Organisation published a report based on worldwide data collected 
in 2007 (WHO 2009). This information revealed the extent of the TB epidemic, estimating 
9.27 million new cases (139 per 100,000 population) and 1.6 million deaths during that one 
year alone. India and China have the highest incidence of new TB cases, with Asia as a 
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whole contributing 55 % to the global occurrence. Of total TB occurrences, old and new per 
country, of the top fifteen highest countries, thirteen are in Africa, of which most are sub-
Saharan (Figure 1-3). With the vast majority of cases occurring in the developing world, 
problems arise with regard to affording such large quantities of antibiotics and logistically 
dispensing the drugs. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-3. Tuberculosis epidemiology in 2009. World map of prevalence of all forms of 
TB per 100,000 inhabitants (WHO 2009). 
 
During the 18th and 19th centuries, respiratory tuberculosis by far caused the most deaths 
compared with other contagious diseases such as typhus, scarlet fever and cholera (Table 1-1, 
Figure 1-4). The natural decline in mortality from TB has been attributed to improving 
nutrition throughout the 19th century and natural selection but, according to Davies et al. 
(1999), cannot be explained by the bettering of social conditions (Health Protection Agency 
2009, McKeown & Lowe 1977). 
!"#"$%"
$&"#"%'"
&!"#"''" ()"*+,-./*"
0!!"#"$''"
1"2!!"
!"#$%&'()*'+),-).%"'")/%00)
123$"4)5'3)6778777)52590%#2*)
Chapter 1 General Introduction 
 
 9 
TABLE 1-1. Cases of tuberculosis in the nineteenth century. Statistics for England and 
Wales comparing the deaths recorded due to infectious diseases during two decades in the 
19th century (McKeown & Lowe 1977). 
 
Cause 1851 – 1860 1891 – 1900 
Respiratory 2,772 1,418 
Other forms 706 603 Tuberculosis 
Total 3,478 2,021 
Diarrhoea, dysentery, cholera 990 715 
Typhus, enteric fever, other fever 891 184 
Scarlet fever 779 152 
Whooping cough 433 363 
Measles 357 398 
Smallpox 202 13 
Diphtheria 99 254 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-4. Cases of tuberculosis in England and Wales, 1840 – today. Graph showing 
the decline in mortality due to M. tuberculosis infection in England and Wales from 1840 to 
today (Health Protection Agency 2009, McKewon & Lowe 1977, WHO 2009). 
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Having been largely overlooked for a period of twenty years, the global threat caused by TB 
was brought to the fore once again in the late 1980s. A clear correlation is seen between 
regions of high TB and HIV-1 prevalence. The 2009 WHO report estimated that 14.8 % of 
total TB cases were coincident with HIV-1 infection and nearly 80 % of these occurred in 
Africa. This has added to the current epidemic since the probability of TB infection is greatly 
increased in immunocompromised people. Research has shown that there is a distinct 
synergy between TB and HIV-1: Specifically, M. tuberculosis infection modifies chemokine 
and cytokine concentrations, as well as their receptors, in such a way that not only permits 
but also boosts viral replication (Hanna et al. 2005, Toossi 2003). 
 
1.4. Mechanisms of disease and immunological response 
1.4.1. Overview of TB disease. 
Tuberculosis is a disease primarily of the lungs; in patients that suffer from active TB, 75 % 
of cases are pulmonary. However, the disease can affect many organs and systems in the 
body, in which case it is referred to as extrapulmonary TB. Most commonly this occurs in the 
lymphatic system, pleura, bones and joints (most often the spine), the nervous system, liver 
and spleen. Miliary TB is disease that is widely disseminated throughout the body. 
Symptoms of tuberculosis can include a prolonged cough (for more than 2 weeks), purulus 
sputum that can contain blood, chest pain, fever, fatigue, weight loss and sweats (Miller et al. 
2000). In addition to this, symptoms can occur that are not related to the site of infection, for 
instance haematological abnormalities such as anaemia, as well as electrolyte imbalance and 
psychological effects (Chung & Hubbard 1969, Ebrahim et al. 2009, Sukhova 2004). 
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1.4.2. Diagnosing TB. 
Correct and rapid diagnosis is essential in the battle against TB. Accurate early diagnosis can 
halt the spread of disease and treatment can be started, especially in cases with HIV-1/TB 
co-infection. However, the method of diagnosis also needs to be cost-effective, particularly 
since the vast majority of cases are found in developing countries. More recently, studies 
have emerged comparing the various methods with respect to cost. TB is normally detected 
through a tuberculin skin test, chest X-ray and/or microscopy, culturing and biopsy of the 
affected tissue. The WHO has firmly advocated sputum smear tests as the preferred method 
of diagnosis. Based on the Ziehl-Neelsen staining technique and direct microscopy, it is 
cheap and very quick but is less sensitive than culturing, where active disease can be detected 
from as few as 10 cells (API Consensus Expert Committee 2006). The main problem with 
culturing, however, is the extensive time required, normally 3–6 weeks, although this method 
can be used to detect extra-pulmonary disease as well and more data can be obtained such as 
drug resistance. 
 
More recently, PCR has been employed to diagnose TB, where the IS6110 insertion element 
is used to amplify DNA of any M. tuberculosis complex species (API Consensus Expert 
Committee 2006). A recent study comparing Ziehl-Neelsen staining with PCR found that the 
latter technique is approximately 60 % more sensitive and has a quicker turn-around but is 
more expensive and 25 % less specific (Ani et al. 2009). 
 
One final in vitro diagnostic method currently used, which is capable of indentifying both 
active and latent disease, is a blood test. One such test is QuantiFERON®-TB Gold, 
approved by the FDA in 2005 (Mazurek et al. 2005). Based on the enzyme-linked 
immunosorbent assay (ELISA), QuantiFERON®-TB Gold detects the release of interferon-g 
from immune cells within whole blood when they come into contact with mycobacteria-
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specific antigens. The blood is incubated with synthetic antigens that imitate early secretory 
antigenic target-6 (ESAT-6) and culture filtrate protein-10 (CFP-10), proteins that are 
expressed in M. tuberculosis and M. bovis but not in M. bovis BCG, the attenuated strain 
used in vaccines. This technique is therefore more specific than the tuberculin skin test, 
which can present false positive results in people that have been vaccinated with BCG. One 
recent report compared the effectiveness of the tuberculin test with that of ELISpot-Plus, a 
test similar to QuantiFERON®-TB Gold, but which uses a novel antigen, Rv3879c, 
alongside ESAT-6 and CFP-10 (Dosanjh et al. 2008). Results showed that ELISpot-Plus was 
89 % sensitive compared to 79 % for the tuberculin test. Combined sensitivity of the two 
diagnostic procedures was 99 %, showing that using both techniques would greatly reduce 
the likelihood of false positives. 
 
1.4.3. M. tuberculosis infection. 
Infection is initially and primarily of the lungs, more specifically, the alveolar macrophages. 
As such, the bacteria are almost exclusively transmitted by the inhalation of aerosol droplets 
expelled in the cough or sneeze of an infected patient. It is estimated that each person with 
untreated active TB will infect 10 to 15 people each year (WHO 2010). The smallest droplet 
nuclei are the most infectious, measuring approximately 5 mm and containing a maximum of 
three bacilli, since these are able to travel through the narrow passages to the alveoli (Rastogi 
2003). Alveolar macrophages act as the main defence against respiratory pathogens (Rubins 
2003). An essential part of the innate immune system, these cells clear the respiratory tract of 
infectious, toxic and allergic particles by ingestion. It is thought that the bacteria in the 
droplet also make contact initially with alveolar epithelial type II pneumocytes. These cells 
are found in larger numbers than macrophages in the alveoli and it has been shown that M. 
tuberculosis is capable of infecting and subsisting in them ex vivo (Birkness et al. 1999). 
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The tubercle bacilli that reach the alveoli make contact with the macrophages and are 
ingested via various cell surface receptors (Ernst 1998). The process is initiated by bacterial 
contact with macrophage mannose and/or complement receptors. Surfactant protein-A, a 
glycoprotein on alveolar macrophage surfaces, enhances the binding and uptake of bacteria 
by up-regulating mannose receptor expression (Beharka et al. 2002). It has been reported that 
cholesterol is also vital for the uptake of M. tuberculosis, particularly at sites of steroid-rich 
lipid rafts, and depletion of cholesterol actually reduces bacilli internalisation (Gatfield & 
Pieters 2000, Muñoz et al. 2009). Macrophages take up the bacteria non-specifically and at 
this stage do not become activated. 
 
M. tuberculosis and other intracellular pathogens initially reside in the phagosome, an 
endocytic vacuole that provides the bacteria with a semi-protected environment where they 
are capable of logarithmic growth until bursting. When faced with highly virulent microbes, 
such as M. tuberculosis, the macrophages also secrete a plethora of cytokines, chemokines 
and arachidonic acid metabolites to recruit further macrophages and neutrophils to the site of 
infection. This leads to the development of an early tubercle. Once T-cells are 
chemotactically attracted to the site and presented with and activated by M. tuberculosis 
antigen, interferon-g is released, activating the macrophages. Once activated, the macrophage 
is able to subject the phagocytosed microbes to a variety of killing mechanisms, including a 
decrease in pH from phagosome-lysosome fusion, as well as reactive oxygen and nitrogen 
intermediates. It has been shown, however, that M. tuberculosis is able to prevent pH 
reduction and the phagocytic vacuole remains at a pH of approximately 6.5 (Sturgill-
Koszycki et al. 1994). The precise mechanism of this has yet to be elucidated, however 
several suggestions have been proposed, and it is likely that the process is multi-factorial 
(Pethe et al. 2004). One mechanism is the poor recruitment of vesicular proton-ATPase, a 
known agent for phagosomal acidification, by pumping H+ ions into the vacuolar space 
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(Sturgill-Koszycki et al. 1994, Xu et al. 1994). Another is the production of ammonia and 
other weak bases by the infecting M. tuberculosis through the degradation of urea by urease 
(Sinai & Joiner 1997). Non-acidification arrests the phagosome maturation cycle thereby 
preventing phagolysosome formation. A third, more recently identified phagosome 
modulator, is isotuberculosinol (also called edaxadiene), which the product of a five-gene 
operon including Rv3377c and Rv3378c. Although the mechanism of action is currently 
unknown, Mann et al. (2009) provided evidence that this molecule is both enzymatically 
biosynthesised and is able to prevent the intraphagaosomal pH from dropping below 5.5, 
compared to pH 5.0 in a control with no isoprene. A further study by the same group showed 
that it is the reduction in Mg2+ experienced by bacilli upon engulfment into macrophage 
phagosomes that induces the expression of this operon, rather than just macrophage entry 
(Mann et al. 2011). Another report has shown, however, that membrane-associated 
diterpenes are found in membranes of M. tuberculosis cells cultured outside macrophages. 
Having isoprenoid molecules already present in the cell membrane would be a great 
advantage for M. tuberculosis, considering that phagolysosome fusion occurs rapidly once a 
bacillus has been ingested, leaving little time to synthesise new proteins and lipids (Prach et 
al. 2010). 
 
Later events in infection include the development of granulomatous focal lesions. These are 
composed of macrophage-derived giant cells and lymphocytes, which form when 
macrophages at the centre of tubercles die and release the contained bacteria. This efficiently 
aids the spread of bacteria, since they are then taken up by other macrophages and monocytes 
arriving from the blood stream (Skeiky & Sadoff 2006). As cellular immunity develops, the 
macrophages loaded with bacilli are killed. This results in the formation of a caseous necrosis 
at the centre of the granuloma, surrounded by a zone of fibroblasts, lymphocytes and 
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monocytes. Although unable to multiply in these harsh conditions, the tubercle bacilli can 
persist in a dormant, or latent state for extended periods (Colston & Cox 1999). 
 
One feature of the granuloma environment is anoxia. In order for M. tuberculosis to survive 
without oxygen it uses the ‘glyoxylate shunt’, a mechanism of generating glucose 
independently of the O2-consuming steps of the TCA cycle (Bishai 2000). Here, acetyl-CoA 
from lipid catabolism is used as the substrate for malate, which is subsequently fed into the 
citrate cycle to generate glucose, its carbon source (Figure 1-5). 
 
In patients with an efficient cell-mediated immunity, infection may be permanently halted at 
the granuloma stage. At this point the granulomas subsequently heal, or resolve. This process 
forms fibrous calcified lesions by an accumulation of fibrin and collagen, which seals the 
granuloma thus confining infection (Porth & Matfin 2010). The patient displays a positive 
tuberculin skin test but shows no symptoms of active TB. Conversely, if the patient is unable 
to control the initial infection or the immune system becomes weakened, for example by 
HIV-1, ageing or malnutrition, the centre of the granuloma becomes liquefied. The liquid 
environment, possibly caused by an excess of lytic enzymes (Lawn & Griffin 2008), provides 
a rich medium for reactivating the bacilli enabling them to replicate uncontrollably. The 
bacteria can also now multiply extracellularly for the first time allowing them to spread to 
other tissues via the lymphatic and blood systems. There is also the risk of the granuloma 
bursting into neighbouring bronchi allowing the cells to disseminate through the airways to 
not only other parts of the lungs but also outside the patient (Rastogi 2003). The disease is 
then referred to as extrapulmonary or miliary TB. 
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FIGURE 1-5. The glyoxylate shunt. In anoxic conditions, M. tuberculosis generates glucose 
without the O2-dependent steps of the TCA cycle. The carbon atoms normally lost as CO2 
are retained, thus with the use of two acetyl-CoA molecules, a C4 product, malate, can be 
made. Adapted from Lorenz & Fink (2001). 
 
Reactivation is dependent not only on the environment but also on the secreted resuscitation 
promotion factor (rpf) proteins. The rpf genes encode c-type lysozyme-like enzymes, which 
possibly remodel the peptidoglycan cell wall throughout growth (Cohen-Gonsaud et al. 
2005). M. tuberculosis has five rpf genes (A–E), which all produce proteins of the same 
function demonstrating their importance. Indeed, without them the bacteria remain in the 
latent state (Kana et al. 2008). 
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1.5. The mycobacterial cell wall 
1.5.1. General structure and functions. 
M. tuberculosis is a rod-shaped bacterium with a cell envelope that sets it apart from the 
well-established Gram-positive and Gram-negative classifications. All species of the 
mycobacteria genus are acid-fast; they are resistant to staining by acids in conventional 
Gram-staining techniques (Wheeler & Ratledge 1994). The cell wall of mycobacteria is 
unique among prokaryotes and, as well as causing acid fastness, acts as a major virulence 
factor (Bhatt et al. 2007a) (Figure 1-6). It is thought that the characteristic pathogenesis of M. 
tuberculosis is closely related to the complex lipids and polysaccharides within the cell wall 
(Minnikin et al. 2002). Generally, the cell envelope consists of three main components: (i) 
the plasma membrane, (ii) a covalently linked structure of a thin peptidoglycan layer 
connected to arabinogalactan, which is in turn linked to mycolic acids, and (iii) an outer 
protein-, lipid- and carbohydrate-rich layer (Crick et al. 2001). The cell wall also acts as a 
protective shell around the bacterium, providing endogenous resistance to both the host’s 
immune system and anti-TB drugs (Takayama et al. 2005). 
 
1.5.2. Peptidoglycan-arabinogalactan. 
The principal structural constituent of the cell wall in mycobacteria is the insoluble cross-
linking peptidoglycan (PG) (Alderwick et al. 2007). The glycan component consists of 
alternating !(1!4)-linked N-acetylglucosamine (GlcNAc) and N-glycolyl muramic acid 
(MurNGlyc) residue strands. Oligopeptide chains of between three and five amino acids, 
usually D-alanine, D-glutamate, meso-diaminopimelic acid (DAP) and occasionally glycine, 
are connected to the muramic acid components (Figure 1-7). These molecules can cross-link 
the glycan by DAP-ala and DAP-DAP covalent interactions (Crick et al. 2001). 
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FIGURE 1-6. The M. tuberculosis cell wall. Peptidoglycan forms the main constituent of 
the cell wall. Arabinogalactan with attached mycolic acids (mAG) is connected directly to 
the peptidoglycan by a galactan linker. The outer-most complex free lipids, comprising 
sulfatides, diacyltrehalose, phthiocerol dimycocerosates and polyacyltrehalose, are thought 
to intercalate with the mycolates attached to the mAG. Lipoarabinomannan and 
phosphatidyl-myo-inositol hexamannoside are anchored to the plasma membrane by their 
fatty acyl chains (adapted from Abdallah et al. 2007, Esko et al. 2009, Hoffmann et al. 
2008). 
 
The PG layer is not anchored to the cell membrane but is covalently linked by a linker unit 
consisting of a rhamnose and N-acetylglucosamine molecule, [L-Rhap-(1!4)-D-GlcNAc-
PO4-], through the muramic acid residues of PG in a phosphodiester bond (Amar & Vilkas 
1973, McNeil et al. 1990). Linear galactan, made of approximately 30 D-galactofuranose 
(Galf) residues alternately linked !(1!5), !(1!6) by the enzyme GlfT, further extends the 
linker unit (Bhamidi et al. 2008, Kremer et al. 2001a, Mikusova et al. 2000). The arabinan 
domain consists of 31 arabinofuranose (Araf) residues, made up of distinct structured motifs 
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consisting of "(1!5), "(1!3) and !(1!2) linkages. Three arabinan chains are connected to 
each galactan chain (Bhamidi et al. 2008). The more recent development and use of MALDI-
TOF mass spectrometry and NMR have allowed a detailed model of the cell wall mAG to be 
described, showing that the Araf chains are attached to the O5 of Galf residues 8, 10 and 12 
(from the reducing end) and that the mycolic acid chains are esterified to the 5 position of 
both the terminal !-D-Araf and penultimate "-D-Araf residues (Bhamidi et al. 2008). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7. The structure of peptidoglycan before peptide trimming. R1 and R2, N-
glycolylmuramic acid residue of another monomer; R3, H or the linker unit of AG; R4, OH, 
NH2 or glycine; R5, OH or NH2; R6, H or cross-linked to penultimate D-Ala or to the D-
centre of another meso-DAP residue; R7, OH or NH2. Adapted from Mahapatra et al. 
(2005). 
 
1.5.3. Lipids. 
Mycobacteria are unusual in that over 60 % of the cell wall may consist of lipids. These 
lipids are large, complex and highly distinctive and are arranged so that some are covalently 
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linked to the PG-AG domain, and some are ‘free’ (Figure 1-6). Families of lipids include 
mycolic acids, trehalose-based glycolipids and phthiocerol dimycocerosate waxes. 
 
Mycobacteria are also unusual in that they employ two fatty acid synthase (FAS) systems – 
named I and II – to generate lipids (Figure 1-8). The FAS-I enzyme is found in both 
eukaryotes and prokaryotes, whereas FAS-II is only seen in prokaryotes, Archaea and plants 
(Bhatt et al. 2007a). Atypically, the protozoan parasite Plasmodium falciparum, which causes 
malaria in humans, uses the FAS-II system to generate its fatty acids, a finding which has 
since awarded it with much attention with regard to creating specific anti-malarial drugs 
(Surolia & Surolia 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-8. An overview of fatty acid and mycolic acid biosynthesis in M. tuberculosis. 
Assembled from Bhatt et al. (2007a) and Takayama et al. (2005). 
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1.5.3.1. FAS-I. 
In mycobacteria, FAS-I catalyses de novo fatty acid synthesis using acetyl-CoA primers and 
passes the C20-S-CoA product to the FAS-II cycle for continuous elongation. In both M. 
smegmatis and M. tuberculosis, FAS-I is a single multi-enzyme complex that shuttles the 
growing fatty acid around its subunits. 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-9. The initial four FAS-I reactions. (1) The acetyl-CoA starter unit is 
transacylated to the AcpM-like domain of the FAS-I multi-functional enzyme. (2) Similarly, 
the malonyl-CoA substrate also covalently binds to the same FAS-I enzyme. (3) A 
condensation reaction occurs between the two substrates to yield the !-ketobutyryl-S-FAS-I 
product. (4) Three further reactions in the cycle, !-keto reduction, dehydration and enoyl 
reduction, produce the saturated butyryl-S-FAS-I molecule. Recycling of this C4-acyl chain 
9 and 12 times leads to C20- and C26-chains respectively, which are believed to be the main 
precursors of mycolic acids (Takayama et al. 2005). 
 
Once the acetyl-CoA and malonyl-CoA have been transacylated to the enzyme, the 
elongation process commences by a condensation reaction between these two starter units to 
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yield !-ketobutyryl that is still covalently linked to the FAS-I enzyme via a -S- bond (Figure 
1-9). This intermediate undergoes reduction, dehydration and reduction to remove the 
unsaturated bonds and give the butyryl-S-enzyme product. This C4 chain undergoes more 
cycles of fatty acid synthesis to yield long-chain products. It is thought that the C16- and C18-
CoA fatty acids are channelled into membrane phospholipid synthesis, whereas the C20- and 
C26-CoA products are precursors of mycolic acids and thus fed into the FAS-II cycle 
(Takayama et al. 2005). 
 
1.5.3.2. Mycolic acids and their biosynthesis. 
It was during the 1930s that the strongly hydrophobic lipid components of the M. 
tuberculosis cell wall were first studied and the mycolic acids, which make up approximately 
half of the lipids, were identified (Minnikin et al. 2002). Mycolic acids are long-chain (C30–
C90) "-alkyl, !-hydroxy fatty acids that are found in all species of the Corynebacterineae 
suborder (Figure 1-10). 
 
 
 
 
 
FIGURE 1-10. "-Mycolic acid from M. tuberculosis. The meromycolate chain is longer 
and contains proximal and distal cyclopropane modifications. 
 
Within this group, the mycolic acids vary in both modifications and chain length, for 
example the “corynomycolic acids” of Corynebacterium glutamicum are 32 to 36 carbons 
long, whereas the “eumycolic acids” of M. tuberculosis are 60 to 90 carbons long (Watanabe 
et al. 2001, 2002). The mycolates of M. tuberculosis account for many of its features, 
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including drug and chemical resistance, virulence and persistence (Bhatt et al. 2007a). There 
are five known types of mycolic acid in M. tuberculosis. All have the same general structure 
of an "-branch of C22-26 and a longer, very hydrophobic meromycolate chain of C54-63, but 
modifications to this give rise to "-, methoxy- and keto-mycolates (Figure 1-11). The "-
mycolic acid, which is a cis, cis-dicyclopropyl fatty acid, is the most abundant in the M. 
tuberculosis cell wall (~50 %; Wanatabe et al. 2002) and is widespread amongst 
mycobacterial species. Of the keto- and methoxy-mycolates, which are found in both the cis 
and trans configuration, the keto-mycolic acids are present in many mycobacteria whereas, 
to-date, methoxy-mycolates have only been isolated from a small number of species (Yuan & 
Barry 1996). 
 
Mycobacteria employ a second fatty acid synthase cycle, FAS-II, to generate mycolic acids. 
Unlike FAS-I, FAS-II is only able to extend already long-chain fatty acids made by FAS-I; it 
is incapable of de novo synthesis. Also unlike FAS-I, the system consists of four discrete 
enzymes and employs an acyl carrier protein (ACP, termed AcpM in M. tuberculosis) to 
shuttle the substrates between each enzyme active site (Kremer et al. 2001b) (Figure 1-8, 1-
12). 
 
!  1.5.3.2.1. AcpM. 
AcpM is a small protein of 115 amino acid residues (14 kDa) and exists in three forms, apo, 
holo and palmitoylated, each of which can be over-expressed when in certain culturing 
conditions (Kremer et al. 2001b). Kremer and co-workers (2001b) showed by electrospray 
mass spectrometry that the apo-AcpM form refers to the inactive native enzyme, whereas 
holo-AcpM is the active form occurring after ligation with 4"-phosphopantetheine. A high 
amount of the palmitoylated form was always present, which the group attributed to the holo-
form having a great affinity for this fatty acid. 
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FIGURE 1-11. Structures of the main mycolic acids of M. tuberculosis H37Rv and M. 
smegmatis mc2155. Assembled from Brown et al. (2009), Watanabe et al. (2002) and 
Minnikin (1982). 
 
!  1.5.3.2.2. Mt-FabD. 
The initial mycolic acid biosynthesis reaction requires the substrate malonyl-AcpM. This is 
made in the transacylation reaction of holo-ACP with malonate and is catalysed by the 
enzyme Mt-FabD (malonyl-CoA:ACP transacylase). The crystal structure of Mt-FabD 
revealed that the protein has two sub-domains: one large, one small (Ghadbane et al. 2007, Li 
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et al. 2007). The active site is located in a cleft between the two domains, with the small sub-
domain forming a lid-like structure. The key catalytic residues were found to be Ser-91, Arg-
116 and His-194. A salt bridge is thought to form between the malonyl carboxyl group and 
the guanido group of the arginine, helping to position the substrate. The M. tuberculosis 
genome also encodes a second fabD gene, fabD2 (Rv0649). However, the two protein 
products share only a 28 % identity and FabD2 does not have the G-X-S-X-G active site motif 
of FabD that is common to all serine-dependent acyl-hydrolases (Takayama et al. 2005). 
More recently, Huang et al. (2006) have shown that FabD2 does have malonyl-CoA:ACP 
transacylase activity, albeit to a lesser extent than FabD. Expression of both genes was 
monitored under stress conditions and, although fabD showed higher expression when in acid 
conditions and at 42 °C, fabD2 had greater expression in the untreated cells. The authors 
speculated that FabD2 is initially expressed during chronic infection and once the cell is 
engulfed by a macrophage, expression of FabD increases and takes over during persistence. 
 
 
 
 
FIGURE 1-12. Map of the M. tuberculosis FAS-II enzyme-encoding genome region. 
 
!  1.5.3.2.3. Mt-FabH. 
Once the malonyl-AcpM substrate has been produced by Mt-FabD, it can then undergo a 
condensation reaction with the acyl-CoA primer from FAS-I, catalysed by the enzyme Mt-
FabH (!-ketoacyl-ACP synthase III). The product is then channelled into the FAS-II system 
and, as such, Mt-FabH is thought to act as a critical link between the two fatty acid synthase 
systems. 
 
!"#$% !"#&% "''()%*+,,-,% ."/(%"'01%
"'23%
Chapter 1 General Introduction 
 
 26 
The importance of Mt-FabH has awarded it much attention and, as a result, a good deal is 
known about the enzyme. Studies have shown that saturated, unbranched acyl-CoA (rather 
than acyl-AcpM) substrates of intermediate chain length (C12–C20) are preferred, with 
lauroyl-CoA being processed most proficiently (Choi et al. 2000). The acyl-CoA accepted by 
Mt-FabH is, however, disputed due to the impracticalities of testing longer chain CoA-linked 
fatty acids; chains of more than twenty carbons are difficult to purify and difficult to 
introduce into an aqueous enzyme assay. Choi et al. (2000) also over-expressed Mt-FabH in 
M. bovis BCG, which resulted in certain complex lipids, including PDIMs and multi-acylated 
trehaloses, being up- or down-regulated. This suggests that expression of Mt-FabH is crucial 
in the production of cell wall lipids. 
 
The crystal structure of the Mt-FabH homodimer has been solved and provides insight into 
the substrate specificity of the enzyme (Scarsdale et al. 2001). Although Mt-FabH has 46.8 % 
similarity to Escherichia coli FabH (Ec-FabH) and the active site residues (Cys-112, His-244 
and Asn-274) are conserved, Ec-FabH uses much shorter acyl-CoA primers of two to six 
carbons. The difference occurs at the substrate-binding pocket: whereas Ec-FabH has a small 
acyl-binding domain adjacent to the pantetheinate-binding channel, Mt-FabH has an “L”-
shaped binding channel in each monomer (Sachdeva et al. 2008a). Upon solving the crystal 
structure of a Cys-112-Ala Mt-FabH mutant with bound lauroyl-CoA, it became clear that the 
CoA binds weakly at the pantetheinate arm of the “L”, the acyl group occupies the elongated, 
hydrophobic arm of the “L”, and the catalytic triad lies at the junction of the two arms 
(Musayev et al. 2005, Sachdeva et al. 2008a). It is the closed acyl channel that provides the 
substrate specificity; the chain length is limited to a maximum of sixteen carbons by a 
capping "-helix (Sachdeva et al. 2008b). The energetically expensive route taken by the acyl 
group through the pantetheinate channel and past the hydrophilic active site residues implied 
by the binding pocket structure has led to a new hypothesis in Mt-FabH conformation. It has 
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been proposed that the enzyme assumes an “open” conformation allowing the acyl substrate 
to bind directly and not via the solvent portal (Sachdeva et al. 2008a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-13. Mt-FabH reactions. (1) The acyl-CoA chain covalently attaches to the FabH 
active site cysteine. (2) Malonyl-CoA is decarboxylated leaving a reactive carbon atom. (3) 
FabH catalyses the condensation of the malonyl-CoA extender unit with the fatty acyl chain 
and releases the !-ketoacyl-AcpM product. Based on Davies et al. (2000). 
 
It is thought that Mt-FabH performs two half reactions of transacylation and decarboxylation 
(Davies et al. 2000) (Figure 1-13). Firstly, an acetyl-enzyme intermediate is formed, 
substituting the CoA group for AcpM. During this reaction, a thiolate anion is produced on 
Cys-122 of the Mt-FabH active site (Davies et al. 2000). The nucleophilicity of this residue is 
also increased by the "-helix dipole effect since the active site is near the N-terminus of the 
helix; a phenomenon caused by the collective effect of all the carbonyl group dipoles in the 
helix. The thiolate, now being more chemically reactive than the thiol, can attack the acetyl-
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CoA substrate. The negatively charged tetrahedral transition state is stabilised by the 
“oxyanion hole”, which is thought to involve the residues Phe-87, Cys-122, Gly-305 and 
Gly-306. The second reaction is the decarboxylation of malonyl-ACP. His-244 and Asn-274 
are involved in this reaction by interacting with malonyl-ACP to stabilise the negative charge 
on the carbonyl oxygen. It is this reactive carbanion that attacks the acetyl linked to the 
thiolate on Cys-122. 
 
!  1.5.3.2.4. Mt-KasA and Mt-KasB. 
!-Ketoacyl-ACP-synthases A and B (KasA and KasB) of mycobacterial FAS-II catalyse the 
mero-chain elongation condensation reactions. These enzymes, which are from the same 
operon (Figure 1-12), share 67 % sequence homology and are therefore thought to have 
overlapping functions (Figure 1-14). Current opinion suggests, however, that Mt-KasA may 
perform the early stages of mycolate chain elongation, to be taken over later by Mt-KasB 
(Slayden & Barry 2002, Takayama et al. 2005). 
 
The first study to purify and characterise mycobacterial KasA and KasB identified that the 
enzymes preferentially accept long-chain acyl-AcpMs of at least 16 carbons atoms (Schaeffer 
et al. 2001). This finding contrasted with other !-ketoacyl-ACP-synthase (KAS) enzyme 
homologues, for example that of E. coli, which accepts C6 to C12 acyl-ACPEc primers, and is 
therefore consistent with Mt-KasA and Mt-KasB being involved in FAS-II mycolate 
biosynthesis (Schaeffer et al. 2001). This study also identified the enzymes’ sensitivity to the 
KAS inhibitors thiolactomycin and cerulenin, thus highlighting them as attractive drug 
targets. Mt-KasA was later acknowledged as a FAS-II component by Kremer and co-workers 
(2002a). The group over-expressed Mt-kasA in M. smegmatis using the pMV261 vector and 
saw a significant decrease in ""-mycolates and a compensatory increase in "- and epoxy-
mycolates (Figure 1-11), suggesting a role for KasA in elongating mycolic acid intermediates 
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to full-length "-mycolic acids. A later study demonstrated the essentiality of KasA by the 
inability to knock out the gene and how conditional depletion of KasA results in cell lysis in 
M. smegmatis (Bhatt et al. 2005). Lipid profiles of kasA-depleted mutant strains showed a 
decrease in "- and epoxy mycolic acids and an accrual of ""-mycolates. In contrast, Mt-KasB 
is non-essential and it has been shown that gene deletion results in persistence of mutant 
bacilli in mice without causing disease for up to 600 days (Bhatt et al. 2007b). Altered 
colony morphology of the #kasB strain suggested that the cell wall was affected. Indeed, a 
shift was seen in the ratio of mycolic acid classes: more "- and less keto-mycolates were 
being made in the mutant compared to the wild-type, and those being made were shorter than 
wild-type mycolates by two to six carbon atoms (Bhatt et al. 2007b). 
 
The homodimeric structure of Mt-KasB was solved in 2007 where the active site was 
identified as being composed of the highly conserved residues Cys-170, His-311 and His-346 
(Sridharan et al. 2007). The structure of dimeric Mt-KasA was solved more recently 
(Luckner et al. 2009), although a hypothetical model had been suggested based on that of Mt-
KasB (Sridharan et al. 2007). The binding and catalytic mechanisms suggested are 
comparable to those of Mt-FabH (Sachdeva et al. 2008a), where a gate formed by residues 
115–147 opens and closes to allow direct and less energetically costly access to the acyl 
channel and the active site. 
 
!  1.5.3.2.5. Mt-MabA. 
MabA, also known as FabG1, is an essential enzyme that catalyses the second step of the 
FAS-II cycle, the NADPH-dependent reduction of the !-keto functional group to !-hydroxy 
(Parish et al. 2007). It is thought to form an operon with the downstream inhA gene and, 
although they are both !-ketoacyl-ACP-reductases with similar substrates, the two genes 
share only 20 % similarity. 
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FIGURE 1-14. Sequence alignment of Mt-KasA and Mt-KasB. Data for the corresponding 
secondary structure for Mt-KasA were obtained from the Protein Data Bank (entry 2WGD; 
Luckner et al. 2009). Red-filled boxes indicate conserved residues and blue boxes are those 
of high similarity. 
 
MabA has been shown to preferentially accept long-chain substrates (C8–C20) and displays 
little activity with C4 chains, supporting the hypothesis that it is involved in FAS-II (Cohen-
Gonsaud et al. 2002). The crystal structure was solved shortly after identification of the 
enzyme, and revealed a tetrameric conformation and a conserved fold found in all short-chain 
dehydrogenases/reductases (Cohen-Gonsaud et al. 2002). When compared with the structure 
of !-ketoacyl-ACP-reductases from E. coli and Brassica napus, the Ile-147 residue in MabA 
                                                                      Mt_KasA
1       10                            20        30        40        50
Mt_KasA V  P  A                       FP VVVT    TT    D E TWK LL   SGI  L D F         VT   SIS  I S     E   A   SQ ST NGG.................... S A A P G AG H E E
Mt_KasB V  P  A                       FP VVVT    TT    D E TWK LL   SGI  L D F         IA   ALA  A T     Q   T   GV PL GASRTDMEGTFARPMTELVTGKA Y G M T L DR R D P
                                                                      Mt_KasA
        60        70        80        90       100       110       120
Mt_KasA V   DL V IGGHL    D    R   RRM Y QRM   L   LWE AGSPEVD  R  V  GTGLG AE T    K      M  L M    V   L Q   S         VV       KW A KDPV SH G D S GK GG PD FA G
Mt_KasB V   DL V IGGHL    D    R   RRM Y QRM   L   LWE AGSPEVD  R  V  GTGLG AE E    R      L  I L    L   V R   N         SI       EF P LEEF HQ T E G ST SR TN LM S
                                                                      Mt_KasA
       130       140       150       160       170       180       190
Mt_KasA   V SYD M A G   VSPL VQ  MPNGAAA  GL   A AGVMTPVSAC SG EAIA AW QIV G ARI       R     A         VI  Q  R          S  S      R   M  E L N G P K MI LG H D
Mt_KasB   V SYD M A G   VSPL VQ  MPNGAAA  GL   A AGVMTPVSAC SG EAIA AW QIV G AEL       K     T         AV  E  K          A  A      Q   L  F D R R M A KY RH R E
                              TT       TT TT                          Mt_KasA
       200       210        220       230       240       250         
Mt_KasA D A CGGVE  IEA PIA F  MR  MST ND P  A RPFD DRDGFVFGE GAL LIETEEHAKARGA V V        L    S   A      E      K            M             GP A M . R E R S A
Mt_KasB D A CGGVE  IEA PIA F  MR  MST ND P  A RPFD DRDGFVFGE GAL LIETEEHAKARGA A I        V    A   V      A      R            L             TR G Q I N D G C G
                                                                    . Mt_KasA
260       270       280       290       300       310       320         
Mt_KasA   LAR  GA ITSD FHMVAP   G RAG A TR   LAGL P DIDHVNAH T T  GD AE  AI      LL             V      SLE    S           I      VKP G A AAD R M A G A P A AN R.
Mt_KasB   LAR  GA ITSD FHMVAP   G RAG A TR   LAGL P DIDHVNAH T T  GD AE  AI      IM             E      AIQ    A           V      ANI S G DPN H I G A G Q L GR NN
                                          TT                          Mt_KasA
330       340       350       360       370       380       390        
Mt_KasA  G    AVYAPKSALGHS GAVGA ES LTVL LRD VIPPTLN    DPEIDLDVVAGEPR G YRYA  Q             I     L  V    T          E                    VA CD A G Y TP Y D
Mt_KasB  G    AVYAPKSALGHS GAVGA ES LTVL LRD VIPPTLN    DPEIDLDVVAGEPR G YRYA  R             V     V  I    A          V                    IL GN P Q L NL P N
                                                                      Mt_KasA
400       410                                                          
Mt_KasA NNSFGFGGHNVA AFGRY                                                                L     
Mt_KasB NNSFGFGGHNVA AFGRY                                                                I     
!1 "1 !2 
"2 !3 #1 "3 "4 #2 !4 
"5 #3 "6 "7 !5 #4 "8 
!6 "9 #5 !7 "10 
!8 "11 #6 !9 "12 
!10 "13 "14 !11 !12 !13 
!14 !15 
Chapter 1 General Introduction 
 
 31 
was suggested as that which recognised substrates with long acyl chains. This residue is a 
hydrophilic asparagine in other species, which would not favour long hydrophobic chains. 
Indeed, an Ile-147-Asn MabA mutant showed much less affinity for long acyl-chain 
substrates (Cohen-Gonsaud et al. 2002). There are a further four fabG genes with putative !-
ketoacyl-ACP-reductase activity in M. tuberculosis, named fabG2–5. Currently, only fabG1 
(mabA) and fabG4 (Rv0242c) have been described as essential in M. tuberculosis and M. 
bovis BCG, respectively (Gurvitz 2009, Parish et al. 2007). Interestingly, fabG4 is located 
upstream of the !-hydroxyacyl-AcpM dehydratase gene htdX (Rv0241c) (Gurvitz et al. 
2009). It could be that these two genes form an operon of long-chain fatty acid biosynthetic 
enzymes. There is little further data published regarding the other fabG genes. The crystal 
structure of FabG3 has been solved but there is no information regarding its activity or 
function (Yang et al. 2002). 
 
!  1.5.3.2.6. !-hydroxyacyl-AcpM dehydratase(s). 
Several proteins have been proposed to catalyse the !-hydroxyacyl-AcpM dehydratase 
(HAD) step of the FAS-II cycle, including Rv0098 (Takayama et al. 2005) and Rv0216 
(Castell et al. 2005). Bioinformatic data have shown that there are no enzymes homologous 
to FabZ or FabA, the dehydratase and dehydratase/ isomerase enzymes found in other 
bacterial and protozoan species, such as E. coli and P. falciparum (Sacco et al. 2007). Both 
of these well-characterised enzymes possess a ‘hotdog fold’, an evolutionary conserved 
structural motif found in a wide range of dehydratases and thioesterases (Dillon & Bateman 
2004). A bioinformatic search for this motif in M. tuberculosis revealed seven such proteins, 
of which Rv3538 and Rv0636 had previously been annotated as essential and, of these, only 
Rv0636 has a homologue in M. leprae, a closely related mycolate-producing organism 
(Castell et al. 2005, Sassetti et al. 2003). Subsequently, two separate concurrent publications 
identified the Rv0635-Rv0636-Rv0637 gene cluster (later named HadA-HadB-HadC) as 
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potentially encoding the HAD proteins in M. tuberculosis (Sacco et al. 2007) and in the M. 
smegmatis homologue MSMEG1341 (Brown et al. 2007a). Importantly, both Rv0636 and 
MSMEG1341 were found to be essential, as are the other genes of the FAS-II cycle. Protein-
protein interaction experiments showed that two heterodimers were formed, HadAB and 
HadBC (Sacco et al. 2007). HadAB was more active in the presence of C16-chains and 
HadBC in the presence of C20-chains, with both being AcpM-dependent. From this data it has 
been suggested that, akin to KasA and KasB, HadAB and HadBC preferentially accept 
medium- and long-chain molecules respectively. Three further enzymes from M. tuberculosis 
that have been characterised as physiologically functional !-hydroxyacyl-thioester 
dehydratases are Rv0241c (HtdX), Rv3389c (HtdY) and Rv0130 (HtdZ) (Gurvitz et al. 2008, 
2009). All three of these enzymes were capable of complementing dehydratase activity in a 
Saccharomyces cerevisiae mutant devoid of mitochondrial FAS-II !-hydroxyacyl-thioester 
dehydratase (Htd2). 
 
!  1.5.3.2.7. Mt-InhA. 
The final reaction in the fatty acid elongation pathway is reduction of 2-trans-enoyl-AcpM to 
yield the acyl-AcpM, an essential step in the FAS-II cycle. Although isoniazid had been used 
as a front-line drug since 1952, its target within the cell was not identified as InhA until the 
1990s (Banerjee et al. 1994). Studies since have shown that the enzyme preferentially 
catalyses long-chain molecules (C12–C24), in accordance with its involvement in mycolate 
biosynthesis (Quémard et al. 1995), and is a prodrug that requires activation before being 
capable of inhibition (Zhang et al. 1992). In 2000, inhA was proven to be an essential gene, 
with inactivation causing inhibition of mycolic acid biosynthesis, accumulation of saturated 
fatty acids and cell lysis (Vilchèze et al. 2000). The product, a fatty acyl-AcpM with two 
more carbons added, is then repeatedly fed back into the FAS-II cycle to elongate the 
meromycolate chain to a maximum of around 56 carbons. 
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!  1.5.3.2.8. Modifications to the meromycolate chain. 
Modifications to the meromycolic acid chain are made before the Pks13-mediated 
condensation reaction, which produces the mature mycolic acid (Qureshi et al. 1984). This 
involves the introduction of cyclopropane rings, desaturation, hydroxylation, methoxylation 
or ketonisation. The suggested effects of these modifications include cell wall permeability, 
resistance to reactive oxygen species and cell wall fluidity (Liu et al. 1996, Yuan et al. 1995). 
The first step, which is necessary for all further modifications, is desaturation, where a 
position-specific double bond is introduced in the chain. It is thought that in M. tuberculosis 
this reaction is catalysed by DesA1, DesA2 and DesA3. DesA1 and A2 are homologous to 
the stearoyl-ACP desaturase enzymes found in plants, where over 75 % of lipids are 
unsaturated. This indicates that the enzymes in M. tuberculosis process acyl carrier protein-
attached fatty acyl chains (Ohlrogge & Browse 1995, Raman et al. 2007). The reaction 
involves the conversion of stearoyl-AcpM to oleoyl-AcpM by introducing a cis-#9 double 
bond. Oleic acid is the most abundant unsaturated fatty acid in mycobacterial species and is 
essential for correct cell membrane physiology (Phetsuksiri et al. 2003). The #9 desaturase 
found in the plant kingdom is soluble, a supposedly unique feature since all others are 
thought to be membrane-bound (Ohlrogge & Browse 1995). Interestingly, although Mt-
DesA1 has been found to be insoluble, Mt-DesA2 was not and the homodimeric structure has 
been solved (Dyer et al. 2005). Despite being unrelated species, when Mt-DesA2 is 
compared with the structure of stearoyl-ACP desaturase from castor seed (Lindqvist et al. 
1996) an excellent correlation is evident, such as the arrangement of a nine-"-helical portion 
and and certain conserved metal-binding residues (Dyer et al. 2005). Two potentially crucial 
differences in Mt-DesA2, however, which could imply alternative functions, are found in the 
di-iron metal binding site, a consistent feature within the acyl-ACP desaturase family, and the 
arrangement of the intersubunit region. 
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DesA3 is annotated as a possible linoleoyl-CoA desaturase, a widely-found enzyme that 
introduces cis-#6 double bonds and has a close sequence similarity to #6 acyl-lipid 
desaturases in plants and cyanobacteria (Phetsuksiri et al. 2003). DesA3 is an essential 
membrane-spanning enzyme in M. tuberculosis and has previously been shown to be the 
target of the drug isoxyl (Phetsuksiri et al. 2003). Interestingly, over-expression of DesA3 
but not A1 or A2 resulted in increased production of oleic acid and an increase in the 
minimum inhibitory concentration (MIC) of isoxyl. 
 
Once the double bond has been introduced, it can be converted into other functional groups. 
Cyclopropane ring-containing lipids are a widespread phenomenon across bacterial genera, 
such as Enterobacter, Lactobacillus and Streptococcus, as well as mycobacteria, but also in 
the oils of some subtropical plants (Buist 2007, Grogan & Cronan 1997). The cma1 gene 
encodes CMAS-1, which Yuan et al. (1995) identified as introducing distal cis-cyclopropane 
rings. The cma2 protein product introduces proximal cis- and trans-cyclopropane rings of 
both methoxy- and keto-mycolates (Glickman et al. 2001). PcaA is a cis-cyclopropane 
synthase, an enzyme that is essential for M. tuberculosis persistence in the mouse infection 
model (Glickman et al. 2000). This result indicates that mycolate cyclopropanation is a key 
factor in M. tuberculosis pathogenesis. 
 
Four further genes that have been identified as modifying mycolic acids are mmaA1, mmaA2, 
mmaA3 and mmaA4. These genes are adjacent in the genome and are thought to function 
together in the methoxy-mycolic acid biosynthetic pathway (Figure 1-15) (Yuan & Barry 
1996). MmaA4 converts the distal cis-double bond to a secondary alcohol, which MmaA3 
then methylates. In mutant strains without mma4, no oxygenated mycolates are produced and 
pathogenicity is highly attenuated (Yuan & Barry 1996). MmaA2 then introduces a cis-
cyclopropane ring at the proximal position. MmaA1 is thought not to be part of this pathway, 
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but instead converts cis-olefins to the trans conformation and catalyses the addition of an 
allylic methyl branch (Yuan & Barry 1996). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-15. The proposed biosynthetic pathway of methoxy-mycolic acids. Adapted 
from Yuan & Barry (1996). 
 
!  1.5.3.2.9. Mt-Pks13 and the ACC complex. 
One of the final steps in mycolic acid biosynthesis is the Claisen-type condensation reaction 
catalysed by Pks13, a large polyketide synthase type I enzyme of 1,733 amino acid residues. 
This enzyme catalyses the condensation of the "-branch from FAS-I (C20–26 acyl-CoA) with 
the meromycolate from FAS-II (C56 acyl-AcpM) to produce an "-alkyl, !-keto acid, which is 
then reduced to give the final mycolic acid product. Pks13 was only identified as the main 
candidate for this reaction over the other nine shared by M. tuberculosis and M. leprae by 
means of its location adjacent to accD4 and fadD32, a then hypothetical acyl-CoA 
carboxylase and acyl-CoA synthase respectively, and that homologous genes are found in 
other mycolate-producing species (Figure 1-16 A) (Portevin et al. 2004). 
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Pks13 was shown to have four catalytic domains required to catalyse the reaction: 
ketosynthase, acyl-transferase, acyl carrier protein and thioesterase (Figure 1-16 B) (Portevin 
et al. 2004). The gene is essential in mycobacteria because mutants deficient in mycolic acids 
are non-viable, but a C. glutamicum pks13-deletion mutant was achievable and analysis 
revealed that the strain was deficient of mycolic acids, although was able to produce fatty 
acid precursors (Bhatt et al. 2005, Portevin et al. 2004, Vilchèze et al. 2000). Pks13 is 
located in the genome downstream of fadD32, which has recently been shown to encode a 
protein that provides the substrate, a meromycolyl-AMP from meromycolic acid plus ATP 
(Figure 1-16 B) (Gavalda et al. 2009). 
 
After being released from the FAS-I enzyme and before it can be a substrate for the 
condensation reaction, the C20–26 acyl-S-CoA molecule is carboxylated to produce 2-
carboxyl-C20–26-S-CoA (Takayama et al. 2005). It is thought that the biotin-dependent acyl-
CoA carboxylase (ACC) enzyme is formed by the complexing of different sub-units, a 
system that is found in bacteria and most plant chloroplasts. In contrast, mammals and fungi 
employ a large single multi-functional polypeptide (Cronan & Waldrop 2002). The ACC 
complex catalyses a two-step reaction, firstly biotin carboxylation by the "-subunit (accA1-3 
in M. tuberculosis) and secondly carboxyl transfer by the !-subunit (encoded by accD1-6) 
(Cole et al. 1998, Daniel et al. 2007). From whole genome analysis, it was suggested that the 
AccA1-AccD1 and AccA2-AccD2 complexes are involved in conversion of propionyl-CoA 
to succinyl-CoA (Cole et al. 1998), whereas more recently AccD4 and AccD5 have been 
implicated in the pre-Pks13 carboxylation reaction (Figure 1-8). Protein purification and 
complex reconstitution experiments by Oh and co-workers (2006) identified four peptides 
that had biotin-dependent acyl-CoA carboxylase activity when complexed in certain 
combinations: AccA3, AccD4, AccD5 and the novel Rv3281 (named the $ subunit). 
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FIGURE 1-16. The FadD32 / Pks13-mediated condensation reaction. (A) Map of the 
genomic region of M. tuberculosis H37Rv pks13. (B) The proposed system for the Claisen-
type condensation between the "-branch and meromycolate chain, one of the final steps in 
mycolic acid biosynthesis (i) loading, (ii) condensation reaction. For clarity, shorter C16 
acyl chains are drawn; actual chain lengths for M. tuberculosis mycolate precursors are 
noted alongside in B (i). ACP, acyl-carrier protein; KS, ketosynthase; AT, acyl-transferase; 
TE, thioesterase. Adapted from Gavalda et al. (2009). 
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AccA3 (Daniel et al. 2007). The enzyme preferentially accepts acetyl-CoA over propionyl-
CoA and, along with its location in the same operon as other FAS-II enzymes, a role in 
providing malonyl-CoA for the FAS-I and FAS-II systems was deduced (Figure 1-12). 
 
!  1.5.3.2.10. Transport and further processing. 
The majority of the mycolic acid product is then esterified to arabinogalactan of the PG-AG 
layer (see section 1.5.2.). It is thought that approximately two-thirds of the arabinan is 
mycolylated (Bhamidi et al. 2008). Some mycolates remain as extractable ‘free lipids’, that 
is, covalently bound to trehalose or glucose to form trehalose monomycolate (TMM), 
trehalose 6,6"-dimycolate (TDM) and glucose monomycolate (GMM). The latter of these is 
also known as cord factor, which is toxic to humans (Minnikin et al. 2002). It is thought that 
these three mycolate derivatives intercalate with the mycolates attached to the PG-AG layer 
(Figure 1-6). Trehalose is a disaccharide of two "-glucose units covalently bonded by an 
","-1,1-glucosidic bond. It has been proposed that attachment of the mycolic acid to 
trehalose occurs via the carrier molecule 6-O-mycolyl-!-D-mannopyranosyl-1-
phosphoheptaprenol (Myc-PL). Then, at the site of an ABC transporter in the cell membrane, 
the mycolyl residue is attached to trehalose in a reaction catalysed by a mycolyltransferase 
(Takayama et al. 2005). The authors note that the product being transported across the cell 
membrane immediately avoids accumulation of TMM inside the cell and the inevitable 
conversion to TDM before being ejected from the cytoplasm. 
 
Three fibronectin-binding proteins belonging to the antigen 85 complex, Ag85A, Ag85B and 
Ag85C (also known as FbpA, FbpB and FbpC, respectively), are thought to be involved in 
this last step of cell wall assembly (Kremer et al. 2002c). Ag85 proteins are major secretory 
proteins of M. tuberculosis and M. leprae, although some members of the complex are found 
attached to the cell surface (Wiker & Harboe 1992). All have been shown to have 
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mycolyltransferase activity in vitro, forming TMM and TDM (Belisle et al. 1997), and, with 
transposon mutagenesis data, Jackson et al. (1999) provided evidence for Ag85C catalysing 
mycolate-attachment to arabinogalactan. As well as having a role in cell wall biosynthesis, 
the proteins induce intense cell-mediated and humoral immune responses in the host, and as 
such are being developed as new TB vaccines (see section 1.7.1.). 
 
!  1.5.3.2.11. Interaction of FAS-II enzymes. 
Two successive papers by Veyron-Churlet et al. (2004, 2005) have explored the interactions 
between the proteins of the FAS-II system using the yeast two-hybrid method. The protein-
protein interactions observed are summarised in Table 1-2. 
 
TABLE 1-2. Interactions between the FAS-II enzymes of M. tuberculosis (adapted from 
Veyron-Churlet et al. 2005). The more ‘+’ signs indicates greater interaction. No protein-
protein interaction is indicated by ‘–’. NT, not tested. 
 
 FabD FabH KasA KasB MabA InhA MmaA1 MmaA2 MmaA3 MmaA4 Pks13 
FabD +++ +++ +++ +++ – ++ +++ +++ +++ ++ NT 
MmaA1 +++ + +++ +++ – – +++ ++ – +++ NT 
MmaA2 +++ – +++ + – + +++ + + + NT 
MmaA3 – – ++ ++ – – +++ ++ – +++ NT 
MmaA4 ++ – ++ ++ – – ++ ++ – – NT 
Pks13 ++ + + ++ – + + + ++ ++ +++ 
 
The results suggest that FabD, InhA, MabA and the dehydratase enzymes, HadA, HadB and 
HadC, form a central core that interacts with KasA, KasB and Pks13 for the sequential 
phases of meromycolate chain extension (Veyron-Churlet et al. 2004). Initially, the group 
identified four specialised complexes and coined names for each phase. The ‘initiation-FAS-
II’ allows the acyl-CoA transition from FAS-I to FAS-II via FabH. The second elongation 
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phase is E1-FAS-II (‘type 1 elongation-FAS-II’), made up of the core enzymes plus KasA. 
Similarly, the final phase is E2-FAS-II (‘type 2 elongation-FAS-II’), which comprises the 
same core enzymes plus KasB. The speculative fourth, ‘termination’, complex involving 
Pks13 catalysed the condensation reaction between the product of E2-FAS-II and the acyl-
CoA from initiation-FAS-II. This model was modified in the later report and is reviewed in 
Figure 1-17. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-17. Model of FAS-II enzyme interactions. The specialised complexes first 
identified by Veyron-Churlet et al. (2004) are circumscribed by a pink bubble. I-FAS-II 
(‘initiation FAS-II’), E1-FAS-II (‘type 1 elongation FAS-II’) and E2-FAS-II (‘type 2 
elongation FAS-II’). The core is thought to comprise FabD, InhA, MabA and the 
dehydratases HadA, HadB and HadC (Rv0635, Rv0636 and Rv0637 respectively). Solid 
black arrows indicate the putative route taken by intermediates from one complex to 
another. Dashed arrows indicate the binding of MmaA proteins with KasA and KasB. 
Adapted from Veyron-Churlet et al. (2005). 
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1.5.3.3. Other lipids. 
The mycobacterial cell wall also contains complex lipids that have multiple methyl branched-
fatty acids esterified to their backbone and various large molecules based on trehalose and 
phthiocerol. Examples of the latter include phenolphthiocerol and phthiocerol 
dimycocerosates, whereas members of the trehalose family include sulfatides, 
diacyltrehaloses, triacyltrehaloses and polyacyltrehaloses (Jackson et al. 2007, Minnikin et 
al. 2002). All of these molecules are thought to form a link between the mycolic acids (via 
the acyl chains) and the outer capsule of the bacterium. 
 
1.5.4. Lipoarabinomannan and phosphatidyl-myo-inositol mannosides. 
In addition to the lipids described above, another component of the mycobacterial cell wall, 
lipoarabinomannan (LAM), also contains fatty acyl groups. LAM is found in both pathogenic 
and non-pathogenic mycobacteria and is composed of three sections: a mannosyl-
phosphatidyl-myo-inositol (MPI) anchor, a polysaccharide backbone and various capping 
units, which are used to distinguish between LAM types. The anchor connects the LAM to 
the plasma membrane by long-chain fatty acyl groups esterified to the phosphate, usually 
palmitic (C16) and 10-methyl-octadecanoic (C19) acids (Nigou et al. 2003). The main portion 
of LAM is the backbone, comprising the polysaccharides D-mannan and D-arabinan. The 
branched mannan section is made up of 30–35 "(1!6)-linked mannopyranose residues while 
the arabinan is composed of ~60 "(1!5)-linked Araf residues, with occasional branches 
(Nigou et al. 2003). The precise linkage between the domains has, as yet, not been 
elucidated. Generally, with regard to the capping motifs, slow-growing mycobacteria, 
including M. tuberculosis, possess ManLAMs (with capping mannooligosaccharides), 
whereas the fast-growing species, such as M. smegmatis, have PILAMs, or phosphoinositide 
units. LAM of the fast-growing species M. chelonae, however, is devoid of any capping unit, 
either mannose or inositol phosphate (Guérardel et al. 2002). LAM is a major 
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immunomodulatory virulence factor that is involved in macrophage deactivation (Sibley et 
al. 1988), repression of T cell proliferation (Moreno et al. 1988) and removal of free radicals 
(Anthony et al. 1994, Chan et al. 1991). The cap is an important feature in this immune 
response and there is evidence suggesting that polysaccharides lacking a cap, as found in M. 
chelonae, having increased ability to induce TNF-" release (Guérardel et al. 2002). 
 
Other members of the glycolipid family include the phosphatidyl-myo-inositol mannosides 
(PIMs). The soluble lipoglycans, lipomannans (LMs), are closely related to LAMs in their 
biosynthetic pathway; it is thought that the enzyme PimA, an "-mannosyltransferase, 
converts phosphatidyl-myo-inositol into PIM. Further enzymes then attach more mannose 
units to produce PIMs2-6. It is thought that the LMs are subsequently produced from PIM4 by 
the addition of branching mannose residues and that the LAMs are the result of an arabinan 
domain being introduced (Mishra et al. 2011). 
 
1.5.5. The mycobacterial ‘outer cell membrane’. 
Numerous models have been proposed for the outer most section of the mycobacterial cell 
wall. Although technically described as Gram-positive, the Corynebacterineae suborder have 
what has been described as an ‘outer permeability barrier’ similar to the lipid bi-layer outer 
membranes of Gram-negative species (Zuber et al. 2008). Gram-positive bacteria possess an 
inner plasma membrane, a thin periplasmic space and an outer peptidoglycan layer. Gram-
negative bacteria have an outer membrane comprising a phospholipid bi-layer with 
lipopolysaccharides and proteins, in addition to the other layers shared by Gram-positive 
species. Minnikin (1982) first postulated that mycobacteria have an asymmetrical outer 
membrane bi-layer, whereby mycolic acids function as the inner leaflet and extractable lipids 
such as TMM, TDM and GPL act as the outer leaflet (Figure 1-6; Liu et al. 1995, Zuber et al. 
2008). Nevertheless, it is not until recently that visual evidence supporting the hypothesis has 
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become available. Zuber et al. (2008) and Hoffmann et al. (2008) have lately provided a 
wealth of information using cryo-electron microscopy, which allows the ultrastructure of 
hydrated cell samples to be visualised. Both groups provided tangible proof for the existence 
of a lipid bi-layer in mycobacteria (Figure 1-18). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-18. The cell envelope of Gram-negative and Gram-positive bacteria. The cell 
envelopes were visualised by Zuber and co-workers (2008) using cryo-electron microscopy 
of vitreous sections (left panels) and the electron density profiles were subsequently 
obtained from the microscopy results (right panels) (A) M. smegmatis mc2155, (B) M. bovis 
BCG, (C) the characteristic Gram-negative bacterium E. coli, and (D) the Gram-positive 
species Streptococcus gordonii. OM, outer membrane; PL, peptidoglycan layer; PM, plasma 
membrane; GL, granular layer. Adapted from Zuber et al. (2008). 
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1.5.6. Regulation of the cell wall. 
The cell wall is an incredibly important feature of M. tuberculosis but surprisingly little is 
known about the molecular mechanisms underlying the regulation of its biosynthesis. There 
is a growing pool of evidence suggesting that many fundamental cellular processes are 
regulated by eukaryotic-like serine/ threonine protein kinases not only in M. tuberculosis, 
such as cell division and virulence, but also by the pathogen to alter signalling in the infected 
host cell (Molle et al. 2010, Scherr & Pieters 2009, Wehenkel et al. 2008). Phosphorylation 
is a reversible post-translational modification that introduces negative charges through 
addition of a [PO4]3- group. This causes a conformational change in the target protein, thus 
switching the activity on or off. The usual residues to undergo phosphorylation are serine, 
threonine and tyrosine, although in prokaryotes histidine, arginine and lysine may also be 
modified (Marks 1996). The majority of kinases are membrane-bound, thus providing a 
mechanism for the cell to respond to external environmental stimuli. 
 
The M. tuberculosis genome (Cole et al. 1998) highlighted eleven genes encoding two-
component systems and eleven genes encoding Ser/Thr protein kinases. The former system 
is mainly found in prokaryotes and is a coupling mechanism usually involving a histidine 
kinase. The Ser/Thr kinases are found in various numbers across mycobacterial species, for 
example there are four in M. leprae but twenty-four in M. marinum (Wehenkel et al. 2008). 
The reduced genome of M. leprae (Cole et al. 2001) suggests that the four kinases present, 
PknA, PknB, PknG and PknL, are essential and are implicated in key physiological functions. 
Of the eleven kinases in M. tuberculosis, nine are membrane-bound, as indicated by their 
receptor-like transmembrane domains. The other two, PknG and PknK, are presumed to be 
cytosolic (Cole et al. 1998). 
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It is not surprising that enzymes involved in the biosynthesis of cell wall components are 
regulated by phosphorylation. Being closely related to cell division, these enzymes are 
indirectly affected by the environment via kinase signalling. Stress conditions can therefore 
alter mycolate biosynthesis allowing the cell to adapt to external conditions (Tyagi et al. 
2008). KasA, KasB and FabH were the first enzymes of the FAS-II system to be identified as 
being regulated by phosphorylation, indeed part of this project explores the role of 
phosphorylation on Mt-FabH activity (Chapter 3; Molle et al. 2006, Veyron-Churlet et al. 
2009). The activity of KasA and FabH is reduced by phosphorylation but that of KasB is 
increased, suggesting a complex mechanism of cellular adaptation. Neither KasA, KasB nor 
FabH have the characteristic phosphorylation recognition domains (forkhead-associated 
domains; FHA) but have 11-stranded !-sandwiches that mediate phosphorylation-dependent 
protein-protein interaction (Pallen et al. 2002). KasA, KasB and FabH are phosphorylated by 
M. tuberculosis PknA, PknB, PknE, PknF and PknH and are dephosphorylated by Ser/Thr 
phosphatase PstP (Molle et al. 2006, Veyron-Churlet et al. 2009). 
 
Similarly, the activities of both InhA and MabA are controlled by phosphorylation. With both 
genes being in the same operon and both having important roles in mycolate biosynthesis, 
this may not be unexpected. InhA is a substrate for PknA, PknB, PknE and PknL, as is 
MabA, which can also phosphorylated by PknD. Phosphorylation occurs at Thr-266 on InhA 
and was found to deactivate the enzyme (Molle et al. 2010). Point mutations at Thr-266 that 
mimic phosphorylation by adding a negative charge (T266D and T266E) severely reduced 
reductase activity. MabA is phosphorylated at three sites, Thr-21, Thr-114 and Thr-191, of 
which the latter is the principal phosphoacceptor. A similar phosphomimicary mutant was 
made (T191D) and, from activity studies compared to the wild-type, it could be inferred that 
phosphorylation deactivates MabA (Veyron-Churlet et al. 2010). Phosphorylation of these 
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enzymes therefore may well be another way of allowing M. tuberculosis to control mycolate 
production. 
 
Most recently, a study by Slama et al. (2011) has identified that the FAS-II dehydratase 
enzyme complexes, HadAB and HadBC, are also regulated by phosphorylation. Each of the 
HadA, B and C subunits were phosphorylated in vitro and in vivo at least to some degree by 
all the Ser/Thr protein kinases tested (PknA, B, D, E, F, H and L). Interestingly, the group 
found that phosphorylation down-regulates dehydratase activity and occurs mainly during 
stationary growth phase. From this, it was hypothesised that the bacilli switch off 
meromycolate chain production when not replicating as a means of controlling dormancy 
(Slama et al. 2011). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-19. M. tuberculosis FAS-II phosphorylation. Schematic representation of how 
phosphorylation is used to activate and de-activate FAS-II enzymes. ‘-’ indicates protein de-
activation; ‘+’ indicates protein activation. Based on Bhatt et al. (2007a) and Slama et al. 
(2011). 
 
!"
!"#$%
&'()%
&'()% !"
*'+$%
*'+$%
!"+,-%
!"+,-%!" !"
!+.!% !+.!%
!"#$%
!" !"
#$%&'$##"
!"#$%&'(%&'(")*#+($,
#-!(&'(%&'(")*#+($,
()$%&'$##" *$%&'$##"
+" +" ,-+"
!"
*'+/%
*'+/% !"
,"
)'0$/%
)'0/1%
!"
+"
(.$%&'$##"
2'($%
2'($% !"
+"
!"#$% !"#$%
3#4$%
3#4$% !"
)'0$/%
)'0/1%
!"#$%
+"
Chapter 1 General Introduction 
 
 47 
Another cell wall enzyme under the control of protein kinases is EmbR, a transcriptional 
regulator of arabinosyl transferases EmbC, EmbA and EmbB, which is activated by PknA, 
PknB and PknH phosphorylation (Molle et al. 2003a, Sharma et al. 2006). Activation 
promotes arabinan biosynthesis by inducing transcription of the embCAB operon. Both 
EmbR and the Pkn kinases are therefore directly implicated in virulence and pathogenesis of 
M. tuberculosis, since it is well known that LAM and LM are modulators of the host immune 
response (Chatterjee & Khoo 1998, Nigou et al. 2003). PknH may also be involved in the 
response to nitric oxide stress. Evidence from Papavinasasundaram and co-workers (2005) 
have shown that a M. tuberculosis #pknH mutant was hypervirulent and displayed higher 
resistance to acidified nitrite stress. It could be that this environmental stimulus triggers 
PknH activation. Indeed, it has been found that the kinase is up-regulated in macrophages 
(Sharma et al. 2006). Mycobacterial MurD, a cytoplasmic UDP-N-acetylmuramoyl-L-
alanine:D-glutamate-ligase involved in peptidoglycan synthesis, is also a substrate for PknA 
(Thakur & Chakraborti 2008). 
 
There are several pieces of evidence that together support the idea that PknA and PknB are 
involved in cell shape and cell division. Firstly, as described above, many of the substrates 
are enzymes of cell wall biosynthesis. Other substrates include FtsZ, a GTPase homologous 
to eukaryotic tubulin involved in septum formation, Wag31, a cell shape/cell division and 
septum formation regulation protein essential for cell growth (Kang et al. 2008a, Nguyen et 
al. 2007), and penicillin binding proteins (PBPs), which are involved in cell wall expansion, 
cell shape maintenance, septum formation and cell division (Dasgupta et al. 2006). Secondly, 
both kinases are expressed during the exponential growth phase and are down-regulated 
during periods of starvation. Thirdly, in experiments where PknA and PknB are over-
expressed or partially deleted (deletion mutants are non-viable), cells were found to be 
abnormally narrow, elongated, branched and sometimes di-nucleoidal, as well as having 
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noticeably reduced growth rates compared to the wild-type (Kang et al. 2005). Finally, 
evidence comes from their location in the M. tuberculosis genome. pknA and pknB are in an 
operon with pstP, a Ser /Thr phosphatase, pbpA, a penicillin binding protein and rodA, which 
encodes a cell division enzyme that works with PbpA to switch between peptidoglycan 
synthesis and septum formation. 
 
Other mycobacterial Pkn kinases are thought to be involved in transport across the cell 
membrane. PknD is co-transcribed with pstS, which encodes one of four membrane-bound 
phosphate-specific transporters (Av-Gay & Everett 2000, Vanzembergh et al. 2010). Another 
putative substrate for PknD is MmpL7, one of thirteen MmpL proteins in M. tuberculosis 
(Perez et al. 2006). MmpL7 transports phthiocerol dimycocerosate (PDIM) and sulfolipids to 
the cell wall and as such is essential for virulence. The PknD of M. bovis, however, has lost 
the transmembrane domain (Peirs et al. 2000), but it is able to phosphorylate the FHA 
domain of the ABC transporter encoded by Rv1747. PknF, which is only found in pathogenic 
mycobacteria, also interacts with this enzyme. Evidence from Curry et al. (2005) suggests 
that PknF regulates environment-dependent transport of solutes, including glucose uptake 
(Deol et al. 2005). In the case of PknG, one of the assumed cytoplasmic kinases, its genetic 
locus may suggest a role in glutamine uptake. The pknG gene is part of an operon with glnH, 
which encodes a membrane-bound extracellular glutamine binding protein and, although 
PknG is not essential, it is only found in M. tuberculosis complex species, thus implying a 
role in pathogenicity (Av-Gay & Everett 2000). Indeed, Walburger et al. (2004) identified 
that PknG inhibits phago-lysosome fusion, a key tool in mycobacterial survival in the host. 
Deletion of pknG had no effect in vitro, however, in macrophages, mutant cells were quickly 
transferred to lysosomes and killed. 
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1.6. Fatty acid !-oxidation 
As with other bacteria, mycobacteria also carry out the !-oxidation of lipids (Figure 1-20). 
Indeed, it is thought that they are principally lipolytic and not lipogenic due to the lipid-rich 
nature of their host tissues. It is thought that, in vivo, the lipids of the cell wall are largely 
derived from incorporated host fatty acids, and it has been demonstrated that mycobacteria 
do favour using host cell lipids over de novo synthesis (Wheeler et al. 1990, Wheeler & 
Ratledge 1994). A similar observation is made in Pseudomonas aeruginosa lung infections in 
cystic fibrosis patients (Kang et al. 2008b, 2010, Son et al. 2007). The highly virulent and 
pathogenic cells replicate rapidly inside the lungs and the fatty acid degradation pathways are 
thought to be key in maintaining this. P. aeruginosa adapts to the environment and induces a 
number of genes to exploit its surroundings. Lung surfactant is thought to be a main source of 
nutrients, 80 % of which being phosphatidylcholine. The phospholipid is cleaved by lipases 
and subsequently metabolised by degradation enzymes, including those encoded by the 
fadBA operon. 
 
The E. coli !-oxidation pathways are well studied and understood in contrast to studies 
investigating the equivalent in mycobacteria. In E. coli, the FadR protein globally regulates 
fatty acid metabolism at transcription level; it is able to repress and induce all fad and ace 
genes (the latter of which are involved in the glyoxylate shunt) as well as fabA, an 
unsaturated fatty acid biosynthesis gene (Black & DiRusso 1994). It is known that FadR is in 
turn regulated directly by acyl-CoA molecules (DiRusso et al. 1992). FadR binds long-chain 
acyl-CoAs with high affinity when they are in high concentrations, which changes the 
conformation of the protein allowing its induction. In E. coli, the FadB and FadA activities, 
which together catalyse at least five steps required for fatty acid oxidation, are collectively 
found as a single multi-enzyme complex with an "2!2 structure (DiRusso 1990). This same 
arrangement is seen in M. leprae, which possesses a single multi-functional FadB-FadA 
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enzyme, although this is likely to be a result of its extreme reductive evolution. Interestingly, 
the oldest known organism to process fatty acids by !-oxidation, the archaeon Archeoglobus 
fulgidus, does not have a multi-functional enzyme like E. coli, but discrete mono-functional 
enzymes, like M. tuberculosis (Klenk et al. 1997). As such, it is thought that the multi-
functional enzyme evolved from non-covalent interactions between these mono-specific 
proteins and/or gene fusion rather than dissociation of a large multi-domain protein (Winkler 
et al. 2003). 
 
M. tuberculosis possesses a huge abundance of enzymes involved in lipid metabolism; where 
in E. coli there are around 50 enzymes, there are at least 250 in M. tuberculosis (Côtes et al. 
2008). M. tuberculosis has multiple homologues of the fatty acid degradation (Fad) enzymes, 
whereas in E. coli there is only one. For example, there are 36 FadD enzymes alone (Black 
and DiRusso 1993, Cole et al. 1998, Fujita et al. 2007). Approximately 52 % of the genes in 
M. tuberculosis have been created by gene duplication, which has resulted in massive 
functional redundancy. The reason for this could be the huge diversity of lipids in 
mycobacteria – certain homologues catalyse normal !-oxidation reactions, some may be 
involved in the recycling of complex lipids unique to the genus and others may have 
unrelated functions. An example of this is FadD33, now renamed MbtM, which, although 
being homologous to a lipid metabolism protein, has recently been shown to convert fatty 
acids into acyl-adenylates (Krithika et al. 2006). A similar finding has also been reported for 
the FadD15 homologue. Trivedi and co-workers (2004) demonstrated that the protein was 
able to catalyse the production of acyl-adenylates from long-chain fatty acids or, with the 
inclusion of CoA-SH, the corresponding fatty acyl-CoA. These activated metabolites are not 
only used for lipid metabolism but also as substrates in biosynthetic pathways. 
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FIGURE 1-20. The !-oxidation pathway in M. tuberculosis. Extracellular fatty acids are 
first activated by CoA-attachment and translocated across the cell membrane by an acyl-
CoA synthetase, possibly encoded by one or more of the fadD genes. An acyl-CoA 
dehydrogenase catalyses the first oxidation step, currently annotated as 36 fadE genes. It is 
thought the hydration step is catalysed by FadB1, the second oxidation step converting the 
!-hydroxy group to a !-keto by FadB2, and the thiolysis step by one or more of the FadA 
enzymes. Further enzymes are required to process unsaturated fatty acids, possibly 
including FadH, currently annotated as a 2,4-dienoyl-CoA reductase. Based on Fujita et al. 
(2007). 
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In complete contrast, all gene families in M. leprae have undergone a massive reduction in 
number resulting in the species possessing approximately 74 % of the genes found in M. 
tuberculosis, of which only about half encode proteins (Cole et al. 2001). The remaining 
genes are either regulatory or are pseudogenes. This is a sharp contrast to M. tuberculosis, 
where over 90 % of the genome is protein-encoding (Scherr & Pieters 2009). Despite this, M. 
leprae is also an extremely successful pathogen and it is believed that it retained the 
minimum genetic functionality required for pathogenicity and intracellular survival (Cole et 
al. 2001). 
 
The FadB and FadA enzymes of M. tuberculosis are thought to catalyse the last three steps in 
the !-oxidation pathway (Figure 1-20). FadB1, a non-essential gene according to Sassetti et 
al. (2003), is thought to be a !-enoyl-CoA hydratase, converting the trans double bond into a 
OH functional group. FadB1 is a large protein of 720 amino acids and is located in the 
genome downstream of fadA, a !-ketoacyl-CoA thiolase that is thought to catalyse the final 
step in !-oxidation, and far, a fatty acid-CoA racemase, which is involved in the !-oxidation 
of branched fatty acids (Figure 1-21) (Rhee et al. 2005). It could be speculated that FadB1 is 
a multi-functional enzyme much like the single, multi-domain FadB protein in E. coli. This 
could further augment the degeneracy between the putative five Mt-FadB enzymes. 
 
 
 
FIGURE 1-21. Map of the M. tuberculosis genome region encoding the !-oxidation 
enzymes fadA and fadB. It is thought fadA catalyses the last step in the pathway, thiolysis, 
whereas fadB catalyses the hydration of the !-enoyl double bond to a !-hydroxy group. The 
upstream gene far encodes a fatty acid-CoA racemase, which is involved in the !-oxidation 
of branched fatty acids. 
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FadB2 (!-hydroxyacyl-CoA dehydrogenase), also non-essential, is thought to subsequently 
reduce the hydroxyl group to a keto function. There are three additional FadB enzymes 
(FadB3–5), whose function(s) are as yet unknown. The genes may be involved in !-
oxidation, but it is equally likely, as found with the fadD homologues, that they catalyse 
different steps of lipid metabolism or have an unrelated function. Regarding FadA, there are 
six known genes in M. tuberculosis numbered 1 to 6. In E. coli, FadA is a !-ketoacyl-CoA 
thiolase, which completes the !-oxidation process using CoA-SH to produce acetyl-CoA and 
a new acyl-CoA chain that is shorter by two carbons. Recently, fadA5 (Rv3546) has been 
shown to be involved in cholesterol !-oxidation and is essential for utilisation of cholesterol 
as the cells’ sole carbon source (Nesbitt et al. 2010). These studies demonstrated that the 
reaction catalysed by FadA5 was thiolysis using acetoacetyl-CoA, which they found to be 
consistent with !-ketoacyl-CoA thiolysis in cholesterol metabolism. 
 
Two further enzymes are required for the metabolism of unsaturated fatty acids in order to 
remove the cis double bond (Figure 1-22). The first is a 2,4-dienoyl-CoA reductase, named 
FadH in E. coli, which yields the trans bond (3-enoyl-CoA), and the second is enoyl-CoA 
isomerase, which moves the double bond to an even carbon (e.g. #3!#2) to resume normal 
!-oxidation (van Roermund et al. 1998). FadH is a strictly NADPH-dependent flavoprotein 
(1 mol FAD/mol enzyme), which occurs as a monomer with a calculated molecular weight of 
70,000 kDa (Dommes & Kunau 1984). Studies performed on the substrate specificity of E. 
coli FadH (Ec-FadH) have demonstrated that it is capable of reducing both 2-trans,4-trans-
enoyl-CoA and 2-trans,4-cis-enoyl-CoA, but has no activity on either cis- or trans-
monounsaturated acyl-CoA esters (Dommes & Kunau 1984). The Ec-FadH enzyme reaction 
is thought to occur in two half reactions (He et al. 1997): 
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The importance of the genes involved in lipid metabolism is evident from the high 
percentage of the M. tuberculosis genome dedicated to the task; altogether, around 250 
enzymes are implicated in fatty acid metabolism (Cole et al. 1998). Taking all this into 
consideration, it is clear that the enzymes of these essential pathways could offer excellent 
drug targets, although overcoming the apparent redundancy may be a problem. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1-22. The !-oxidation of unsaturated fatty acids. Two further enzymes are 
required for the metabolism of unsaturated fatty acids in order to remove the cis double 
bond. The first is NADPH-dependent 2,4-dienoyl CoA reductase (FadH), which yields the 
trans bond and the second is enoyl CoA isomerase, which moves the double bond to an 
even carbon to resume normal !-oxidation. Adapted from van Roermund et al. (1998). 
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1.7. Control of tuberculosis 
1.7.1. Vaccines. 
Currently, the only vaccine against TB is the attenuated form of M. bovis: Bacille Calmette-
Guérin (BGC). This BCG vaccine is part of a collaborative project with organisations such as 
WHO, UNICEF and GAVI called the Expanded Programme on Immunization. Established in 
1974, the project aimed to immunise every child in the world against a variety of lethal 
diseases, including TB, by 1990 (UNICEF 2010). It has been shown that the vaccine is most 
effective in newborns and children, reducing the risk of TB by an average of 50 % (Colditz et 
al. 1995). However, the report showed that in adults this protection has been found to range 
from 0–83 %. 
 
It is because of this limited protection that new vaccines are being developed. Two such 
examples are the recBCG vaccine and the MVA85A booster vaccine. The recombinant 
#ureC hly+ BCG, or recBCG, vaccine is aimed at replacing the current BCG vaccine. This 
strain is deficient in the urease enzyme ureC and expresses the listeriolysin O protein of 
Listeria monocytogenes, a pore-forming hemolysin (Geoffroy et al. 1987). Compared to the 
normal BCG vaccine, the recBCG reduced bacterial load in the lungs and spleen of mice 
challenged with M. tuberculosis H37Rv by 1 log (Tchilian et al. 2009). 
 
Another vaccine, currently being tested, is the modified vaccinia virus Ankara strain, which 
expresses the M. tuberculosis antigen 85A (MVA85A). This has been designed to work 
synergistically with the BCG vaccine to boost efficacy. One group has shown that co-
administration of BCG and MVA85A significantly increased the 85A-specific CD4 response 
in the spleen. Nevertheless, this viral booster did not improve on the protection achieved with 
BCG or recBCG vaccine alone (Tchilian et al. 2009). Another group, however, has found 
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promising results, demonstrating enhanced protection especially in the lungs of BCG-
MVA85A co-immunised cattle, reducing the median bacterial lung scores from 10.5 to 2.5 
(Vordermeier et al. 2009). 
 
1.7.2. WHO initiatives. 
In 1991, the WHO introduced the DOTS treatment, an acronym for Directly Observed 
Therapy, Short-course. This follows the patient from the initial positive screen for disease 
through to appropriate medication and monitored outcome (Obermeyer et al. 2008). 
Although many countries have adopted the DOTS scheme, the WHO also initiated a “Stop 
TB” campaign in 2006 (WHO 2010). This strategy established six main aims for 2006–2015, 
including increasing uptake of DOTS and promoting awareness of the rising multidrug-
resistant and extensively drug-resistant cases of TB. The target by 2015 is to have reduced 
the prevalence of TB by 50 % compared to that in 1990. During the years from 1990 to 2007, 
the WHO estimated the prevalence dropped from 300 to 206 per 100,000 population. By 
2050, the aim is to reduce this to just 1 case per million people per year (WHO 2009). 
 
Despite being a called a short course, DOTS chemotherapy requires a strict therapeutic 
regimen involving a cocktail of drugs administered over a minimum of six months. The 
current standard DOTS treatment involves taking rifampicin, isoniazid, ethambutol, 
pyrazinamide and (in some cases) streptomycin daily for the first two months, followed by 
isoniazid and rifampicin thrice weekly for the ensuing four months (Cox et al. 2006). If the 
cells are resistant to one or more drugs, the regimen is changed and extended (Table 1-3) 
(Campbell & Bah-Sow 2006). Due to this regime, one of the main reasons for relapse in TB 
infection is drug non-adherence, especially when in most cases the patient’s symptoms are 
reduced within a few months. Non-completion of the DOTS course not only leaves the 
patient infected but also can result in drug resistance. 
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TABLE 1-3. Common treatment regimens for patients suffering from drug-resistant 
tuberculosis. 
 
 
1.7.3. Currently used drugs. 
Anti-tubercular treatment involves targeting essential systems in the cell. Due to the 
uniqueness and vast number of genes involved in lipid metabolism, the enzymes involved in 
this pathway provide excellent drug targets. Some of the most successful anti-TB treatments 
currently used act against this aspect of M. tuberculosis, and much work is underway to find 
new drug targets and novel compounds against these essential components. Other drugs used 
include those that disrupt DNA replication, translation and protein synthesis. 
 
1.7.3.1. Isoniazid, pyrazinamide and ethionamide. 
These three drugs are fatty acid synthase (FAS) inhibitors. Isonicotinic acid hydrazide, or 
isoniazid (Figure 1-23 A), was first introduced in 1952 and today is one of the most widely 
prescribed and potent anti-tubercular drugs, with a minimum inhibitory concentration in 
drug-sensitive M. tuberculosis strains of <0.05 µg/ml (Herzog 1998, Kremer & Besra 2002). 
Isoniazid is a pro-drug that targets mycolic acid biosynthesis. It is activated by mycobacterial 
KatG, a catalase peroxidase, which has been shown to oxidise the drug via a series of highly 
reactive transition states (Zhang et al. 1992, Zhang & Young 1993). It is these electrophilic 
intermediates that form adducts with NAD+, which act as competitive inhibitors of InhA in a 
two-step process (Ducasse-Cabanot et al. 2004). The inhA gene encodes the NADH-
Rifampicin-resistant TB Isoniazid-resistant TB Multi-drug-resistant TB 
• Isoniazid 18 months 
• Ethambutol and /or 
pyrazinamide 18 months 
• Rifampicin 12 months 
• Ethambutol or 
pyrazinamide 12 months 
• Five drugs initially, then 
three drugs for 18–24 
months 
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dependent enoyl-AcpM reductase, which, in the last step of the FAS-II cycle, removes the 
#2-double bond to produce the saturated fatty acid (Figure 1-8) (Bhatt et al. 2007a). This 
hypothesis is derived from evidence where mutation of the katG or inhA gene confers 
resistance, although mutations in other genes, for example ahpC and kasA, have the same 
effect (Kremer & Besra 2002, Vilchèze et al. 2000). Vilchèze and co-workers (2000) 
demonstrated that inhA is essential for cell viability by isolating a strain of M. smegmatis 
with a temperature-sensitive mutation in the inhA gene. When inactivated at 42 °C, mycolic 
acid biosynthesis was halted and the cells lysed, an effect seen also upon isoniazid treatment. 
Isoniazid has also been shown to inhibit MabA (!-ketoacyl-ACP reductase), the enzyme that 
catalyses the second step in the FAS-II cycle, reducing the !-keto functional group to a !-
hydroxyl (Ducasse-Cabanot et al. 2004). The report by Ducasse-Cabanot et al. (2004) 
showed how structurally and functionally similar InhA and MabA are, and demonstrated in 
vitro that an adduct forms between the activated isoniazid drug and the NADPH co-factor, 
which MabA uses, binds to and obstructs the enzyme active site. 
 
 
 
 
 
FIGURE 1-23. Currently used anti-tubercular drugs that target fatty acid biosynthesis. 
(A) Isoniazid, (B) Pyrazinamide, (C) Ethionamide. 
 
Pyrazinamide (Figure 1-23 B) is used along with isoniazid and rifampicin to shorten the 
DOTS course from one year to six months. It appears to work specifically against semi-
dormant bacilli i.e. those in the acidic conditions of the phagosome. Akin to isoniazid, 
pyrazinamide is a pro-drug that is activated by its conversion to pyrazinoic acid, an amide 
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hydrolysis reaction catalysed by the product of pncA, pyrazinamidase (Zimhony et al. 2007). 
The target of pyrazinoic acid is the FAS-I system, where it prevents the elongation of C16 to 
C24 / 26 (Zimhony et al. 2000). 
 
Ethionamide is a second-line drug and is mainly used in the treatment of drug-resistant 
tuberculosis (Wang et al. 2007a). It is the structural analogue of isoniazid (Figure 1-23 C) 
and consequently both compounds have been shown to target InhA. Indeed, a single Ser-94-
Ala point mutation in the inhA gene is sufficient to cause both isoniazid and ethionamide 
resistance (Banerjee et al. 1994). Ethionamide is also similar to isoniazid in that it too is a 
pro-drug, although mutational studies in the katG gene have shown that it is not activated in 
the same way (Morlock et al. 2003). Subsequent studies identified the activator gene as ethA, 
a flavin mono-oxygenase that catalyses the cleavage of a carbon-carbon bond next to 
carbonyl, thus detoxifying ketones to esters and cyclic ketones to lactones via a Baeyer-
Villiger oxidation reaction (DeBarber et al. 2000, Dover et al. 2004). 
 
More recently, other compounds have been shown to inhibit mycolic acid biosynthesis in 
mycobacteria. One example of a promising anti-TB drug is platensimycin. A report by Wang 
et al. (2006) showed that the compound has good activity against Staphylococcus aureus, 
Enterococcus faecalis and Streptocococcus pneumoniae by specifically targeting the !-
ketoacyl-ACP synthases FabF and FabH of the FAS-II cycle. Part of this PhD project has 
been to test the activity of platensimycin against mycobacteria (see Chapter 2). Another 
prospective drug is thiolactomycin, which has been shown to target the mycobacterial FAS-II 
system with an MIC of 30 µg/ml in M. bovis BCG (Kremer et al. 2000a, Slayden et al. 1996). 
Treatment of wild-type M. bovis BCG with thiolactomycin alters both the "- and keto-
mycolic acids, even at low concentrations (10 µg/ml). With evidence that over-expression of 
Mt-KasA and Mt-KasB in M. bovis BCG confers resistance, it appears that the drug targets 
Chapter 1 General Introduction 
 
 60 
these enzymes specifically (Kremer et al. 2000a). The most promising aspects of developing 
thiolactomycin as a novel TB drug are that, because it targets FAS-II exclusively, and not 
FAS-I, it is unlikely to be cytotoxic and, also, it has been shown that isoniazid-resistant 
strains of mycobacteria are particularly sensitive to thiolactomycin treatment (Kremer et al. 
2000a, Slayden et al. 1996). 
 
Triclosan has typically been used as a non-specific microbicide in items such as deodorant, 
soaps and toothpaste (Bhargava & Leonard 1996). It has since been shown, however, to 
directly target E. coli FabI, the homologue of which in mycobacteria is InhA (Heath et al. 
1998). More recently, the binding model of triclosan has been described as reversible and 
dependent on NAD+ binding, indicating that it competes with the fatty acyl substrate for 
binding (Kuo et al. 2003). 
 
Further examples of prospective drugs are those that target the !-hydroxyacyl-AcpM 
dehydratase enzymes of the FAS-II cycle. The FabZ and FabA dehydratase enzymes of 
pathogens such as Campylobacter jejuni, Plasmodium falciparum, Pseudomonas aeruginosa 
and E. coli have been well studied, however, there are still several candidate genes for the 
homologous enzymes in M. tuberculosis (Heath & Rock 1996a, Kimber et al. 2004, 
Kirkpatrick et al. 2009, Sharma et al. 2003). It was only recently that the enzymes encoded 
by the Rv0635-Rv0636-Rv0637 gene cluster were identified in M. tuberculosis as the 
potential missing dehydratases, and their essentiality highlights them as excellent new 
candidates for anti-TB drugs (Brown et al. 2007b, Sacco et al. 2007). An example of a group 
of compounds that inhibit this activity are flavonoids, polyphenolic ketone-containing 
secondary metabolites found widely in the plant kingdom that are collectively known as 
Vitamin P. These compounds are known to help defend plants from attack by microbes, 
insects and fungi and have therefore attracted attention as potential anti-microbials for use in 
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mammals (Galeotti et al. 2008, Orhan et al. 2009). Recently, one study has shown that 
various flavonoids isolated from the marine sponges Spongia spp. and Ircinia spp. have in 
vitro activity against species of the parasitic protozoa Trypanosoma, Leishmania and 
Plasmodium (Orhan et al. 2010). Previously, Tasdemir et al. (2006) showed that the 
flavonoid targets within P. falciparum are enzymes of fatty acid biosynthesis, FabG, FabZ 
and FabI. Knowing the similarity between this fatty acid biosynthetic system and FAS-II of 
mycobacteria, Brown et al. (2007b) tested five flavonoids against M. bovis BCG. Two in 
particular, butein and isoliquirtigenin, appeared to inhibit this enzyme with MICs as low as 
150 µM. Butein appeared to target FAS-II specifically, although over-expression of Rv0636 
did not afford much resistance. It is therefore likely that the flavonoid targets more than one 
enzyme of the cycle. 
 
The compounds NAS-21 (4,4,4-trifluoro-1-(4-nitrophenyl)butane-1,3-dione) and NAS-91 (4-
chloro-2-[(5-chloroquinolin-8-yl)oxy]phenol) have previously been shown to target the 
homologous enzyme, FabZ, in P. falciparum (Sharma et al. 2003). A library of NAS-21 and 
NAS-91 analogues was generated by Bhowruth et al. (2008) and the compounds were tested 
in a similar way to the flavonoids, against wild-type M. bovis BCG and the Rv0636 over-
expressing strain. Several new compounds had encouraging results, showing MIC99 values as 
low as 18 µg/ml against whole cells. One NAS-21 analogue (4,4,4-trifluoro-1-(4-
ethyl)butane-1,3-dione) demonstrated FAS-II specificity with an IC50 of 19 µg/ml, a figure 
that increased 4-fold in the over-expressing strain. This provides evidence not only that 
Rv0636 is involved in the !-hydroxyacyl-AcpM dehydratase reaction but also that the 
scaffold on which the NAS analogues are based has promising anti-mycobacterial activity. 
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1.7.3.2. Ethambutol. 
Ethambutol (Figure 1-24) was first introduced as an anti-TB drug in 1962. It is a very 
efficient agent and is normally used in conjunction with isoniazid. It is a bacteriostatic drug 
that is only active against actively dividing cells. Evidence from mutational studies has 
shown that ethambutol targets the emb locus, which encodes arabinosyltransferases, therefore 
acting by specifically inhibiting AG and LAM synthesis (Kremer & Besra 2002). The 
incorporation of D-arabinose into AG and LAM of the cell wall is prevented, thus inducing a 
build-up of the intermediate decaprenyl-P-arabinose (Takayama & Kilburn 1989). This 
indirectly affects the lipids of the cell wall, since disruption of the AG layer removes the 5-
hydroxyl groups to which the mycolic acids are attached. This not only results in an 
accumulation of TMM, TDM and free mycolic acids, but also increases the permeability of 
the cell wall, allowing other drugs used in combination (e.g. isoniazid) to gain full access to 
the cell’s cytoplasm. 
 
 
 
FIGURE 1-24. Ethambutol. 
 
1.7.2.3. Rifampicin and streptomycin. 
Both of these drugs inhibit protein synthesis. Rifampicin (Figure 1-25 A) was introduced as 
an anti-tubercular agent in 1968, significantly reducing the length of TB treatment. The 
compound targets DNA-dependent RNA polymerase, specifically the !-subunit of the 
catalytic core of prokaryotic RNA polymerase. Ezekiel and Hutchins (1968) and others have 
found that mutations conferring rifampicin resistance are almost solely in the rpoB gene, 
which encodes the RNA polymerase !-subunit. Rifampicin acts by blocking the second or 
third phosophodiester bond between nucleotides from being made (McClure & Cech 1978). 
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The same study showed that, once an RNA chain has been synthesised and has entered the 
elongation phase, the transcript and polymerase are unaffected by rifampicin, leading to the 
hypothesis that the compound works by steric hindrance. Evidence from co-crystallisation of 
the drug and the RNA polymerase core of Thermus aquaticus supported this theory, showing 
how the drug is positioned alongside a highly conserved loop domain, which is flanked by 
regions that contain mutations in rifampicin-resistant strains (Campbell et al. 2001, Zhang et 
al. 1999). The consequence of this obstruction is prevention of transcription of DNA to RNA, 
which subsequently provides no mRNA for protein translation. 
 
 
 
 
 
 
 
 
FIGURE 1-25. Currently used anti-tubercular drugs that target protein synthesis. (A) 
Rifampicin, (B) Streptomycin. 
 
The antimicrobial activity of streptomycin (Figure 1-25 B), a member of the aminoglycoside 
group of compounds, was discovered in 1943 by Selman Waksman and co-workers (Jones et 
al. 1944) and was the first effective drug to be used against TB (Emmart 1945, Greenwood et 
al. 2007, Herzog 1998, Schatz & Waksman 1944, Smith & McClosky 1945, Wolinsky & 
Steenken 1947, Youmans 1945). Originally isolated from the actinomycete Streptomyces 
griseus, it is a broad-spectrum compound that is bactericidal towards Gram-positive and 
Gram-negative cells. Streptomycin also inhibits protein synthesis but its mechanism differs 
N
N
N
NH
O
OH
HO
OH
O
OH
OH
H
O
O
O
O
O
O
HO
HO
NH
O
HO
H3C
O
HO
O
OH
CH3
OH
OH
HO
N
N
NH2H2N
H2N
NH2
!" #"
Chapter 1 General Introduction 
 
 64 
from that of rifampicin. The drug binds irreversibly to the S12 protein of the 30S subunit of 
bacterial ribosomes. Resistance to streptomycin can be achieved by a single point mutation 
within the S12 protein, for example Lys-42-Asp/Thr/Arg or Lys-87-Arg. The drug inhibits 
the initiation of peptide chains by preventing the transfer of peptidyl tRNA from the A-site to 
the P-site. This stalls peptide synthesis because there is no space for the next formyl-
methionyl-tRNA to bind. Streptomycin can stop synthesis at the start of translation as well as 
slowing elongation of partly completed chains. The structural differences between 
mammalian and bacterial ribosomes allows for target specificity. Today, because bacterial 
resistance is acquired so rapidly, streptomycin is used in combination with other agents to 
treat TB as a second-line drug and where other more expensive treatments cannot be 
afforded. 
 
1.8. Drug resistance 
Statistics showing an increase in multidrug-resistant (MDR) and extensively drug-resistant 
cases (XDR) of TB clearly demonstrate the immense necessity for new therapeutics. The 
2009 WHO report estimated that, of the 10.4 million cases of TB worldwide, nearly 5 % 
were MDR-TB. More than half of these were in newly presenting cases, with only 1.9 % 
being in patients that had previously been treated for TB. It is not then surprising that the 
countries with the highest incidence of MDR-TB correlate with those of the highest incidence 
of newly diagnosed TB cases – India and China. 
 
Resistance can be acquired through a variety of means, such as spontaneous chromosomal 
mutation in the target gene, gene over-expression, drug efflux or inactivation mechanisms, 
and preventing the drug from reaching the target (Zhang et al. 2005). Drug resistant TB 
strains first arose shortly after the introduction of streptomycin. Changes to the cell that 
confer resistance are selected for under the pressure of chemotherapeutics. The rationale for 
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combination therapy, therefore, is to reduce the probability of drug resistance developing; a 
cell is much more likely to acquire one mutation in a gene targeted by a drug than two or 
three unlinked genes. Generation of spontaneous genetic mutations is accelerated by mono-
therapy, be it due to patient drug non-adherence, shortfalls in drug distribution or poor drug 
prescription (Zhang & Yew 2009). The genes found to have mutations in clinical isolates and 
the subsequent drug resistance are outlined in Table 1-4 (Zhang & Yew 2009). 
 
Much work is underway looking at M. tuberculosis with a view to finding new drug targets. 
With the publication of the high G+C-rich M. tuberculosis H37Rv genome in 1998, a strain 
originally isolated in 1905, this task has been taken to a new level and the insight into the 
pathogen has advanced greatly (Cole et al. 1998). With this and the enormous progression in 
molecular biology over the past decade or so, the understanding of M. tuberculosis – biology, 
mechanisms of drug action and resistance – has increased vastly. 
 
1.9. Project aims 
With the prevalence of multidrug-resistant cases of tuberculosis on the increase and reports 
telling of strains evolving that are resistant to all drugs currently used, the need for new, 
cheap and effective chemotherapy is as great now as it was 100 years ago. Therefore, there 
are two main aims to this PhD project: 
 
1. To test novel compounds against known and highly effective targets such as the 
essential FAS-II enzymes. A combination of whole cell experiments using the well 
established lab surrogates, M. bovis BCG and M. smegmatis, as well as M. 
tuberculosis, and in vitro protein assays will be used. 
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2. To find new essential genes that have the potential to be novel drug targets, focussing 
on the little-explored !-oxidation (Fad) enzymes of M. tuberculosis, M. bovis BCG 
and M. smegmatis. Biochemical characterisation will help elucidate protein functions 
in vitro, and generating knock-out mutants using the same non-pathogenic models 
will aid the study of protein functionality in vivo. 
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  CHAPTER 2 
Novel compounds targeting 
mycobacterial fatty acid and 
mycolic acid biosynthesis 
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2.1. Introduction 
Tuberculosis remains one of the foremost diseases of the world despite infection of drug-
susceptible strains being almost entirely curable (Palomino et al. 2009). There are several 
well-recognised key issues that prevent TB from being eradicated, including the extensive 
period of time necessary for treatment and the plethora of drugs required. These factors are 
inextricably linked to cost of treatment, failure to complete drug courses and the evolution of 
drug-resistant strains, the synergistic co-infection of TB and HIV-1, and the nature of TB 
infection – persistent M. tuberculosis cells lying dormant in an asymptomatic host for 
potentially decades (Palomino et al. 2009). The drugs used today are those developed in the 
mid-twentieth century; no new anti-TB drugs have passed the clinical trials stage and been 
approved for general use since the 1960s. The need for inexpensive new drugs that are vastly 
more efficient is therefore imperative. 
 
Today, several strategies are available for screening new compounds for anti-tubercular 
activity. The potentiality of compounds tested here have been identified and developed in the 
following ways: 
 
1. From screening thousands of naturally occurring small molecules and testing against 
a wide range of bacterial species. 
2. From in silico drug design, using the crystal structures of known essential M. 
tuberculosis enzymes and creating a library of pharmacophores. 
3. From a chemically synthesised library of analogues based on a scaffold that has 
previously been identified as having anti-microbial and anti-fungal properties. 
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All the compounds tested here are related by targeting enzymes that are involved in 
mycobacterial fatty acid biosynthesis (Figure 2-1). The fatty acid synthase I (FAS-I) enzyme 
is found in mammals as well as bacteria meaning compounds that target this system are 
generally not desirable. FAS-II, however, is only found in bacteria, Archaea and plants and, 
although an ideal drug target would be unique to mycobacteria so as to minimise transfer of 
resistance factors to and from other bacteria, the system nevertheless represents an excellent 
pathway to block (Tripathi et al. 2004). Briefly, the FAS-II process in M. tuberculosis is 
initiated by the condensation of an acyl-CoA (starter unit from FAS-I) and malonyl-AcpM 
(extending unit), a reaction catalysed by Mt-FabH (Brown et al. 2005). AcpM then shuttles 
the growing fatty acyl chain between the active sites of the other FAS-II components 
(Kremer et al. 2001b). The resulting !-ketoacyl-AcpM is reduced by a !-ketoacyl-AcpM 
reductase (MabA) (Banerjee et al. 1998) to form a !-hydroxyacyl-AcpM intermediate, which 
is then dehydrated by the !-hydroxyacyl-AcpM dehydratase (Rv0635/Rv0636/Rv0637, 
named HadA, HadB and HadC respectively) to form an enoyl-AcpM intermediate (Brown et 
al. 2007a, Brown et al. 2007b, Sacco et al. 2007). Reduction to the aliphatic chain and 
completion of the cycle is performed by an enoyl-AcpM reductase (InhA) to yield an AcpM-
bound acyl chain that is two carbons longer (Banerjee et al. 1994, Kikuchi & Kusaka 1984, 
Quémard et al. 1995). Two other KAS enzymes, KasA and KasB, initiate the subsequent 
reductive FAS-II cycles (Figure 2-1; Kremer et al. 2000a, Mdluli et al. 1998, Schaeffer et al. 
2001). The C56 mero-chain is then condensed with a C26 fatty acid, a reaction catalysed by 
Pks13, to yield an oxo-mycolic acid intermediate that is then reduced to form a mature 
mycolic acid (Gande et al. 2004, Lea-Smith et al. 2007, Portevin et al. 2004, Portevin et al. 
2005, Takayama et al. 2005). 
 
The products of both FAS-I and FAS-II provide precursors for the lipid-rich cell wall, which 
acts as both a virulence factor and a shield against natural host killing mechanisms and 
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chemotherapy (Bhatt et al. 2007a). However, its uniqueness also provides a very attractive 
drug target, which has been exploited by the use of isoniazid, a front-line drug that impedes 
the production of essential cell wall components, such as mycolic acids. Isoniazid 
specifically inhibits two FAS-II cycle enzymes: primarily InhA, which catalyses the last step 
of the cycle, but also MabA, which catalyses the second, reduction step. To date, isoniazid is 
the only drug used that targets the FAS-II system, however there are many reports of newly 
discovered compounds that also take advantage of this system (Brown et al. 2007b, Slayden 
et al. 1996, Wang et al. 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2-1. Fatty acid and mycolic acid biosynthetic pathways in M. tuberculosis. 
Many of the currently used drugs target enzymes of FAS-II because the system is not 
present in mammals. Similarly, new compounds being developed aim to inhibit these same 
targets. Based on Brown et al. (2009). 
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Platensimycin (Figure 2-2 A) is a small molecular weight secondary metabolite from 
Streptomyces platensis whose antibacterial activity was originally recognised after screening 
over 80,000 naturally occurring small molecules (Wang et al. 2006). It has been shown to 
possess potent anti-microbial activity against Gram-positive bacteria including methicillin-
resistant Staphylococcus aureus (the hospital ‘super-bug’, MRSA) and vancomycin-resistant 
Enterococci. Activity against Gram-negative species, such as E. coli, appears to be lessened 
by the employment of efflux pumps. One of the main encouraging features of platensimycin 
is that it has minimal mammalian cytotoxicity and apparent lack of antifungal activity, 
indicating that platensimycin acts selectively (Wang et al. 2006). 
 
 
 
 
 
FIGURE 2-2. Novel compounds being tested for their ability to inhibit mycobacterial 
fatty acid biosynthesis enzymes. (A) Platensimycin, (B) Thiolactomycin, (C) Indole. 
 
Platensimycin has previously been shown to target fatty acid biosynthesis by specifically 
inhibiting the KAS I / II enzymes, FabB and FabF, of FAS-II (Wang et al. 2006, Wang et al. 
2007b). The homologous enzymes in M. tuberculosis are Mt-KasA and Mt-KasB, 
respectively (Brown et al. 2005, Choi et al. 2000). Here, the whole cell susceptibility of M. 
smegmatis and M. bovis BCG to platensimycin has been assessed. In addition, using discrete 
enzyme assays with purified Mt-KasA, Mt-KasB and Mt-FabH, platensimycin has been 
established as a promising lead compound for drug development. 
 
Thiolactomycin (Figure 2-2 B) is also a naturally occurring compound produced by a species 
of Nocardia that was originally found in a Japanese soil sample (Oishi et al. 1982). The 
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molecule contains a unique thiolactone moiety, classing it separately from other antibiotics. 
Whilst demonstrating in vivo activity against pathogens such as malaria and trypanosomes as 
well as TB, the promising aspect of thiolactomycin is its specificity towards FAS-II 
inhibition but not against FAS-I (Jones et al. 2004). Indeed, thiolactomycin benefits from its 
low molecular weight, its high water solubility, meaning it is absorbed rapidly when 
administered orally, and its apparent minimal toxicity in the mouse model (de Souza 2009, 
Miyakawa et al. 1982, Oishi et al. 1982). Thiolactomycin has been shown to nestle very well 
into the FabB active site (Mt-KasA homologue), causing minimal structural rearrangement, 
where it forms reversible, non-covalent hydrogen bonds with the two active site histidine 
residues (Price et al. 2001). Slayden et al. (1996) tested the activity of thiolactomycin against 
M. tuberculosis and M. smegmatis and found that the compound targets the AcpM-dependent 
FAS-II system with minimum inhibitory concentrations (MICs) of 25 and 75 µg/ml, 
respectively. Since then, the specific targets have been identified as KasA and KasB (Kremer 
et al. 2000a) and, more recently, the structure of Mt-KasA has been solved complexed with 
thiolactomycin (Luckner et al. 2009). Here, a library of thiolactomycin pharmacophores was 
developed with cost-effectiveness of compound production in mind. A chiral centre at the 5-
position of the structural scaffold means that synthesising analogues is expensive, both in 
terms of time and money, a fact that must be contemplated in view of drug accessibility in 
developing countries. The analogue library was therefore formed by simple modifications 
whilst basing the compound structure on that of the Mt-FabH active site and the reaction 
mechanism suggested by Sachdeva et al. (2008a, 2008b). 
 
Indole-containing compounds are known to have anti-microbial properties and indeed there 
are several reports of compounds containing the indole ring structure dating back over 10 
years (Figure 2-2 C). In 2003, a report was published showing how indole naphthyridinones 
act as inhibitors of the bacterial enoyl-ACP reductases FabI and FabK (Seefeld et al. 2003). 
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In the case of targeting the FAS-II enzyme InhA (the homologue of E. coli FabI), unlike 
diazoborines and triclosan, which act non-selectively, indole derivatives such as indole-5-
amides act directly against the enzyme. One problem with the current front-line drug 
isoniazid is that it requires activation by the enzyme KatG. This immediately provides the 
opportunity for resistance to develop and it has been estimated by Escalante et al. (1998) that 
50 % of clinical isoniazid-resistant cases of TB are caused by katG mutations. Therefore, 
drugs that do not require this activation are the most promising. In 2003, Kuo et al. undertook 
a high-throughput screen of approximately 500,000 compounds against Mt-InhA. One 
compound, Genz-10850, an indole-5-amide, was found to have activity against both drug-
sensitive and drug-resistant M. tuberculosis and P. falciparum, the malaria-causing protozoan 
that also has a FAS-II system. When assayed against purified Mt-InhA, Genz-10850 
displayed an IC50 of 0.16 µM and one brominated derivative had an IC50 of 0.12 µM. Genz-
10850 was co-crystallised with Mt-InhA and the compound was found to occupy a larger 
portion of the active site than where the fatty acyl substrate or inhibitor triclosan binds (Kuo 
et al. 2003). Not only have indoles been used to target fatty acid biosynthesis but also a 
report from 2007 demonstrated how a novel N-substituted tetracyclic indole is capable of 
mimicking the binding of NAD+ with the essential M. tuberculosis enzyme LigA, a NAD+-
dependent DNA ligase, thus acting as an inhibitor (Srivastava et al. 2007). A report from 
2009 also highlighted azole-containing compounds that are normally used to treat fungal 
infection to be active against M. tuberculosis H37Rv. The possible mechanism is inhibition of 
the P450-dependent sterol 14!-demethylase, perhaps through co-ordination of the azole 
nitrogen with the haem iron in the cytochrome (Zampieri et al. 2009). Most recently, the 
structure of Mt-InhA with bound Genz-10850 has been used to study the bioactive 
conformation of the enzyme and as a basis for identifying new hypothetical compounds (Lu 
et al. 2010). 
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2.2. Materials and Methods 
2.2.1. Plasmids, strains and DNA manipulation. 
The E. coli mycobacterial shuttle vector pVV16 (a gift from Varalakshmi Vissa, Colorado 
State University, CO, USA) containing the hsp60 promoter and encoding a 6-histidine C-
terminal tag was used for the over-expression of Mt-KasA and Mt-KasB. All DNA 
manipulations were performed using standard protocols, as described by Sambrook & Russell 
(2001). Mt-kasA PCR amplification was performed using the upstream primer 5"-
gatcgatcaagcttgatgagtcagccttccaccg-3" and the downstream primer 5"-
gatcgatcaagcttgtaacgcccgaaggcaagc-3", which both contain HindIII restriction sites 
(underlined). The 1251 bp PCR product was then digested with HindIII and ligated with 
similarly digested pVV16, giving rise to pVV16-Mt-kasA. Mt-kasB was cloned similarly 
using the upstream primer 5"-gatcgatccatatggatgggggtccccccgctt-3" and the downstream 
primer 5"-gatcgatcaagcttgtaccgtccgaaggcgat-3", which contain NdeI and HindIII restriction 
sites, respectively (underlined). The 1317 bp PCR product was then digested with NdeI and 
HindIII and ligated with similarly digested pVV16, giving rise to pVV16-Mt-kasB. Mt-fabH 
was cloned similarly using the upstream primer 5"-gatcgatccatatggtaccgtccgaaggcgat-3" and 
the downstream primer 5"-gatcgatcaagcttacccttcggcattcgca-3", which contain NdeI and 
HindIII restriction sites, respectively (underlined). The 1033 bp PCR product was then 
digested with NdeI and HindIII and ligated with similarly digested pVV16, giving rise to 
pVV16-Mt-fabH. The pVV16-kasAB was constructed using the Mt-kasA upstream primer 
and the Mt-kasB downstream primer, the 2623 bp PCR product was then digested with NdeI 
and HindIII and ligated with similarly digested pVV16, giving rise to pVV16-Mt-kasAB. 
 
The pET28b-Mt-acpM and pET28b-Mt-fabD, pET28a-Mt-kasA and pET28b-Mt-kasB over-
expression plasmids for protein purification were provided by Dr. L. Kremer (Laboratoire de 
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Dynamique des Interactions Membranaires Normales et Pathologiques, Universités de 
Montpellier II et I) and the pET28a-Mt-fabH plasmid was constructed by Dr. A. Brown 
(Applied Biosciences, Northumbria University). 
 
The kasB-knockout phage phAE404 was used to construct a kasB deletion in M. bovis BCG 
(Bhatt et al. 2007b). The mutant was generated by Dr. A. Bhatt using specialised 
transduction, as described in Bardarov et al. (2002). The validity of the M. bovis BCG #kasB 
was confirmed by Southern blot analysis. The coding sequences of all the recombinant genes 
were verified by DNA sequencing. 
 
2.2.2. Protein over-expression and purification. 
2.2.2.1. Purification of Mt-AcpM. 
Over-expression of mycobacterial AcpM was performed as described (Kremer et al. 2001b). 
The pET28b-Mt-acpM over-expression plasmid was transformed into E. coli C41 (DE3) cells 
and incubated on Luria-Bertani (LB; Difco) agar supplemented with kanamycin (25 µg/ml). 
One colony was used to inoculate 5 ml LB broth containing kanamycin (25 µg/ml) and the 
culture was incubated in a rotary incubator overnight at 37 °C. The mini-culture was used to 
inoculate 1 l Terrific Broth containing kanamycin (25 µg/ml) and was incubated in a rotary 
incubator (180 rpm) at 37 °C until the OD600 had reached 0.6. At this point the cells were 
induced by adding 1 mM isopropyl !-D-1-thiogalactopyranoside (IPTG) and the culture was 
incubated overnight at 16 °C. The cells were harvested by centrifugation (4,500 $ g for 15 
min at 4 °C) and the pellets were stored at -20 °C for purification. 
 
Mt-AcpM-containing pelleted cells were resuspended in buffer A (0.02 M sodium phosphate, 
pH 7.9, 0.5 M NaCl) and lysed twice by French press. The crude lysate was centrifuged at 
27,000 $ g for 40 min at 4 °C to remove the insoluble components and the resulting clarified 
Chapter 2 Anti-mycobacterial Compounds 
!
 77 
lysate was applied to a Ni2+-charged 5 ml HisTrap™ HP affinity column (GE Healthcare). 
The column was washed with 10 column volumes of buffer A and the protein was eluted 
with a step-wise imidazole gradient of 10 mM, 20 mM, 30 mM, 40 mM (each of 25 ml), 50 
mM (30 ml) and 150 mM (15 ml). The fractions were analysed by 14 % SDS-PAGE 
followed by Coomassie staining. The 150 mM fraction contained the most pure AcpM 
protein, where two bands were visible corresponding to holo-AcpM (14.875 kDa) and acyl-
AcpM (15.135 kDa) (Kremer et al. 2001b). This fraction was dialysed twice against 50 mM 
Tris%HCl (pH 7.9), 50 mM NaCl at 4 °C. Dithiothreitol (DTT, 1.5 %) was added to the 
protein preparation to remove any contaminants and the acylated form of AcpM, followed by 
incubation in a rotary incubator at 37 °C for 36 h. Progress of the precipitation was 
monitored by SDS-PAGE gel and once completed, the preparation was centrifuged at 4,500 $ 
g for 10 min at 4 °C. The DTT was removed by dialysing the protein twice against 50 mM 
Tris%HCl (pH 7.9), 50 mM NaCl at 4 °C. The AcpM may be further purified using an 
additional two columns. Firstly using a Q-Sepharose anion exchange column (GE 
Healthcare), maintained at pH 7.9, where the protein is eluted using a salt gradient (0.05–1 M 
NaCl). Secondly using a Thiopropyl-Sepharose 6B column (Amersham Pharmacia Biotech) 
equilibrated in O2-free 50 mM Tris%HCl (pH 7.9). Here, the protein is eluted with a DTT 
gradient (10–25 mM). 
 
2.2.2.2. Purification of Mt-FabD. 
Over-expression of mycobacterial FabD was performed as described (Kremer et al. 2001b). 
The pET28b-Mt-fabD over-expression plasmid (provided by Dr. L. Kremer) was transformed 
into E. coli C41 (DE3) cells and incubated on LB agar supplemented with kanamycin (25 
µg/ml). One colony was used to inoculate 5 ml LB broth containing kanamycin (25 µg/ml) 
and the culture was incubated in a rotary incubator overnight at 37 °C. The mini-culture was 
used to inoculate 1 l Terrific Broth containing kanamycin (25 µg/ml) and was incubated in a 
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rotary incubator (180 rpm) at 37 °C until the OD600 had reached 0.6. At this point the cells 
were induced by adding 1 mM IPTG and the culture was incubated for 16 h at 16 °C. The 
cells were harvested by centrifugation (4,500 $ g for 15 min at 4 °C) and the pellets were 
stored at -20 °C for purification. 
 
Mt-FabD-containing pelleted cells were resuspended in buffer A and lysed by French press. 
The crude lysate was centrifuged at 27,000 $ g for 40 min at 4 °C to remove the insoluble 
components and the resulting clarified lysate was applied to a Ni2+-charged 1 ml HisTrap™ 
HP affinity column (GE Healthcare). The column was washed with 50 ml of buffer A and the 
protein was eluted with a step-wise imidazole gradient of 25 mM, 50 mM, 75 mM, 100 mM, 
150 mM, 250 mM and 500 mM (each of 10 ml). The fractions were analysed by 12 % SDS-
PAGE followed by Coomassie staining. One band at approximately 35 kDa was visible in the 
500 mM fraction. This fraction was dialysed three times against 50 mM Tris%HCl (pH 7.9), 
50 mM NaCl, 1 % glycerol at 4 °C. Protein concentration was estimated using the BCA 
Protein Assay kit (ThermoScientific) and the fraction was stored at -80 °C. 
 
2.2.2.3. Purification of Mt-FabH. 
Over-expression of mycobacterial FabH was performed as described (Heath & Rock 1996b). 
The pET28a-Mt-fabH over-expression plasmid was transformed into E. coli C41 (DE3) cells 
and incubated on LB agar supplemented with kanamycin (25 µg/ml). One colony was used to 
inoculate 5 ml LB broth containing kanamycin (25 µg/ml) and the culture was incubated in a 
rotary incubator overnight at 37 °C. The mini-culture was used to inoculate 1 l Terrific Broth 
containing kanamycin (25 µg/ml) and was incubated in a rotary incubator (180 rpm) at 37 °C 
until the OD600 had reached 0.6. At this point the cells were induced by adding 1 mM IPTG 
and the culture was incubated for 3 h at 37 °C. The cells were harvested by centrifugation 
(4,500 $ g for 15 min at 4 °C) and the pellets were stored at -20 °C for purification. 
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Mt-FabH-containing pelleted cells were resuspended in buffer A and lysed by French press. 
The crude lysate was centrifuged at 27,000 $ g for 40 min at 4 °C to remove the insoluble 
components and the resulting clarified lysate was applied to a Ni2+-charged 1 ml HisTrap™ 
HP affinity column (GE Healthcare). The column was washed with 50 ml of buffer A and the 
protein was eluted with a step-wise imidazole gradient of 25 mM, 50 mM, 110 mM and 500 
mM (each of 10 ml). The fractions were analysed by 12 % SDS-PAGE followed by 
Coomassie staining. One band at approximately 40 kDa was visible in the 500 mM fraction. 
This fraction was dialysed three times against 50 mM Tris%HCl (pH 7.9), 50 mM NaCl, 1 
mM EDTA, 5.6 mM !-mercaptoethanol, 1 % glycerol at 4 °C. Protein concentration was 
estimated using the BCA Protein Assay kit and aliquots of the fraction were stored at -80 °C. 
 
2.2.2.4. Purification of Mt-KasA. 
Over-expression and purification of mycobacterial KasA was adapted from Kremer et al. 
(2002a). The pET28a-Mt-kasA over-expression plasmid was transformed into E. coli Tuner™ 
cells and incubated on LB agar supplemented with kanamycin (25 µg/ml). One colony was 
used to inoculate 5 ml LB broth containing kanamycin (25 µg/ml) and the culture was 
incubated in a rotary incubator overnight at 37 °C. The mini-culture was used to inoculate 1 l 
Terrific Broth containing kanamycin (25 µg/ml) and was incubated in a rotary incubator (180 
rpm) at 37 °C until the OD600 had reached 0.6. At this point the cells were induced by adding 
1 mM IPTG and the culture was incubated for 16 h at 16 °C. The cells were harvested by 
centrifugation (4,500 $ g for 15 min at 4 °C) and the pellets were stored at -20 °C for 
purification. 
 
Mt-KasA-containing pelleted cells were resuspended in buffer A containing one EDTA-free 
complete protease inhibitor-cocktail tablet (Roche) to prevent Mt-KasA degradation during 
purification and a few grains of DNase I (New England Biolabs) to reduce the viscosity of 
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the lysate and remove unwanted DNA. Cell lysis was by French press and the crude lysate 
was centrifuged at 27,000 $ g for 40 min at 4 °C to remove the insoluble components. The 
resulting clarified lysate was applied to a Ni2+-charged 1 ml HisTrap™ HP affinity column 
(GE Healthcare). The column was washed with 50 ml of buffer A containing 50 mM 
imidazole and the protein was eluted in 5 ml fractions with a step-wise imidazole gradient of 
100 mM, 150 mM, 200 mM, 300 mM and 500 mM. The fractions were analysed by 12 % 
SDS-PAGE followed by Coomassie staining. One small band at approximately 40 kDa was 
visible in the 150 mM and 200 mM fractions. These fractions were pooled and dialysed three 
times against 50 mM Tris%HCl (pH 7.5), 20 mM NaCl, and 10 % glycerol at 4 °C. The first 
dialysis contained 1 mM EDTA to remove any leached nickel. Protein concentration was 
estimated as 0.3 mg/ml using the BCA Protein Assay kit and the protein was stored at -20 °C. 
 
2.2.2.5. Purification of Mt-KasB. 
Over-expression of mycobacterial KasB was performed as described (Sridharan et al. 2007). 
The pET28b-Mt-kasB over-expression plasmid was transformed into E. coli C41 (DE3) cells 
and incubated on LB agar supplemented with kanamycin (25 µg/ml). One colony was used to 
inoculate 5 ml LB broth containing kanamycin (25 µg/ml) and the culture was incubated in a 
rotary incubator overnight at 37 °C. The mini-culture was used to inoculate 1 l Terrific Broth 
containing kanamycin (25 µg/ml) and was incubated in a rotary incubator (180 rpm) at 37 °C 
until the OD600 had reached 0.6. At this point the cells were induced by adding 1 mM IPTG 
and the culture was incubated for 16 h at 16 °C. The cells were harvested by centrifugation 
(4,500 $ g for 15 min at 4 °C) and the pellets were stored at -20 °C for purification. 
 
Mt-KasB-containing pelleted cells were resuspended in buffer A and lysed by French press. 
The crude lysate was centrifuged at 27,000 $ g for 40 min at 4 °C to remove the insoluble 
components and the resulting clarified lysate was applied to a Ni2+-charged 1 ml HisTrap™ 
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HP affinity column (GE Healthcare). The column was washed with 50 ml of buffer A and the 
protein was eluted in 10 ml fractions with a step-wise imidazole gradient of 25 mM, 50 mM, 
75 mM, 100 mM, 150 mM, 250 mM and 500 mM. The fractions were analysed by 12 % 
SDS-PAGE followed by Coomassie staining. One band at approximately 60 kDa was visible 
in the 100 mM fraction. This fraction was dialysed three times against 50 mM Tris%HCl (pH 
7.9), 50 mM NaCl, 1 mM EDTA, 5.6 mM !-mercaptoethanol, 1 % glycerol at 4 °C. Protein 
concentration was estimated using the BCA Protein Assay kit and aliquots of the protein 
were stored at -20 °C. 
 
2.2.3. Preparation of FAS-I and FAS-II crude cell-free extracts. 
The soluble cytosolic and particulate cell wall enzyme fractions from M. smegmatis were 
prepared as described (Slayden et al. 1996). Wild-type M. smegmatis mc2155 cultures (15 
litres) were grown to an OD600 of 0.8 and centrifuged at 6,000 $ g to obtain one pellet. The 
cells were resuspended in 30 ml buffer A (50 mM MOPS%KOH, pH 7.9, 10 mM MgCl2, 5 
mM !-mercaptoethanol) and lysed by probe sonication (10 cycles of 60 sec pulses followed 
by 90 sec cooling intervals). The crude lysate was centrifuged at 27,000 $ g for 1 h at 4 °C. 
The supernatant was removed and centrifuged at 100,000 $ g for 3 h. The resulting 
supernatant was decanted into a clean tube and, to precipitate the protein, 6.78 g ammonium 
sulfate was added initially to give a final saturation concentration of 40 % (computed using 
<http://www.proteinchemist.com/cgi-bin/s2.pl>). The solution was mixed at 4 °C overnight. 
The next day, the preparation was centrifuged at 27,000 $ g for 1 h; the pellet being the 0–40 
% fraction. Again, the supernatant was removed and 8.68 g ammonium sulfate was added to 
give a new final saturation concentration of 80 %. The solution was mixed for 4 h at 4 °C 
before pelletting the 80 % fraction by centrifugation (27,000 $ g for 1 h at 4 °C). The 
supernatant was discarded and the pellet was resuspended in 5 ml buffer A. The 
concentration of the protein preparation, containing both FAS-I and FAS-II activity, was 
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determined using the BCA Protein Assay kit and the protein was stored for as little time as 
possible at -20 °C before use. FAS-I extracts from C. glutamicum were kindly provided by 
Dr. A. Brown. 
 
2.2.4. Generation of the pharmacophore libraries. 
The library of thiolactomycin-derivatives was produced by Al-Balas and co-workers (2009) 
at the Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde University, 
and the compounds were provided for in vitro testing. Briefly, using the structure of the E. 
coli Mt-FabH homologue Ec-FabB complexed with thiolactomycin, the positioning of the 
drug in the active site was first assessed. The computer program GOLD was then used to 
calculate protein-ligand docking of the thiolactomycin scaffold within the Mt-FabH active 
site. Once the key functional groups and active site residue interactions had been identified, a 
series of thiazole derivatives was chemically synthesised. 
 
The series of 1,6-disubstituted indole-2-carboxylic acid analogues tested here has previously 
been tested against pathogenic Francisella tularensis bacteria (Wen et al. 2009). This group 
provided the same compounds for in vitro testing against M. tuberculosis. 
 
2.2.5. Whole cell effects of platensimycin on Mycobacterium spp. 
Experiments using M. tuberculosis CDC1551 was kindly performed by Dr. A. Bhatt. Briefly, 
the strain was grown in 7H9 broth supplemented with 10 % Middlebrook OADC enrichment 
(BBL™) and 0.05 % Tween®-80 to an OD600 of 0.4. Following serial 10-fold dilutions, 20 µl 
of each dilution was spotted on to 7H10 agar plates containing 0–128 µg/ml platensimycin. 
The minimum concentration of platensimycin required to inhibit growth of single colonies 
was noted as the MIC. 
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M. smegmatis-pVV16 and over-expression strains were grown in LB broth (10 ml) with 25 
µg/ml kanamycin and 0.05 % Tween®-80 at 37 °C to an OD600 of 0.25. At this point, the 
minimum inhibitory concentration of platensimycin was added (14 µg/ml) and the OD600 was 
recorded over 72 h. Samples (100 µl) were taken periodically and stored at 4 °C for viable 
count analysis. After 72 h the cells were pelleted by centrifugation and washed with 8 ml of 
phosphate-buffered saline (PBS) to remove the platensimycin and the pellet was resuspended 
in fresh LB media. The OD600 was recorded over 55 h and 100 µl samples taken and viable 
counts determined at each time point. Briefly, the 100 µl samples were serially diluted to 10-7 
and 10 µl samples, in triplicate, were spotted on to LB selective agar thrice. Following 
incubation at 37 °C, the colonies were counted and converted into colony forming units 
(CFU/ml). 
 
The MICs of platensimycin against M. smegmatis and M. bovis BCG were calculated by 
Alamar Blue testing as previously described (Franzblau et al. 1998). Briefly, 200 µl of sterile 
deionised water was added to all outer-perimeter wells of a sterile 96-well plate (Corning 
Incorporated, Corning, NY, USA) to minimise evaporation of the medium in the test wells 
during incubation. The wells in rows B to G in columns 3 to 11 received 100 µl of 7H9 
medium plus ADC (Beckton Dickinson, Sparks, MD), and contained 25 µg/ml kanamycin, 
50 µg/ml hygromycin for the strains harbouring the pVV16 vector. Platensimycin was added 
to rows B-G in column 2 followed by 1:2 serial dilutions across the plate to column 10, and 
100 µl of excess medium was discarded from the wells in column 10. A bacterial culture (100 
µl) was added to the wells in rows B to G in columns 2 to 11, where the wells in column 11 
served as drug-free controls. The plates were sealed with Parafilm and were incubated at 37 
°C for 24 h for M. smegmatis strains or 5 days for M. bovis BCG strains. A freshly prepared 
1:1 mixture of Alamar Blue (Celltiter-Blue™, Promega Corp, Madison, WI, USA) reagent 
and 10 % Tween®-80 (50 µl) was added to well B11 (drug-free control). The plates were re-
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incubated at 37 °C for 24 h. If the well turned pink, corresponding to cell growth, the Alamar 
Blue mixture was added to the remaining wells, re-sealed with Parafilm and incubated at 37 
°C for a further 7–12 h for M. smegmatis or 24 h for M. bovis. The colours of all the wells 
were recorded using a 96-well plate fluorescence reader at the wavelengths (nm) 
560Ex /590Em. Viable cells turned the reagent pink, whereas wells containing non-viable cells 
remained blue. The MIC99 was defined as the lowest concentration of drug that prevented a 
change in colour from blue to pink. 
 
2.2.6. The in vivo effects of platensimycin on cell envelope lipid synthesis. 
M. smegmatis cultures were grown to an OD600 of 0.4 in the presence of 0.25 % Tween®-80 
in Sautons medium at 37 °C. Platensimycin was added at various concentrations followed by 
incubation at 37 °C for 16 h for M. bovis BCG and 8 h for M. smegmatis at which point 1 
µCi/ml [1,2-14C] acetate (57 Ci/mol, GE Healthcare, Amersham Bioscience) was added to the 
cultures. The M. bovis BCG and M. smegmatis cultures were further incubated at 37 °C for 
24 h and 12 h, respectively. The [14C]-labelled cells were harvested by centrifugation at 2,000 
" g, washed with PBS and processed as described below. 
 
The [14C]-labelled cells were initially resuspended in methanol /0.3 % NaCl (2 ml, 100:10, 
v/v) and mixed with 1 ml of petroleum ether (60–80 °C) for 15 min. The upper petroleum 
ether layer was removed and a further 1 ml of petroleum ether added, followed by further 
mixing for 15 min (Dobson et al. 1985). The petroleum ether extracts were combined and 
evaporated under nitrogen using a heating block. The dried apolar lipid extract was 
resuspended in 200 µl of CH2Cl2 prior to thin-layer chromatography (TLC) and 
autoradiography. Polar lipids were extracted by the addition of chloroform/methanol /0.3 % 
NaCl (2.3 ml, 9:10:3, v/v/v) to the lower methanolic saline phase and mixed for 1 h. The 
mixture was centrifuged and the pellet re-extracted twice with chloroform/methanol /0.3 % 
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NaCl (750 µl, 5 :10:4, v/v/v). Chloroform (1.3 ml) and 0.3 % NaCl (1.3 ml) were added to 
the combined extracts and the mixture centrifuged. The lower layer containing the polar 
lipids was recovered and dried (Dobson et al. 1985). The polar lipid extract was resuspended 
in chloroform/methanol (2:1, v/v). The apolar lipid extract (50,000 cpm) was applied to the 
corners of 6.6 $ 6.6 cm plates of silica gel 60 F254 TLC plates (Merck 5554, Darmstadt, 
Germany). The plates were then developed using direction 1, chloroform/methanol /water 
(100:14:0.8, v/v/v), and direction 2, chloroform/acetone/methanol /water (50:60:2.5:3, 
v/v/v/v), to separate [14C]-labelled lipids (trehalose dimycolate and glucose monomycolate). 
Lipids were visualised by autoradiography by overnight exposure of Kodak X-Omat AR film 
to the TLC plates to reveal [14C]-labelled lipids and compared to known standards (Dobson et 
al. 1985). 
 
2.2.7. The in vivo effects of platensimycin on mycolic acid synthesis. 
The delipidated cells and whole cell pellets were similarly subjected to alkaline hydrolysis 
using 5 % aqueous tetrabutylammonium hydroxide (TBAH) at 100 °C overnight, followed by 
the addition of 4 ml CH2Cl2, 500 &l CH3I, 2 ml H2O and then followed by mixing for 30 min. 
The upper aqueous phase was discarded following centrifugation and the lower organic phase 
washed thrice with water and evaporated to dryness. The resulting fatty acid methyl esters 
(FAMEs) and mycolic acid methyl esters (MAMEs) were dissolved in diethyl ether and 
insoluble residues removed by centrifugation. The ethereal solution was evaporated to 
dryness and re-dissolved in 200 &l CH2Cl2. Equivalent volumes of the resulting solution of 
FAMEs and MAMEs were subjected to TLC using silica gel plates (5735 silica gel 60F254; 
Merck), developed in petroleum ether /acetone (95:5). Autoradiograms were produced by 
overnight exposure of Kodak X-Omat AR film to the plates to reveal [14C]-labelled FAMEs 
and MAMEs. Ag2+-TLC was performed as described previously using Ag2+-impregnated 
TLC plates developed twice in direction 1, hexane/ethyl acetate (95:5, v/v), and then thrice 
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in direction 2, petroleum ether /acetone (85:15, v/v) (Kremer et al. 2002b). 
 
2.2.8. The in vitro effects of platensimycin, thiolactomycin analogues and indole 
derivatives using crude cell-free extracts. 
FAS-I extracts from M. smegmatis and C. glutamicum and FAS-II cell-free extracts from M. 
smegmatis were prepared as described previously using the 40–80 % ammonium sulfate 
fraction (Slayden et al. 1996). The thiolactomycin analogues and indole derivatives were 
initially screened for activity against the M. smegmatis FAS-I system at 200 µg/ml. The 
thiazole derivatives were defined simply as active or not active at this concentration, whereas 
of the indole derivatives, those active at 200 µg/ml were then titred (0.5–100 µg/ml) into the 
standard reaction to obtain IC50 values. Platensimycin was titred into the M. smegmatis and 
C. glutamicum FAS-I-containing reactions from 0.1 to 150 µg/ml. The standard reaction for 
incorporation of radioactivity from [2-14C] malonyl-CoA into C16–C24 fatty acids catalysed 
by FAS-I contained: 100 mM Tris·HCl (pH 7.9), 5 mM EDTA, 5 mM DTT, 300 µM acetyl-
CoA, 100 µM NADPH, 100 µM NADH, 1 µM flavin mononucleotide, 500 µM !-
cyclodextrin, 300 µM CoA-SH, 20 µM malonyl-CoA, 100,000 cpm of [2-14C] malonyl-CoA 
(specific activity 53 Ci/mol; GE Healthcare, Amersham Biosciences) and 1 mg of the 
cytosolic enzyme preparation in a total volume of 500 µl. The activity of the thiolactomycin 
analogues and the indole derivatives against mycobacterial FAS-II enzymes was tested using 
a cell-free extract rather than in discrete assays using purified proteins. The thiazole 
derivatives were again defined as active or not active at 200 µg/ml, whereas the indole 
derivatives that were active at 200 µg/ml were titred (0.5–100 µg/ml) into the standard 
reaction to monitor incorporation of radioactivity from [2-14C] malonyl-CoA into C24–C30 
fatty acids catalysed by FAS-II: 100 mM potassium phosphate buffer (pH 7.0), 5 mM EDTA, 
5 mM DTT, 10 µM palmitoyl-CoA, 140 µM NADPH, 140 µM NADH, 100 µg AcpM, 40 
µM malonyl-CoA, 200,000 cpm of [2-14C] malonyl-CoA (specific activity 53 Ci/mol) and 
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200 mg of cytosolic enzyme preparation in a total volume of 250 µl. In both FAS-I and FAS-
II experiments, reactions were performed in triplicate at 37 °C for 1 h and terminated by the 
addition of 500 µl of 20 % potassium hydroxide in 50 % methanol at 100 °C for 30 min. 
Following acidification with 300 µl of 6 N HCl, the resultant [14C]-labelled fatty acids were 
extracted three times with petroleum ether. The organic extracts were pooled, washed once 
with an equal volume of water and dried in a scintillation vial prior to counting using 5 ml of 
EcoScintA (National Diagnostics, Hull, UK). 
 
2.2.9. The in vitro effects of platensimycin, thiolactomycin analogues and indole 
derivatives using purified proteins. 
Mt-KasA, Mt-KasB and Mt-FabH proteins were purified and assayed as described previously 
(Brown et al. 2005, Kremer et al. 2002a, Sridharan et al. 2007). Platensimycin was titred into 
all three discrete enzymatic reactions (0.1–150 µg/ml), whereas the thiolactomycin analogues 
and indole derivatives were only tested for Mt-FabH inhibition. The Mt-KasA and Mt-KasB 
reactions were performed as follows: Holo-AcpM (40 µg) was incubated on ice for 30 min 
with !-mercaptoethanol (0.5 µmol) in a total volume of 40 µl. [2-14C] malonyl-CoA (100,000 
cpm, 6.78 nmol, 1.66 kBq), Mt-FabD (40 ng) and 25 µl of 1 M potassium phosphate buffer 
(pH 7.0) were added followed by incubation at 37 °C for 30 min. C16-AcpM/holo-AcpM 
heterogeneous mix (22.5 µg) was added to obtain a final volume of 89 µl. Mt-KasA or Mt-
KasB (0.25 µg) was added to initiate the reaction and was held at 37 °C for 1 h. The reaction 
was quenched by the addition of 2 ml of a NaBH4 reducing solution (5 mg/ml NaBH4 in 0.1 
M K2HPO4, 0.4 M KCl and 30 % (v/v) THF). The reaction was kept at 37 °C for a further 1 h 
followed by two extractions with 2 ml of water-saturated toluene. The combined organic 
phases were pooled and washed using 2 ml of toluene-saturated water. The organic layer was 
removed and dried under a stream of nitrogen in a scintillation vial. The [14C18]-1,3-diol 
product was then quantified by liquid scintillation counting using 5 ml of EcoScintA. 
Chapter 2 Anti-mycobacterial Compounds 
!
 88 
The activity of Mt-FabH was determined as previously described (Brown et al. 2005). As for 
the cell-free extracts experiments, the thiolactomycin analogues and indole derivatives were 
initially tested at 200 µg/ml and those active at this concentration were titred (0.5–100 µg/ml) 
into the standard reaction. Platensimycin (0.1–150 µg/ml) was titred similarly into the 
following standard reaction to observe inhibition of the condensing activity of Mt-FabH: 50 
µM holo-ACP/AcpM, 1 mM !-mercaptoethanol, 0.1 M sodium phosphate buffer (pH 7.0) 
were initially mixed and incubated at 4 °C for 30 min to ensure complete reduction of AcpM. 
To this, 50 µM malonyl-CoA, 45 nCi of [2-14C] malonyl-CoA (specific activity 53 Ci/mol), 
12.5 µM palmitoyl-CoA primer and 0.3 µg purified Mt-FabD were added and mixed in a 
volume of 50 µl and incubated at 37 °C for 30 min. Mt-FabD was added to generate the 
malonyl-AcpM reaction substrate from malonyl-CoA and AcpM in situ. The reaction was 
initiated by the addition of 0.5 µg of Mt-FabH followed by incubation at 37 °C for 40 min. 
The Mt-FabH assays were quenched and processed as described for the Mt-KasA/B assays. 
 
2.3. Results 
2.3.1. Activity of platensimycin against slow-growing mycobacteria. 
Platensimycin has previously been shown to be an effective inhibitor of Gram-positive 
bacteria with MIC values as low as 1 µg/ml for S. aureus, E. faecalis and S. pneumoniae 
(Wang et al. 2006). To test the anti-mycobacterial potency of platensimycin against slow-
growing mycobacteria, the activity of the antibiotic was tested against M. tuberculosis strains 
CDC1551 and H37Rv. The MIC of platensimycin required to inhibit the growth of 99 % of 
both M. tuberculosis strains on solid medium was 12 µg/ml, indicating a comparable potency 
for this drug against this slow growing pathogen (Table 2-1). Surprisingly, the growth of the 
vaccine strain M. bovis BCG in the presence of platensimycin was different to that of M. 
tuberculosis and the strain grew normally in medium containing up to 128 µg/ml 
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platensimycin. The insensitivity of M. bovis BCG to platensimycin may be attributed to a yet 
unknown efflux system present in M. bovis but not in M. tuberculosis. Wang et al. (2006, 
2007b) previously showed that a tolC efflux-negative E. coli strain was sensitive to 
platensimycin whereas the wild-type was not, indicating that the efflux of the compound 
plays a major role in species resistance. 
 
TABLE 2-1. Influence of Mt-KasA, Mt-KasB and Mt-FabH over-expression on 
platensimycin in whole cell inhibition of M. tuberculosis, M. smegmatis and M. bovis 
BCG. 
 
Strain MIC99 (µg/ml) 
M. tuberculosis CDC1551 12 
M. tuberculosis H37Rv 12 
M. smegmatis 14 
M. smegmatis pVV16 14 
M. smegmatis pVV16-kasA 30 
M. smegmatis pVV16-kasB 124 
M. smegmatis pVV16-kasAB 126 
M. smegmatis pVV16-fabH 16 
M. bovis BCG >128 
M. bovis BCG pVV16 >128 
M. bovis BCG pVV16-kasA >128 
M. bovis BCG pVV16-kasB >128 
M. bovis BCG #kasB 61 
 
In an effort to investigate the apparent resistance of BCG to platensimycin, we sought to test 
the effects of increased membrane permeability by generating a M. bovis BCG #kasB mutant 
(Figure 2-3). It had previously been shown that a #kasB null mutant in M. tuberculosis 
synthesised shorter mycolic acids with an almost complete loss of trans-cyclopropanation of 
oxygenated mycolic acids that resulted in increased susceptibility to lipophilic antibiotics 
(Bhatt et al. 2007b). Interestingly, the M. bovis BCG #kasB mutant was sensitive to 
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platensimycin (MIC 61 µg/ml) suggesting that the increased permeability in comparison to 
the parental M. bovis BCG strain has indeed increased the sensitivity of M. bovis BCG to 
platensimycin (Table 2-1). The increased levels of platensimycin able to penetrate the cell 
may overwhelm any potential efflux protection system therefore killing the cell by cessation 
of FAS-II and mycolate biosynthesis. However, the high MIC of the mutant BCG strain in 
comparison to that of M. tuberculosis indicates that it is still unclear whether the resistance of 
BCG to platensimycin was solely due to decreased permeability to the drug. 
 
 
 
 
 
 
 
 
 
 
FIGURE 2-3. Generation of a M. bovis BCG !kasB mutant. Maps of the kasB region in 
the M. bovis BCG genome and its corresponding region in the conditional mutant #kasB are 
shown on the left, with the corresponding Southern blot on the right (produced by Dr. A. 
Bhatt). The regions used as probes are indicated by solid lines with round ends, while the 
expected bands are indicated by broken lines (with sizes indicated). hyg, hygromycin 
resistance gene from Streptomyces hygroscopicus; res, '( resolvase recognition sites. 
 
To facilitate further studies of the effects of platensimycin on MIC, growth and in vivo fatty 
acid biosynthesis, the non-pathogenic mycobacteria M. bovis BCG and M. smegmatis mc2155 
were used in place of M. tuberculosis. Not only are these species safer to use, but both have a 
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much faster doubling time than M. tuberculosis and have been shown to be equally effective 
in testing anti-tubercular agents (Shiloh & DiGiuseppe Champion 2009). 
 
2.3.2. Whole cell activity of platensimycin against M. smegmatis. 
Platensimycin was tested for inhibitory properties against the non-pathogenic, fast-growing 
M. smegmatis mc2155. The MIC of this strain in liquid medium was found to be 14 µg/ml 
(Table 2-1). The growth of M. smegmatis was then monitored in LB broth in the presence or 
absence of 14 µg/ml platensimycin for a period of 72 h (Figure 2-4). 
 
 
 
 
 
 
 
 
 
Figure 2-4. In vivo effect of platensimycin against M. smegmatis. (A) Clarification of 
cultures due to clumping and cellular lysis at time point 72 h. (B) Cultures were grown to an 
OD600 of 0.4 upon which 14 µg/ml of platensimycin was added. Samples were taken over a 
72 h period and viable counts were calculated as per the methods where the mean CFU per 
ml from three independent experiments was calculated. ! M. smegmatis; " M. smegmatis 
+ platensimycin. 
 
While M. smegmatis grew normally in medium devoid of platensimycin, the culture in the 
presence of platensimycin showed a decrease in OD600 values with time resulting in clumping 
after 24 h of incubation (Figure 2-4 A). Monitoring of viable colony forming units (CFU) 
demonstrated that the culture grown in medium with platensimycin possessed a 2-log 
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decrease in CFU (Figure 2-4 B). The plateau shape observed with the treated cells would 
suggest that platensimycin is bacteristatic in nature. Further experimentation utilising cells 
exposed to platensimycin for 72 h showed that, after washing and re-inoculating into fresh 
media, treated cultures could be revived. This furthers the notion that platensimycin is 
bacteristatic against M. smegmatis. 
 
2.3.3. Platensimycin inhibits the biosynthesis of fatty acids and mycolic acids. 
To study the biochemical effects of platensimycin treatment, cultures of M. smegmatis were 
metabolically labelled with [14C] acetate following exposure to platensimycin. Fatty acids 
and mycolic acids were extracted from [14C]-labelled cells and methylated using phase-
transfer catalysis and iodomethane. Extracts of total fatty acid methyl esters (FAMEs) and 
mycolic acid methyl esters (MAMEs) from untreated and platensimycin treated cultures (5–
60 µg/ml) were analysed by TLC-autoradiography. Biosynthesis of fatty acids and !- and 
epoxy-mycolic acids was significantly inhibited upon platensimycin treatment (20–40 µg/ml) 
(Figure 2-5 A, B). Interestingly, an accumulation of !"-MAMEs was observed at lower 
concentrations of platensimycin (10–20 µg/ml). This is similar to studies observed upon 
thiolactomycin treatment of M. smegmatis, a known inhibitor of FAS-II enzymes KasA and 
KasB (Figure 2-5 B) (Slayden et al. 1996). The inhibition of fatty acids is in contrast to 
studies involving the FAS-II inhibitor isoniazid where inhibition of mycolic acid biosynthesis 
leads to an accumulation of fatty acids (Baulard et al. 2000). These results suggest that 
platensimycin also inhibits fatty acid biosynthesis via inhibition of mycobacterial FAS-I. 
 
Further analysis of the same samples by 2D-Ag2+ TLC reinforced these findings and revealed 
more clearly that synthesis of !- (!1 and !2) and epoxy-mycolic acids (Figure 1-11) was 
abolished at lower concentrations (Figures 2-6 A), in comparison with the initial 
accumulation and then cessation of !"-mycolic acid biosynthesis (Figure 2-5 A). Futhermore, 
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extracts of cell wall-bound mycolic acids afforded similar profiles upon platensimycin 
treatment (Figure 2-6 B). In addition, analysis of [14C]-labelled lipids extracted from 
platensimycin-treated cultures also revealed that the synthesis of mycolate containing lipids 
glucose monomycolate and trehalose dimycolate were reduced (Figure 2-6 C). These results 
demonstrated that platensimycin targeted fatty acid and mycolic acid biosynthesis in M. 
smegmatis. 
 
2.3.4. Platensimycin resistance of M. smegmatis strains over-expressing Mt-KasA, 
Mt-KasB or Mt-FabH. 
The use of gene over-expression to identify cellular targets of anti-mycobacterial drugs has 
been highly successful (Belanger et al. 1996, Kremer et al. 2000a, Larsen et al. 2002). Given 
that the targets of platensimycin in other bacteria were !-ketoacyl synthases, the effects of 
over-expression of Mt-KasA, Mt-KasB or Mt-FabH on platensimycin resistance in M. 
smegmatis were tested. The three !-ketoacyl-ACP synthases, cloned into the E. coli-
Mycobacterium shuttle vector pVV16, were introduced into M. smegmatis by electroporation. 
Multiple copies and constitutive expression driven by the hsp60 promoter ensures over-
expression of the cloned genes in the host Mycobacterium. First, levels of each recombinant 
protein were assessed by Western blot to confirm that any observed change in resistance 
could be attributed to increased levels of the target protein. Over-expression of Mt-KasA 
conferred a modest 2-fold increase in resistance to platensimycin, increasing the MIC from 
14 to 30 µg/ml (Table 2-1). Conversely, Mt-KasB over-expression resulted in a substantial 9-
fold increase in the MIC to 124 µg/ml (Table 2-1). A combination of Mt-KasA/B over-
expression failed to enhance resistance to platensimycin further and possessed a MIC of 126 
µg/ml. Interestingly, although platensimycin was previously shown to target FabH in other 
bacteria (Wang et al. 2007b), over-expression of Mt-FabH failed to confer resistance to 
platensimycin; the MIC only increased to 16 µg/ml (Table 2-1). 
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FIGURE 2-5. TLC-autoradiography of FAMEs and MAMEs from M. smegmatis strains 
over-expressing Mt-KasA, Mt-KasB and Mt-FabH following platensimycin treatment. 
Platensimycin (0–60 µg/ml) was titred into M. smegmatis cultures at an OD600 of 0.4 prior to 
labelling with 1 µCi/ml [1,2-14C] acetate for 12 h. [14C]-FAMEs and MAMEs were 
extracted and resolved by TLC. An equivalent aliquot of the resulting solution of FAMEs 
and MAMEs was subjected to TLC using silica gel plates developed twice in petroleum 
ether /acetone (95:5). Autoradiograms were produced by overnight exposure to Kodak X-
Omat film to reveal [14C]-labelled FAMEs and MAMEs. (A) M. smegmatis pVV16, (B) M. 
smegmatis pVV16-Mt-kasA, (C) M. smegmatis pVV16-Mt-kasB and (D) M. smegmatis 
pVV16-Mt-kasAB. SF, solvent front; FAMEs, fatty acid methyl esters; MAMEs, mycolic 
acid methyl esters; PLT, platensimycin. 
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FIGURE 2-6. TLC-autoradiography of M. smegmatis lipid extracts and cell wall bound 
mycolates following platensimycin treatment. Platensimycin (0, 20, 30, 40 µg/ml) was 
added to M. smegmatis cultures at an OD600 of 0.4 for 8 h prior to labelling with 1 µCi/ml 
[1,2-14C] acetate for 12 h. (A) 2D-Ag2+ TLC using silica gel plates developed twice in 
hexane /ethyl acetate (95 :5) (direction 1) then thrice in petroleum ether /diethyl ether 
(85 :15) (direction 2, Ag2+). (B) Cell wall bound mycolate profiles were revealed following 
development twice in petroleum ether-acetone (95 :5). (C) [14C]-Polar lipids were extracted 
and resolved by TLC; direction 1, chloroform /methanol /water (100 :14 :0.8); direction 2, 
chloroform /acetone /methanol /water (50 :60 :2.5 :3). Autoradiograms were produced by 
overnight exposure to film to reveal [14C]-labelled lipids. PLT, platensimycin; MAMEs, 
mycolic acid methyl esters; GMM, glucose monomycolate; TDM, trehalose dimycolate. 
 
These observations were similar to resistance studies conducted with thiolactomycin and 
strains over-expressing Mt-FabH (Choi et al. 2000). The 9-fold increase in resistance to 
platensimycin by M. smegmatis over-expressing Mt-KasB suggests that platensimycin 
preferentially targets KasB. 
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To further confirm the targeting of mycobacterial KasA and KasB enzymes by 
platensimycin, the ability of the recombinant KAS over-expressing M. smegmatis strains to 
incorporate [14C] acetate into fatty acids and mycolic acids was examined. TLC analysis of 
FAMEs and MAMEs extracted from different strains treated with platensimycin revealed 
that, whilst mycolic acid biosynthesis was only partially restored in the Mt-KasA over-
producing strain, over-expression of either Mt-KasB or Mt-KasAB fully restored fatty acid 
and mycolic acid biosynthesis (Figure 2-5 B–D). 
 
2.3.5. In vitro activity of platensimycin, thiolactomycin analogues and indole 
derivatives against FAS-I and FAS-II extracts. 
To date, no crystal structure of Mt-FabH has been solved complexed with an inhibitor, so the 
ligand docking used to synthesise the thiolactomycin analogues here was based on the 
interaction between thiolactomycin and the homologous enzyme in E. coli, FabF (Price et al. 
2001). The key interactions identified are outlined in Table 2-2. 
 
TABLE 2-2. The key interactions between E. coli FabF (homologous to Mt-FabH) and 
the ligand thiolactomycin (Al-Balas et al. 2009). 
 
Ligand Active site interaction 
C3 methyl group Hydrophobic pocket defined by Phe-229 and Phe-392 
5-isoprenoid moiety Wedged between Val-271 / Phe-272 and Gly-391 / Phe-392 
2-carbonyl group oxygen Two H bonds with the active site histidines, His-298 and His-333 
4-hydroxy group Network of H2O molecules positioned by the carbonyl O of Val-271 and amide NH of Gly-305 
 
Taking these interactions into consideration, the achiral scaffold of 2-amino thiazole-5-
carboxylate was chosen and derivatives were chemically synthesised by Al-Balas and co-
workers (2009) using the methods described by Barton et al. (1982) (Figure 2-7). 
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FIGURE 2-7. The structure of 2-amino thiazole-5-carboxylate. The scaffold on which the 
thiolactomycin pharmacophore library was based. 
 
The effects of all the compounds on the FAS-I and FAS-II systems in vitro were evaluated by 
observing the impact upon [14C] malonyl-CoA incorporation into fatty acids and mycolic 
acids, respectively. The FAS-I systems of both M. smegmatis and C. glutamicum were used 
to assess the anti-FAS-I activity of platensimycin, whereas just that of M. smegmatis was 
used for the thiazole compounds and indole derivatives. For platensimycin, the mycolate-
producing FAS-II system was assessed by discrete assays using pure Mt-KasA, Mt-KasB and 
Mt-FabH (see section 2.3.6.), whereas for the thiazole library and indole derivatives a crude 
cell-free extract with FAS-II activity was used to evaluate activity (Brown et al. 2005, 
Kremer et al. 2000a, Kremer et al. 2002a, Radmacher et al. 2005). 
 
Interestingly, when platensimycin was titred into crude cell-free extracts enriched with FAS-I 
of either M. smegmatis or C. glutamicum, activity was inhibited at an IC50 value of 12 µg/ml 
and 6.5 µg/ml, respectively. It could be argued that this inhibition of FAS-I activity could be 
detrimental to the effectiveness of platensimycin as a lead compound. In the recent patent 
publication using human cell-free FAS-I assays, it was demonstrated that both platensimycin 
and platencin had activity (IC50) of 0.132 µg/ml (0.3 µM) and 2.68 µg/ml (6.3 µM), 
respectively (Singh et al. 2008). However, it was previously demonstrated in whole cell 
assays by the patent applicants, Wang et al. (2006), that platensimycin had low mammalian 
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cell toxicity (IC50) of HeLa MTT >1000 µg/ml. The authors also confirmed a lack of 
antifungal activity against Candida albicans, which synthesises fatty acids via a type I fatty 
acid synthase (>64 µg/ml). 
 
Of the thiazole derivatives tested, all the compounds possessing a bromoacetamido group at 
the 2-position showed activity against FAS-I, FAS-II or both systems (Table 2-4). One 
compound, QAB-130a, showed in vitro activity against FAS-II but not FAS-I (60 % 
inhibition at 200 µg/ml). This would be an encouraging result since the compound appears to 
be specific to the bacterial system, however, when aligned with M. tuberculosis MIC data on 
the same compounds (data provided by Dr. Q. Al-Balas, University of Strathclyde), it can be 
seen that these compounds do not display any whole cell activity. 
 
There were five indole derivatives that showed activity against FAS-I and six against FAS-II, 
of which two were active against both systems (Table 2-5). The most encouraging of these is 
WIUAKP-045, which inhibited only FAS-II with an IC50 of 3.64 ± 0.02 µg/ml. The fact that 
none of the FAS-II-inhibiting compounds were active against FabH indicates that some other 
enzyme in the cycle is being targeted. 
 
2.3.6. In vitro activity of platensimycin, thiolactomycin analogues and indole 
derivatives against Mt-KasA, Mt-KasB and Mt-FabH. 
In order to examine whether the compounds target mycobacterial mycolic acid biosynthesis 
or not, purified Mt-KasA, Mt-KasB or Mt-FabH (for platensimycin) or Mt-FabH (for the 
thiolactomycin analogues and indole derivatives) were assessed in discrete assays as 
described earlier (Brown et al. 2005, Kremer et al. 2000a, Kremer et al. 2002a). In these 
assays [14C] malonyl-CoA was transacylated to AcpM via Mt-FabD prior to the addition of 
the relevant substrates (C16-AcpM and C16-CoA) and the enzyme of interest. Upon 
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completion and termination of the experiment the radiolabelled acyl-AcpM derivates were 
extracted using organic solvents. The assays were performed with a titre in triplicate and 
recorded as an IC50 value. 
 
Platensimycin was found to be active against both Mt-KasA and Mt-KasB possessing IC50 
values of 2.0 µg/ml and 4.2 µg/ml, respectively (Table 2-3). These results are consistent with 
platensimycin in vitro inhibition of FabF in S. aureus and E. coli (Wang et al. 2007b). 
Interestingly, the IC50 values obtained with platensimycin are significantly lower than those 
obtained with another mycobacterial KAS inhibitor thiolactomycin (KasA = 4.21 µg/ml [20 
µM], KasB = 18.9 µg/ml [90 µM]) (Schaeffer et al. 2001). Studies by Wang et al (2007b) 
demonstrated that S. aureus FabH activity was inhibited by platensimycin (IC50 = 29.5 µg/ml 
[67 µM]). In contrast Mt-FabH over-expression failed to confer resistance (Table 2-1) and in 
vitro Mt-FabH was relatively insensitive to platensimycin (IC50 >150 µg/ml) in comparison 
to Mt-KasA and Mt-KasB (Table 2-3). 
 
TABLE 2-3. In vitro inhibition (IC50) of platensimycin against purified FAS-II system 
enzymes. Values represent the mean of three replicates ± standard error. 
 
Protein IC50 (µg/ml) 
Mt-KasA 2.0 ± 0.1 
Mt-KasB 4.2 ± 0.1 
Mt-FabH >150 
 
Only three of the thiazole compounds were active against purified Mt-FabH, QAB-61, QAB-
62a and QAB-108a, with IC50 values of 1.04 ± 0.2, 1.1 ± 0.1 and 79.9 ± 1.0 µg/ml, 
respectively. This is interesting considering the compounds were designed to target Mt-FabH, 
however, all three had the bromoacetamido group at the R3 position indicating that this is a 
key feature (Table 2-4). All three of these were also active against FAS-I but, unlike the other 
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two, QAB-61 was not found to be active against FAS-II. Similarly, of the 44 indole 
derivatives tested, only two were found to be active against Mt-FabH, WIUAKP-052 and 
WIUAKP-056, with IC50 values of 109.5 ± 1.15 and 109.1 ± 0.64 µg/ml, respectively (Table 
2-5). 
 
2.4. Discussion 
Mycolic acid biosynthesis is essential for mycobacterial survival and many anti-tuberculosis 
drugs like isoniazid, ethionamide and thiolactomycin target enzymes of this exclusive 
pathway (Banerjee et al. 1994, Kremer et al. 2000a). The identification and functionality of 
novel lead anti-tubercular agents is essential mainly due to the emergence of MDR-TB, and 
more recently, XDR-TB (Kaye & Frieden 1996, Wright et al. 2006). In this worrying climate 
where untreatable strains of XDR-TB are becoming apparent, the impetus for the discovery 
of new anti-tubercular agents becomes crucial. The discovery and characterisation of new 
drugs targeting key enzymes involved in essential mycobacterial biosynthetic pathways is 
paramount, but without the introduction of novel lead compounds, such as platensimycin, 
anti-tubercular therapy will not proceed fast enough to cope with the increasing resistance 
observed today. Not only should drug development focus on the synthesis of active 
analogues of existing anti-mycobacterials, but also on identification of new classes of drugs, 
such as platensimycin. 
 
2.4.1. Platensimycin. 
The Streptomyces platensis natural product platensimycin represents a new chemical class of 
antibiotics (Wang et al. 2006). This study has shown that platensimycin is active against M. 
tuberculosis and, through the use of the M. smegmatis surrogate system, the mode of action 
of platensimycin against Mycobacterium spp. could be investigated and elucidated. 
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TABLE 2-5. The in vitro inhibition (IC50) of the indole-derivative library against Ms-
FAS-I, Ms-FAS-II and Mt-FabH. Compounds were regarded as not active if < 50 % 
inhibition was observed at 200 µg/ml. Values are means of three replicates ± standard error. 
 
IC50 (µg/ml) Compound Structure 
Ms-FAS-I Ms-FAS-II Mt-FabH 
WIUAKP-003 
 
Not active 33.2 ±1.20 Not active 
WIUAKP-005 
 
 
 
 
 
Not active 28.0 ± 0.60 Not active 
WIUAKP-026 
 
89.5 ± 8.50 Not active Not active 
WIUAKP-027 
 
69.0 ± 4.40 Not active Not active 
WIUAKP-028 
 
182.8 ± 9.70 Not active Not active 
WIUAKP-041 
 
182.0 ± 9.50 19.7 ± 1.01 Not active 
WIUAKP-042 
 
191.0 ± 3.50 5.37 ± 0.03 Not active 
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IC50 (µg/ml) 
Compound Structure 
Ms-FAS-1 Ms-FAS-II Mt-FabH 
WIUAKP-045 
 
Not active 3.64 ± 0.02 Not active 
WIUAKP-052 
 
Not active Not active 109.5 ± 1.15 
WIUAKP-056 
 
Not active Not active 109.1 ± 0.64 
WIUAKP-059 
 
Not active 5.22 ± 0.06 Not active 
 
The activity of platensimycin against FAS-I has previously been observed against the human 
and rat FAS in vitro (Singh et al. 2008) but no activity was observed against mammalian 
culture systems in vivo (Singh et al. 2006). Although in mycobacteria the fatty acyl-products 
of FAS-I provide primers for extension to meromycolate precursors of mycolic acids, the 
effects on FAS-II appear to be more complex than a simple deprivation of primer supply 
brought about via FAS-I inhibition. Therefore, the combination of activity observed against 
both FAS-I and the FAS-II components KasA/KasB contribute to the inhibitory effect of 
platensimycin against M. smegmatis. While from the point of view of drug development, 
FAS-II inhibition, which causes cessation of the essential mycolic acids, is desirable, 
inhibition of FAS-I is not since mammalian fatty acid synthases are too similar. However, in 
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previous studies platensimycin has been shown to possess low mammalian cell toxicity in 
HeLa cytotoxicity assays and to lack antifungal activity, indicating that platensimycin may 
not act selectively against mycobacterial FAS-I. 
 
Despite only a moderate level of sequence identity between Mt-KasB and E. coli FabF (~36 
%), the two enzymes display identical folds (Figure 2-8 A). To ascertain whether the active 
site of Mt-KasB would be compatible with the steric requirements of platensimycin, a 
hypothetical structural model of platensimycin-bound Mt-KasB was generated using the Mt-
KasB (PDB code 2GP6) superimposed with platensimycin-bound Ec-FabF with a single 
point mutation Cys-163-Gln (PDB code 2GFX) (Figure 2-8). Subsequent conjugate-gradient 
energy minimisation relieved mild steric clashes between protein and ligand and resulted, 
compared to ligand-free Mt-KasB, in minor to moderate shifts of side chains located within a 
4 Å-radius of platensimycin (root mean square displacement 0.93 Å for 186 main and side 
chain atoms, maximum displacement 3.5 Å). 
 
The model illustrates steric compatibility between platensimycin and the active site of Mt-
KasB, but hints at subtle differences in protein-inhibitor interactions between Ec-FabF and 
Mt-KasB. The benzoic acid ring faces a structural environment that is virtually identical to 
that in Ec-FabF (Figure 2-8 B). However, the ketolide group would appear to be less exposed 
to solvent than it is in the Ec-FabF::platensimycin complex (Figure 2-8 B, C). Indeed, the 
simulated complex structure suggests that the ketolide group makes close hydrophobic 
interactions with Met-212 and Ile-214 (Figure 2-8 B, C), contacts that are not seen in 
platensimycin-bound Ec-FabF, where these residues correspond to alanine side chains. Such 
differences provide scope for design efforts with the aim of enhancing inhibitor affinity in a 
species-specific manner. 
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FIGURE 2-8. Comparison of Mt-KasB with Ec-FabF and simulated 
KasB::platensimycin complex. The structures of E. coli FabF(C163Q) (PBD: 2GFX) 
bound to platensimycin and Mt-KasB (PBD: 2GP6) were superimposed using CNS 1.2 
(Brünger 2007). (A) Ribbon diagram displaying Mt-KasB (cyan) and Ec-FabF (grey) with 
platensimycin shown as sticks (pink). (B, C) Two orthogonal views of the simulated Mt-
KasB::platensimycin complex of Mt-KasB with carbon atoms of the experimental FabF and 
simulated Mt-KasB complex structures in grey and cyan respectively. Residue identifiers 
refer to Mt-KasB. 
 
Previous studies by Wang et al. (2007b) demonstrated that platensimycin poorly inhibited 
FabH in other bacteria. Interestingly, it was shown that platencin (Figure 2-9), a related 
antibiotic, was more active against S. aureus FabH (3.90 µg/ml [9.17 µM]). Platensimycin 
and platencin are structurally similar: Platensimycin contains a pentacyclic motif with a 
cyclic ether ring, whereas platencin contains a unique tetracyclic motif without the ether ring 
(Wang et al. 2007b). 
 
 
 
!"
#"
$"
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FIGURE 2-9. Platencin. 
 
The chemical modification between platensimycin and platencin has been proposed as 
responsible for the change in activity against S. aureus FabH. Platensimycin failed to inhibit 
mycobacterial Mt-FabH as one would expect, therefore, it would be interesting to examine 
whether platencin is active against Mt-FabH. Altogether, the culture inhibition studies and in 
vitro assay data indicate that platensimycin targets Mt-KasA and Mt-KasB. Given that over-
expression of Mt-KasA or Mt-KasB increased the MIC of the host M. smegmatis strain for 
platensimycin, it was surprising that platensimycin was relatively inactive against M. bovis 
BCG. Poor permeability may have been one of the factors responsible for the observed 
resistance. Indeed, deletion of kasB from M. bovis BCG resulted in a strain that was more 
`permeable to lipophilic antibiotics and thus sensitive to platensimycin (Table 2-2) (Bhatt et 
al. 2007b). This data suggests that, in order to realise the full potential of this compound as 
an anti-TB agent, it is imperative that any future modifications to platensimycin include 
designs that render it more diffusible into the lipid-rich envelope of M. bovis BCG. 
Nevertheless, the results here highlight the potential of platensimycin as an inhibitor of the 
essential fatty acid and mycolic acid biosynthesis pathways in mycobacteria. 
 
The promise in this drug has awarded it much attention. More recent work on platensimycin 
has seen the synthesis of congeners. A report by Jang et al. (2010a) has shown that more 
potent anti-bacterial compounds can be made using the platensimycin structure as a central 
OH
OHOH
O
N
H
O
O
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scaffold. The most promising were 7-phenylplatensimycin and 11-methyl-7-
phenylplatensimycin, which displayed MIC values of <0.25 µg/ml against MRSA. 
 
2.4.2. Thiolactomycin analogues. 
Despite most of the compounds not showing any activity at 200 µg/ml against Mt-FabH, it 
can be seen from the data that the three that were active have the bromoacetamido group at 
the R3 position. The esters QAB-61, QAB-62a and QAB-108a inhibited with IC50 values of 
1.04 ± 0.2, 1.1 ± 0.1 and 79.9 ± 1.0 µg/ml, respectively. This functional group was designed 
to be able to facilitate an SN2-type substitution between the ligand and the Cys-122 residue of 
the Mt-FabH active site. It is therefore interesting that compounds QAB-58a, QAB-130 and 
QAB-130a, which have the same bromo-R3 group, did not inhibit the enzyme. Here, the R1 
group may have an effect. Although in the active compounds the R1 groups are different (p-
Cl-C6H4-, C6H5- and C6H5CH2-), they do all share the aromatic benzene ring. Compounds 
QAB-130 and QAB-130a both have a CH3 group at the R1 position, which could explain 
their inactivity. QAB-58a however does have both the bromoacetamido and aromatic 
moieties, although having the Cl constituent at the meta rather than the para position may be 
a large enough difference to produce the results observed. Indeed, the magnitude of activity 
displayed by the compounds is dependent on the substituents at the 4- and 5-positions on the 
ring. By assuming the ligand-enzyme interaction is between the electrophilic bromomethyl 
and the active site cysteine, this observation could be explained by the substituents being 
arranged around the catalytic triad. It is known that the channels of Mt-FabH are lipophilic in 
order for the acyl-AcpM chain to be able to reach the active site. It could be that the methyl 
groups at R1 of compounds QAB-130 and QAB-130a are unable to make the necessary 
hydrophobic interactions to inhibit the enzyme, whereas QAB-61, which has a p-Cl-C6H5 
group, can. 
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From the data obtained by Al-Balas and co-workers (2009) for this study, it can be seen that 
none of the bromoacetamido compounds were active against M. tuberculosis as a whole cell 
organism. One reason for this could be that these compounds are unable to access the FabH 
target inside the cell, in which case the physiochemical properties will need to be altered so 
as to cross the complex hydrophobic cell wall. Another reason could be the cell using efflux 
pumps, such as that encoded by Rv2333c (Ramón-García et al. 2007). Although not well 
understood, it is known that M. tuberculosis actively uses multi-drug efflux transporters as a 
mechanism of drug resistance, including the major front-line anti-TB drug, isoniazid (De 
Rossi et al. 2006). One final explanation could be that the cell is able to chemically or 
metabolically alter or degrade the bromomethyl group thus rendering it inactive. The three 
compounds that did display whole cell activity were inactive against the fatty acid and 
mycolic acid biosynthetic systems tested here. Their mechanism(s) of action must therefore 
involve other targets within the cell. 
 
It is clear from the data that no inhibition of either FAS system was possible when there was 
an amine group at R3, regardless of the other R groups (Table 2-3). This can rule out the 
alternative targets for QAB-4, QAB4a, QAB-8 and QAB-30 being any of the active sites of 
FAS-I or the other enzymes of the FAS-II system. All the bromomethyl compounds tested 
were active against the FAS enzymes, although no obvious trends were seen across the 
series. Since there are so many potential active site targets within the FAS systems, however, 
this is not surprising. 
 
Our collaborators (Dr. Q. Al-Balas, University of Strathclyde) also tested the cytotoxicity of 
these compounds against human foreskin fibroblast HS-27 cells (data not shown). 
Essentially, the results showed that only the carboxyl ester of the bromoacetamido analogues, 
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QAB-130, was toxic at a concentration of 100 µg/ml. One potential reason for this could be 
the indiscriminate alkylation of essential cellular components. 
 
This data indicates that the 2-aminothiazole-4-carboxylate scaffold offers a promising new 
lead for further development. Since many of the compounds do not inhibit the target Mt-
FabH, it is important to elucidate their actual target(s) in order to improve on them. 
 
2.4.3. Indole derivatives. 
Only two compounds were active against purified Mt-FabH, WIUAKP-052 and WIUAKP-
056, with very similar IC50 values of 109.5 and 109.1 µg/ml, respectively. Both of these 
compounds have a p-CF3-phenyl group esterified to the indole scaffold and a functional 
group in the para position on a phenyl ring attached to the indole nitrogen. It is therefore 
interesting that WIUAKP-009, which has the same CF3 group and a para-group on the N-
attached phenyl, does not show any FabH activity. WIUAKP-059 is the only other compound 
tested that has para functional groups on the aromatic rings and this compound was found to 
be active against both FAS-I and FAS-II. Interestingly, neither WIUAKP-052 nor WIUAKP-
056 were found to be active against F. tularensis FabH, despite having conserved active site 
residues (Wen et al. 2009). This could indicate that either the compounds do not dock and 
inhibit activity competitively at the Mt-FabH active site, or that the Ft-FabH conformation is 
sufficiently different from Mt-FabH so that it cannot accommodate either compound. 
 
Encouragingly, there were four indole-derivatives that were active against FAS-II but not 
FAS-I or Mt-FabH. It would be interesting to test these in discrete protein assays to elucidate 
their actual targets. The most promising compound was WIUAKP-045 with an IC50 of 3.64 ± 
0.02 µg/ml against FAS-II. All four FAS-II-inhibiting compounds have a functional group in 
the para-position on the indole nitrogen-attached benzene, however, WIUAKP-045 differs 
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from the other three by having a C6 fatty acid chain esterified to the indole rather than an 
aromatic group. It might be this that increases the potency. Nevertheless, it is interesting to 
note that none of the other compounds with an acyl chain in this position, even with an OMe 
group on the nitrogen-attached benzene, inhibit any of the targets tested here. It would be 
beneficial to test these four compounds against the whole cell to see if they are able to pass 
through the cell wall and still inhibit FAS-II. 
 
2.4.4. Conclusion. 
It is evident from this data, and from the literature, that the indole structure holds promise for 
developing new anti-tubercular drugs (Kuo et al. 2003, Seefeld et al. 2003). The aim with 
this and all the scaffolds presented here will be to generate more derivatives in order to 
increase selectivity, potency and whole cell activity. The huge advances in computer 
modelling and in silico structure design, as well as genetic engineering in M. tuberculosis and 
surrogate species used in the lab, have accelerated the synthesis and discovery of novel 
compounds. However, similarly to the discovery of platensimyin and thiolactomycin, 
naturally occurring products need to be exploited to find new classes of antibiotics. One such 
compound, whose structure is as of yet undisclosed, is FAS20013, which is now in pre-
clinical development. It is formed from both thiolactomycin and cerulenin, a natural product 
of the fungus Cephalosporium caerulens that is a known irreversible inhibitor of !-ketoacyl 
synthase from FAS-I and FAS-II (Nomura et al. 1972, Schaeffer et al. 2001). Created by 
FASgen™ in 2005, the compound has been shown to kill both actively growing and latent 
mycobacteria with an MIC of 50 µg/ml (FASgen, Inc. 2005). This compound demonstrates 
how combining elements of naturally occurring metabolites can produce potent and highly 
promising new anti-tubercular chemotherapy. 
 
  CHAPTER 3 
Mycobacterium tuberculosis !-ketoacyl-
acyl carrier protein synthase III (Mt-FabH) 
is inhibited by phosphorylation on a single 
threonine residue 
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3.1. Introduction 
Within the infected host, M. tuberculosis encounters numerous environmental conditions, and 
induces or represses a number of genes, for quick adjustment to new conditions. The 
infection process of M. tuberculosis involves complex signalling between the host and the 
bacterium, resulting in reprogramming of the host signalling network. Protein 
phosphorylation/dephosphorylation within the bacilli represents a central mechanism for 
distribution of signals to various parts of the cell, regulating growth, differentiation, mobility 
and survival (Stock et al. 1989). In mycobacteria, a common signal transduction pathway is 
transmitted through membrane-embedded sensor kinases, enabling the pathogen to modify 
itself for survival in this hostile environment. 
 
Protein kinases can be classified into two families based on their similarities and enzymatic 
specification: (i) the histidine kinase superfamily, which relies on autophosphorylation of a 
conserved histidine residue and commonly occurs as part of two-component systems, and (ii) 
the superfamily of serine, threonine and tyrosine kinases that phosphorylate on serine, 
threonine and tyrosine residues respectively (Hanks et al. 1988, Hunter 1995, Stock et al. 
1989). Although the two-component systems represent the classical prokaryotic mechanism 
for detection and response to environmental changes, the serine/ threonine/ tyrosine protein 
kinases and phosphatases are also widespread in prokaryotes. The M. tuberculosis genome 
contains 11 Ser/Thr protein kinases (STPKs) (Av-Gay & Everett 2000, Cole et al. 1998), 
most of which are being investigated for their physiological roles and potential application 
for future drug development to combat tuberculosis (Wehenkel et al. 2008). This significant 
number of STPKs suggests that phosphorylation may influence a wide range of biological 
functions, such as adaptation to various environmental conditions, stress, cell wall synthesis, 
cell division and pathogenicity (Cowley et al. 2004, Dasgupta et al. 2006, Deol et al. 2005, 
Fernandez et al. 2006, Jayakumar et al. 2008, Kang et al. 2005, Papavinasasundaram et al. 
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2005, Walburger et al. 2004). The cell wall of M. tuberculosis plays a critical role in the 
defence of this pathogen in the host, since environmental stimuli induce changes in the cell 
wall composition and thus help M. tuberculosis to adapt during infection (Daffé & Draper 
1998, Glickman & Jacobs 2001). Several recent studies support the view that regulation of 
cell wall synthesis involves STPKs. For instance, PknH and PknJ phosphorylate the 
forkhead-associated (FHA) domain-containing protein EmbR, a putative transcriptional 
regulator of the EmbCAB arabinosyltransferases (Jang et al. 2010b, Molle et al. 2003a). 
Activation of EmbR upon phosphorylation by PknH induces transcription of the embCAB 
operon, leading to a higher LAM/LM ratio (Sharma et al. 2006), and regulates the synthesis 
of arabinan, an important component of arabinogalactan, essential for the structural integrity 
of the cell wall. Also, LM and LAM are major cell wall-associated lipoglycans and important 
modulators of the immune system (Briken et al. 2004). Furthermore, a recent study has 
shown that PknH was able to phosphorylate other substrates, such as DacB1 (Zheng et al. 
2007). In Bacillus subtilis, DacB1 is a sporulation-specific protein involved in cell envelope 
biosynthesis. Based on homology with the B. subtilis orthologue, it has been postulated that 
PknH-dependent phosphorylation of M. tuberculosis DacB1 regulates the synthesis of 
peptidoglycan, a key component of the mycobacterial cell envelope (Zheng et al. 2007). A 
final example is MmpL7, a member of the RND (resistance, nodulation and cell division) 
family of transporters, which is thought to be involved in the transport of phthiocerol 
dimycocerosate and known to be essential for virulence (Camacho et al. 2001, Cox et al. 
1999), has been shown to undergo phosphorylation. The last finding suggests that kinases 
could also play an important role in regulating the transport of cell wall components (Pérez et 
al. 2006). 
 
Considering the large repertoire of polyketides and complex lipids present in M. tuberculosis, 
STPKs could play an important role in regulating the metabolism of these molecules. There 
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is now evidence to suggest that phosphorylation may also participate in the regulation of 
mycolic acids. The !-ketoacyl-ACP synthases, KasA and KasB, of the mycobacterial FAS-II 
system involved in fatty acid elongation, represent STPK substrates and phosphorylation of 
KasA and KasB differentially modulates their condensing activity in vitro (Molle et al. 
2006). The present study was undertaken to address the question of whether mycolic acid 
synthesis in general might be influenced by STPK-dependent regulatory mechanisms. Here, 
Mt-FabH has been identified as a new substrate of the M. tuberculosis STPKs and defined its 
phosphorylation state. This has allowed the role and effect of Mt-FabH phosphorylation to be 
investigated (Veyron-Churlet et al. 2009). 
 
3.2. Materials and Methods 
3.2.1. Bacterial strains and growth conditions. 
Strains used for cloning and expression of recombinant proteins were E. coli TOP10 
(Invitrogen) and E. coli BL21(DE3)pLysS (Novagen). Strains were grown at 37 °C in LB 
medium supplemented with 100 µg/ml ampicillin or 25 µg/ml kanamycin when required. M. 
bovis BCG Pasteur 1173P2 strain was plated on Middlebrook 7H10 agar supplemented with 
OADC (Difco) and kanamycin (25 µg/ml) when required or grown in Sauton’s medium 
containing 0.05 % Tyloxapol (Sigma). 
 
3.2.2. Cloning, expression and purification of Mt-FabH and mutant proteins. 
The initial cloning work was performed by Dr. R. Veyron-Churlet and co-workers 
(Universités de Montpellier II et I, France) and vectors were provided for over-expression 
and purification. The Mt-FabH gene was amplified by PCR using M. tuberculosis H37Rv 
chromosomal DNA as a template and the primers 5"-taatagctcatatgacggagatcgccacgaccagc-3" 
and 5"-taatagctgctagctcaacccttcggcattcgcac-3" containing an NdeI or NheI restriction site 
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respectively (underlined). This 1008-bp amplified product was then digested by NdeI and 
NheI and ligated into the pETTev plasmid, a variant of pET15b (Novagen) that includes the 
replacement of the thrombin site coding sequence with a tobacco etch virus protease site 
(Cohen-Gonsaud et al. 2004), thus generating pETTev-Mt-fabH. Site-directed mutagenesis 
was performed directly on pETTev-Mt-fabH using inverse PCR amplification with the 
following self-complementary primers: 5"-cgtccgacgagtggatctacgcccgaaccggcatcaagac-3" and 
5"-gtcttgatgccggttcgggcgtagatccactcggacg-3" for Mt-FabH(T45A) and 5"-
cgtccgacgagtggatctacgaccgaaccgcgatcaagac-3" and 5"-
gtcttgatgccggttcggtcgtagatccactcgtcggacg-3" for Mt-FabH(T45D) (the corresponding 
substitutions are shown in boldface type). All constructs were verified by DNA sequencing. 
Recombinant strains harbouring the Mt-FabH-expressing constructs were used to inoculate 
200 ml of LB medium supplemented with ampicillin and resulting cultures were incubated at 
37 °C with shaking until the OD600 reached 0.5. At this point, 1 mM IPTG was added and 
growth was continued for 3 h at 37 °C. Purifications of Mt-FabH(WT), Mt-FabH(T45A), and 
Mt-FabH(T45D) were performed as described earlier (Molle et al. 2006; see section 2.2.2.3). 
 
3.2.3. Over-expression and purification of Mt-FabH in M. bovis BCG. 
All M. bovis BCG work was performed by the lab of Veyron-Churlet at the Universités de 
Montpellier II et I. Briefly, the M. tuberculosis H37Rv Mt-fabH gene was amplified using the 
following primers: pVV16-Mt-fabH-up (5"-gataggacgcatatgacggagatc-3") and pVV16-Mt-
fabH-lo (5"-aagcttacccttcggcattcgcaccac-3") containing an NdeI and HindIII site, respectively. 
The PCR product was cut with NdeI/HindIII enabling direct cloning into the pVV16 
expression vector cut with the same enzymes (Jackson et al. 2000). This plasmid harbours 
the hsp60 promoter as well as a His tag for expression of C-terminal His-tagged fusion 
proteins. The resulting vector, pVV16-Mt-fabH, was used to transform M. bovis BCG. 
Purification of soluble Mt-FabH-His6 was performed on Ni2+-nitrilotriacetic acid-agarose 
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beads, as described previously (Molle et al. 2006). 
 
3.2.4. In vitro kinase assay. 
In vitro phosphorylation was performed by Dr. R. Veyron-Churlet as previously described 
(Molle et al. 2003a), with 2 µg of Mt-FabH in 20 µl of buffer P (25 mM Tris#HCl, pH 7.0, 1 
mM DTT, 5 mM MgCl2, 1 mM EDTA) with 200 Ci/ml [$-33P]-ATP corresponding to 65 nM 
(3000 Ci/mmol; PerkinElmer Life Sciences) and 0.6–4.2 µg of kinase in order to obtain for 
each specific kinase its optimal autophosphorylation activity for 30 min at 37 °C. Cloning, 
expression, and purification of the eight recombinant GST-tagged STPKs from M. 
tuberculosis were described previously (Molle et al. 2006). 
 
3.2.5. Analysis of the phosphoamino acid content of Mt-FabH. 
Mt-FabH samples phosphorylated in vitro in the presence of GST-tagged PknF (or PknA) and 
[$-33P]-ATP were separated by one-dimensional gel electrophoresis and electroblotted onto 
an Immobilon polyvinylidene difluoride membrane (performed by Veyron-Churlet and 
colleagues). Analysis of the phosphoamino acid content was done as reported previously 
(Molle et al. 2003a). 
 
3.2.6. Mass spectrometry analysis. 
Mass spectrometry experiments and analyses were performed by Dr. R. Veyron-Churlet. 
Purified Mt-FabH(WT) and Mt-FabH(T45A) proteins were subjected to in vitro 
phosphorylation by GST-tagged PknF or PknA as described above, except that [$-33P]-ATP 
was replaced with 5 mM cold ATP. Subsequent mass spectrometry analyses were performed 
as previously described (Fiuza et al. 2008). 
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3.2.7. Two-dimensional gel electrophoresis and western blot analysis. 
M. bovis BCG crude lysates were prepared as described earlier (Molle et al. 2006) and 
performed by Veyron-Churlet et al. Approximately 150 µg of total soluble proteins were 
loaded onto a 7 cm immobiline strip (Bio-Rad, pH 3.9–5.1) and electrophoresed in a Protean 
IEF Cell (Bio-Rad) in the first dimension and on a 10 % SDS-PAGE in the second 
dimension. Proteins were then blotted on a polyvinylidene difluoride membrane and probed 
with a rabbit anti-Mt-FabH antibody raised against recombinant Mt-FabH (1:250 dilution). 
The membrane was then incubated with horseradish peroxidase-conjugated anti-rabbit 
antibodies (1:5,000 dilution), and detection of the different Mt-FabH isoforms was carried 
out using the Western Lightening Reagent (PerkinElmer Life Sciences) according to the 
manufacturer’s instructions. 
 
3.2.8. Mt-FabH condensation assay. 
The condensing activity of Mt-FabH was assayed as described by Brown et al. (2005), by 
mixing 50 µM holo-AcpM (mycobacterial acyl carrier protein), 1 mM !-mercaptoethanol, 0.1 
M sodium phosphate buffer (pH 7.0), 50 µM malonyl-CoA, 45 nCi of [2-14C] malonyl-CoA 
(specific activity, 55 Ci/mol), 12.5 µM palmitoyl-CoA and 0.3 µg of Mt-FabD in a final 
volume of 40 µl. The Mt-FabD protein was added to generate the malonyl-AcpM substrate 
for the reaction in situ. A mixture of holo-AcpM containing 1 mM !-mercaptoethanol was 
incubated at 37 °C for 30 min to ensure complete reduction of AcpM, prior to the addition of 
the remaining components (except Mt-FabH). The reaction was initiated by the addition of 
0.5 µg of Mt-FabH, held at 37 °C for 40 min and quenched by adding 5 mg/ml NaBH4 in 100 
mM K2HPO4, 100 mM KCl, 30 % THF. This resulted in the liberation of !-ketoacyl groups 
from their respective thioesters as acyl-1,3-diols, which were extracted with water-saturated 
toluene. The radiolabelled products were then quantified by liquid scintillation counting. 
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3.2.9. Mt-FabH transacylation assay. 
Acyl transfer was assessed using [9,10-3H]-myristoyl-CoA (specific activity 57.0 Ci/mmol) 
to follow the transacylation of the acyl chain from acyl-CoA to the active site Cys-122 of Mt-
FabH. The reaction mixture consisted of 50 mM Tris#HCl, pH 7.5 (Buffer A), 250 pmol of 
[3H]-myristoyl-CoA (14.6 nCi), and 4 µg of WT or mutant Mt-FabH (110 pmol) in a final 
volume of 60 µl. The reaction was held at room temperature for 15 min, and 200 µl of Ni2+-
charged chelating Sepharose fast flow chromatography medium (50 % slurry in buffer A) 
was added. After a further 5 min, the slurry was diluted by adding 300 µl of buffer A and 
unbound C14-CoA was then removed by filtration (cellulose nitrate, 0.45 µm). The beads 
were washed with 20 ml of buffer A before the filters were removed to vials for liquid 
scintillation counting. 
 
3.2.10. Malonyl-AcpM decarboxylation assay. 
The methods used by Brown et al. (2005) and Shorrosh et al. (1996) have been combined 
and modified to investigate the decarboxylation of malonyl-CoA by wild-type Mt-FabH and 
mutants. Malonyl-AcpM was synthesised from malonyl-CoA and holo-AcpM in situ using 
Mt-FabD. The initial reaction mixture of 25 mM Tris#HCl (pH 7.5), 12 µM AcpM, and 1 mM 
DTT in a volume of 28 µl was held at 4 °C for 30 min. [2-14C]-malonyl-CoA (160 nCi) and 
0.3 µg of Mt-FabD were added and incubated at 37 °C for 1 h prior to the addition of 5 µg of 
either wild-type Mt-FabH or mutants. The reaction was quenched after 1.5 h at 37 °C by the 
addition of 900 µl of ice-cold 10 % (w/v) trichloroacetic acid at 4 °C and 50 µl of 2 mg/ml 
bovine serum albumin and incubated on ice for 20 min. The solution was centrifuged at 
27,000 % g for 15 min, the protein pellets were washed with 900 µl of ice-cold 10 % (w/v) 
trichloroacetic acid and then centrifuged again. The pellet was dried to remove excess 
trichloroacetic acid and resuspended in 40 µl of 50 mM Tris#HCl (pH 7.4). Ten µl of 2 M 
hydroxylamine (pH 7.0) was added to form hydroxamate derivatives of malonyl-CoA and 
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acetyl-CoA and the reaction mixture was incubated at 37 °C for 1 h. Of the resulting mixture, 
5 µl was subjected to scintillation counting, before spotting the remaining 45 µl on 10 % 20 
cm Cellulose 300, F-254 glass-backed TLC plates (Fisher), where [14C]-acetyl-hydroxamate 
and [14C]-malonyl-hydroxamate were separated by butanol /acetic acid/water (8:2:3, v/v/v). 
Autoradiograms were obtained after exposing the plates for 7 days to Kodak X-Omat AR 
film. 
 
3.3. Results 
3.3.1. Mt-FabH is a substrate of mycobacterial STPKs. 
The coupling of the acyl and malonyl groups to form !-ketoacyl derivatives is catalysed by 
the !-ketoacyl-ACP synthase (KAS) components of the FAS-II system (Kremer et al. 2000b, 
Takayama et al. 2005). Three distinct KAS enzymes, Mt-FabH (KAS-III), KasA and KasB, 
operate in the M. tuberculosis FAS-II pathway. The Mt-FabH enzyme has been reported to 
act as the pivotal link between FAS-I and FAS-II by initiating the biosynthesis of very long 
chain fatty acids used in mycolate biosynthesis (Choi et al. 2000). It catalyses the 
condensation of an acyl-CoA substrate (a FAS-I end product) with malonyl-AcpM to 
generate a !-ketoacyl-AcpM product (Choi et al. 2000). Following reduction, an acyl-AcpM 
with two more carbons is generated. KasA and KasB are !-ketoacyl-AcpM synthases that 
further elongate the growing acyl chain in the mycobacterial FAS-II system (Bhatt et al. 
2007a, 2007b, Kremer et al. 2002a, Schaeffer et al. 2001) and have been shown to undergo 
post-translational modification by phosphorylation (Molle et al. 2006). Herein, it was 
investigated whether or not Mt-FabH would also represent a substrate for mycobacterial 
kinases. STPKs of M. tuberculosis (PknA, PknB, PknD, PknE, PknF, PknH, PknK, or PknL) 
were expressed as GST fusions and purified from E. coli as described previously (Molle et al. 
2006). Recombinant Mt-FabH was expressed and purified from E. coli BL21(DE3)pLysS 
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harbouring the pETTev-Mt-fabH plasmid. The protein contained a N-terminal His tag, which 
was subsequently removed following cleavage with the tobacco etch virus protease. 
Interestingly, when the different STPKs were incubated in the presence of Mt-FabH and [$-
33P]-ATP, phosphorylation of Mt-FabH was observed, although levels varied for different 
kinases. PknA and PknF were the most efficient kinases to phosphorylate Mt-FabH (Figure 
3-1 A). PknD, PknE and PknH, which display strong autophosphorylation activity in vitro, 
phosphorylated Mt-FabH to a lesser extent than PknA or PknF. PknB, PknK, and PknL did 
not phosphorylate Mt-FabH, which, at least for PknK and PknL, may be due to their very low 
autokinase activity. STPKs usually migrate as diffuse bands, reflecting the different levels of 
phosphorylation for each isoform and this aberrant profile of migration of M. tuberculosis 
kinases has already been reported in earlier studies (Canova et al. 2008, Molle et al. 2003a, 
2003b, Peirs et al. 1997). These results are consistent with the finding that PknA and PknF 
also efficiently phosphorylate KasA and KasB (Molle et al. 2006). In contrast, although 
PknB efficiently phosphorylates KasA and KasB, it failed to phosphorylate Mt-FabH in vitro 
(Figure 3-1 A). Together, these data suggest different levels of substrate specificity of the 
various STPKs. 
 
3.3.2. PknF phosphorylates Mt-FabH in vitro on threonine residues. 
To examine the nature of the Mt-FabH-phosphorylated residues, the phosphoamino acid 
content of PknF-phosphorylated Mt-FabH was analysed. The Mt-FabH protein (3 µg) was 
labelled with [$-33P]-ATP in vitro, separated by SDS-PAGE, excised and subjected to acid 
hydrolysis. Mt-FabH was exclusively phosphorylated on threonines (Figure 3-1 B). Similar 
results were obtained when Mt-FabH was phosphorylated with PknA. Understanding the 
potential regulatory role that phosphorylation of a given kinase substrate might play 
necessitates the identification of the specific sites undergoing phosphorylation. Although 
experimentally challenging, liquid chromatography/MS/MS mass spectrometry has allowed 
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the different phosphorylation sites to be deciphered in a sequence-specific fashion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3-1. In vitro phosphorylation of Mt-FabH. (A) In vitro phosphorylation of Mt-
FabH by mycobacterial STPKs. Eight recombinant STPKs (PknA-PknL) encoded by the M. 
tuberculosis genome were expressed and purified as GST fusions and incubated with 
purified His-tagged Mt-FabH and [$-33P]ATP. The quantity between the STPKs was varied 
from 0.6 to 4.2 µg in order to obtain for each specific kinase its optimal 
autophosphorylation activity. Samples were separated by SDS-PAGE (top) and visualised 
by autoradiography (bottom). The upper bands illustrate the autokinase activity of each 
STPK, whereas lower bands reflect phosphorylation of Mt-FabH. (B) Phosphoamino acid 
content of Mt-FabH. Mt-FabH was phosphorylated in vitro in the presence of PknF and [$-
33P]ATP, analysed by SDS-PAGE, electroblotted onto an Immobilon polyvinylidene 
difluoride membrane, excised, and hydrolysed in acid. The phosphoamino acids thus 
liberated were separated by electrophoresis in the first dimension (1D) and ascending 
chromatography in the second dimension (2D). After migration, radioactive molecules were 
detected by autoradiography (bottom). Authentic phosphoserine (P-Ser), phosphothreonine 
(P-Thr), and phosphotyrosine (P-Tyr) were run in parallel as internal standard controls and 
visualised by ninhydrin staining (top). Figure produced by Veyron-Churlet et al. (2009). 
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3.3.3. Mt-FabH is phosphorylated on a unique threonine residue. 
To identify which of the 22 threonines of Mt-FabH correspond to the phosphorylated site(s), 
recombinant Mt-FabH was incubated with unlabelled ATP in the presence of PknF and 
subjected to mass spectrometry analysis after tryptic digestion. ProteinPilot® database 
searching software (version 2.0; Applied Biosystems), using the Paragon method with 
phosphorylation emphasis, was used to detect and identify the phosphorylated peptides. The 
sequence coverage of the protein was 98 %, and phosphorylation occurred only on peptide 
26–50 with an 80 Da mass increment from 2,978.41 to 3,058.39 Da (monoisotopic mass). 
The MS/MS spectrum of the corresponding triply charged ion at m/z 1020.47 unambiguously 
confirmed the presence of the phosphate group on the threonine residue Thr-45 (Figure 3-2), 
consistent with phosphoamino analysis (Figure 3-1 B). The absence of mass increments 
lower or higher than 80 Da excludes the eventuality of any other post-translational 
modifications on Mt-FabH. 
 
Definitive identification and localisation of Thr-45 as being the unique phosphorylation site 
in Mt-FabH was achieved by site-directed mutagenesis to introduce a mutation that prevents 
specific phosphorylation (Thr-45-Ala replacement). This mutant was expressed, purified as a 
His-tagged protein in E. coli BL21(DE3)pLysS harbouring pETTev-Mt-fabH(T45A), and 
used in an in vitro kinase assay. After cleavage of the His-tag by the tobacco etch virus 
protease, the recombinant Mt-FabH(T45A) was incubated along with [$-33P]-ATP and PknF. 
The mixture was separated by SDS-PAGE and analysed by autoradiography. As shown in 
Figure 3-3 (left panel), equal amounts of Mt-FabH(WT) or mutant Mt-FabH(T45A) were 
used. Phosphorylation of Mt-FabH(T45A) was completely abrogated, compared with 
phosphorylation of Mt-FabH(WT), as evidenced by the absence of a specific radioactive band 
(Figure 3-3, right panel). These results unambiguously demonstrate that Mt-FabH(T45A) has 
lost its ability to be phosphorylated by PknF. 
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FIGURE 3-2. MS/MS spectrum of the triply charged ion [M + 3H]3+ at m/z 1,020.47 of 
peptide 26–50 (monoisotopic mass 3,058.39 Da). The unambiguous location of the 
phosphate group on Thr-45 was shown by observation of the “y” C-terminal daughter ion 
series. Starting from the C-terminal residue, all y ions lose phosphoric acid (-98 Da) after 
the Thr-45 phosphorylated residue. Figure produced by Veyron-Churlet et al. (2009). 
 
An additional round of mass spectrometry analysis was also performed directly on Mt-
FabH(T45A) pretreated with ATP and PknF, which failed to identify any additional 
phosphate group that could eventually have arisen as a compensatory mechanism to the loss 
of the Thr-45 phosphorylation (data not shown). 
 
In order to investigate whether Thr residue(s) other than Thr-45 could be phosphorylated by 
other STPKs, Mt-FabH was incubated with [$-33P]-ATP in the presence of PknA, PknD, 
PknE, or PknH, which are all able to phosphorylate Mt-FabH in vitro (Figure 3-1 A). In fact, 
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the Thr-45-Ala substitution completely abrogated in vitro phosphorylation of Mt-
FabH(T45A) by PknA/D/E/H in comparison with Mt-FabH(WT), indicating that Thr-45 
represents the unique phosphorylation site for all kinases. It is believed that this is the first 
demonstration that different mycobacterial kinases can interact with and phosphorylate an 
identical phosphorylation site in a given substrate. 
 
 
 
 
 
 
 
 
 
 
FIGURE 3-3. In vitro phosphorylation of the Mt-FabH(T45A) mutant. Purified Mt-
FabH(WT) and Mt-FabH(T45A) were incubated with PknF and [$-33P]-ATP. Samples were 
separated by SDS-PAGE (left) and visualised by autoradiography (right). Figure produced 
by Veyron-Churlet et al. (2009). 
 
3.3.4. Mt-FabH is phosphorylated in vivo in M. bovis BCG on Thr-45. 
To assess the relevance of in vitro phosphorylation, the in vivo phosphorylation pattern of 
Mt-FabH in M. bovis BCG Pasteur was investigated. A proteomic approach was adopted in 
which total soluble M. bovis BCG proteins were resolved on a two-dimensional gel, 
subsequently transferred to a membrane, and probed with antibodies raised against M. 
tuberculosis FabH. Two spots were detected in a pH range close to the predicted pI of 4.8 of 
Mt-FabH (Figure 3-4 A). These spots presumably correspond to two Mt-FabH isoforms 
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differing by a translational modification of the protein. Since a phosphate group renders the 
total charge of a protein more negative, a phosphorylated protein is expected to migrate 
toward a more acidic pH on a two-dimensional gel. Thus, the two isoforms presumably 
correspond to the nonphosphorylated (nP) and the monophosphorylated (P) isoforms of Mt-
FabH (Figure 3-4 A). 
 
To further support in vivo phosphorylation of Mt-FabH, a recombinant M. bovis BCG strain 
was designed allowing the over-expression of a soluble His-tagged version of the protein. 
Cultures of M. bovis BCG harbouring the pVV16-Mt-fabH plasmid were collected, lysed and 
fractionated in order to separate the soluble cytosolic compartment from the cell envelope. 
Soluble Mt-FabH was then purified to homogeneity by affinity chromatography on nickel-
containing beads under native conditions and subjected to two-dimensional gel 
electrophoresis. As shown in Figure 3-4 B, two spots, presumably corresponding to the 
nonphosphorylated form, followed in the acidic direction by a monophosphorylated form of 
Mt-FabH, were clearly detected. The more acidic spot was excised from the acrylamide gel 
and analysed by mass spectrometry after tryptic digestion. The MS/MS spectrum of the 
corresponding triply charged ion unambiguously confirmed the presence of a single 
phosphate group on the threonine residue 45, consistent with the phosphoacceptor identified 
in in vitro phosphorylated Mt-FabH (Figure 3-5). Whether the phosphorylation of Mt-FabH 
remains constant or is a growth phase-dependent phenomenon is presently not known and 
requires investigation. In addition, it would be particularly interesting to monitor the 
dynamics of Mt-FabH phosphorylation in cultures growing under different conditions 
(temperature, low oxygen concentration, etc.). 
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FIGURE 3-4. In vivo phosphorylation of Mt-FabH in M. bovis BCG. (A) Detection of 
phosphorylated Mt-FabH in M. bovis BCG crude lysates. Approximately 150 µg of total 
soluble proteins from M. bovis BCG lysate were loaded on a 7 cm immobiline strip (pH 
3.9–5.1; Bio-Rad) and electrophoresed on a Protean IEF Cell (Bio-Rad) for the first 
dimension and on a 10 % SDS-PAGE for the second dimension. Proteins were then 
transferred to a polyvinylidene difluoride membrane and probed with rabbit antibodies 
raised against the M. tuberculosis Mt-FabH protein. Following incubation with Horseradish 
peroxidase-conjugated anti-rabbit serum as secondary antibody, detection was carried out 
using the Western Lightening Reagent (PerkinElmer Life Sciences). A selected portion of 
the membrane that strongly reacted with the antibodies, corresponding to Mt-FabH (34.8 
kDa, pI 4.8), is represented. (B) Phosphorylation profile of Mt-FabH purified from 
recombinant M. bovis BCG carrying the pVV16-Mt-fabH construct. Cultures were 
recovered and lysed and the soluble fraction was incubated with Ni2+-nitrilotriacetic acid-
agarose beads in order to purify His-tagged Mt-FabH, which was then subjected to two-
dimensional gel electrophoresis and stained with Coomassie Blue. The dashed circle 
indicates the position of the spot that was subsequently excised from the polyacrylamide gel 
and analysed by mass spectrometry. The arrowheads representing the different 
phosphorylated isoforms are indicated. nP, non-phosphorylated; P, monophosphorylated. 
Figure produced by Veyron-Churlet et al. (2009). 
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FIGURE 3-5. MS/MS spectrum of the triply charged ion at m/z 887.38 (monoisotropic 
mass: 2,659.13 Da). Tryptic peptide with no missed cleavage with the characteristic 
phosphorylation on the Thr-45 residue from in vivo purified Mt-FabH. Figure produced by 
Veyron-Churlet et al. (2009). 
 
Overall, these results clearly indicate that (i) Mt-FabH is phosphorylated in vivo, (ii) two 
dominant forms of Mt-FabH co-exist in M. bovis BCG, a nonphosphorylated and a 
monophosphorylated form and (iii) Mt-FabH is phosphorylated on a unique residue (Thr-45) 
both in vitro and in vivo. 
 
3.3.5. Localisation of Thr-45 on the Mt-FabH structure. 
In order to understand the effect of Thr-45 phosphorylation on the enzymatic behavior of Mt-
FabH, the location of this residue with respect to the substrate binding site and the catalytic 
residues was examined, taking advantage of the available three-dimensional structures of Mt-
FabH (Alhamadsheh et al. 2007, Brown et al. 2005, Musayev et al. 2005, Scarsdale et al. 
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2001). As Figure 3-6 illustrates, solvent-exposed Thr-45 is situated more than 20 Å away 
from the catalytic cysteine at the surface of Mt-FabH. Thus, it is unlikely that a phosphoryl 
group on Thr-45 will have a noticeable effect on the catalytic reaction mechanism. However, 
in the structure of apo-Mt-FabH (PDB entries 1HZP (Scarsdale et al. 2001) and 1M1M 
(Brown et al. 2005)), Thr-45 is seen in close proximity (&6 Å) to residues Arg-46 and Trp-
42. Both residues play important roles in binding coenzyme A, the donor substrate in the 
ketoacyl synthase reaction; in the CoA-bound structure of E. coli FabH (PDB entry 1HNJ 
(Qiu et al. 2001)), Arg-46 coordinates the pyrophosphate, whereas Trp-42 stacks on top of 
the adenine base. The latter interaction is also seen in the methyl-CoA disulfide-bound 
structure of Mt-FabH (PDB entry 2EFT (Alhamadsheh et al. 2007)). Indeed, it has been 
shown in a previous study that alanine mutations on these sites markedly reduced (although 
they do not completely abrogate) !-ketoacyl synthase activity (Brown et al. 2005), 
underscoring a role of these residues in substrate binding. A phosphate group on Thr-45 
would offer an alternative salt bridge interaction for Arg-46, which would require this residue 
to assume a rotamer conformation incompatible with simultaneous binding to the CoA-
pyrophosphate. Likewise, a phosphorylated Thr-45 may influence the conformational 
freedom of Trp-42, impeding the stacking interaction of this residue with the adenine base. 
Moreover, it is conceivable that phosphorylation of Thr-45 affects the interaction of Mt-FabH 
with the acyl carrier protein AcpM, which also must bind in the vicinity of the narrow 
substrate binding channel of Mt-FabH. Thus, the structural analysis suggests that 
phosphorylation of Thr-45 may affect substrate binding and/or protein-protein interactions 
with other FAS-II partners (Veyron-Churlet et al. 2004). The condensing activities of wild-
type Mt-FabH with that of point mutants, Thr-45 to alanine and aspartic acid, were assessed 
and compared in vitro in order to test this hypothesis. These point mutations prevent Mt-
FabH phosphorylation and introduce a mimic of the negative charge of a phosphate group, 
respectively. 
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FIGURE 3-6. Location of the Thr-45 phosphorylation site on the Mt-FabH crystal 
structure. (A) Two orthogonal views of the Mt-FabH dimer (PDB entry 1M1M (Brown et 
al. 2005); grey and cyan ribbon) superimposed with malonyl-CoA-bound E. coli FabH 
(PDB entry 1HNJ (Qiu et al. 2001)) illustrating, for one protomer, the respective locations 
of the active site cysteine (yellow spheres), the substrate channel (malonyl-CoA in blue 
spheres), and Thr-45 (red spheres). (B) Close-up view of the Mt-FabH substrate channel, 
demonstrating surface exposure of Thr-45 and its proximity to Mt-FabH residues Arg-46 
and Trp-42. Blue sticks represent residues of E. coli FabH bound to malonyl-CoA (PDB 
entry 1HNJ (Ec-FabH)); green sticks show the corresponding side chains of Mt-FabH (PDB 
entry 1M1M). Residue numbers refer to the amino acid sequence of Mt-FabH. Figure 
produced by Veyron-Churlet et al. (2009). 
 
3.3.6. Enzymatic activity is negatively regulated in an Mt-FabH(T45D) mutant. 
The reaction catalysed by the Mt-FabH homodimer initiates with the binding of an acyl-CoA 
generated by FAS-I, following transacylation of the acyl chain of the bound CoA to the 
!"
#"
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catalytic Cys-122, allowing the CoA moiety to dissociate from the protein and the malonyl-
AcpM to bind to the active site liberated by CoA (Scarsdale et al. 2001). The malonyl-AcpM 
is then decarboxylated to form a carbanion, which in turn reacts with the Cys-122-bound acyl 
group to generate the final product of the reaction, the !-ketoacyl-AcpM. Therefore, an 
assessment was made as to whether or not phosphorylation could have an influence on the 
different activities characterising Mt-FabH (i.e. the condensation, transacylation, and 
malonyl-AcpM decarboxylation). 
 
Following a strategy that has been successfully used to demonstrate that regulation of Wag31 
by phosphorylation is important during active cell growth in mycobacteria (Kang et al. 
2008a), a phosphorylation mimic of FabH, Mt-FabH(T45D), was expressed and purified. 
Previous studies have shown that acidic residues, such as Asp or Glu, qualitatively 
recapitulate the effect of phosphorylation with regard to functional activity (Cottin et al. 
1999). Condensing activities of Mt-FabH(WT), Mt-FabH(T45A), and Mt-FabH(T45D) were 
determined and compared. The overall condensing activities of Mt-FabH(WT) and Mt-
FabH(T45A) were similar (Figure 3-7 A). This suggests that Thr-45, unlike its neighbouring 
residue Arg-46 (Brown et al. 2005), does not play a critical role in the condensation reaction, 
consistent with its surface-exposed localisation (Figure 3-6). In contrast, Mt-FabH(T45D) 
expressed a 42 % reduced activity with respect to Mt-FabH(WT) activity. Since the Asp 
mutant mimics constitutive phosphorylation of Mt-FabH, these results suggest that the 
introduction of a negative charge at position 45 has a negative impact on the condensing 
activity of the enzyme. Phosphorylation may modulate Mt-FabH on a fine tuned level rather 
than a strict on/off mechanism, as previously proposed for Arg-46, involved in the binding of 
acyl-CoA substrates (Scarsdale et al. 2001), since decreased overall activity was observed in 
the Mt-FabH(R46A) mutant (Brown et al. 2005). 
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FIGURE 3-7. Comparative enzymatic activities of wild-type and mutant Mt-FabH 
proteins in KAS-III and part-reaction assays. Legend over page. 
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FIGURE 3-7. Comparative enzymatic activities of wild-type and mutant Mt-FabH 
proteins in KAS-III and part-reaction assays. Each part-reaction step is depicted by a 
schematic representation beside the corresponding bar charts. * Indicates the position of the 
radiolabelled carbon. In each schematic, the final product is shown. (A) Whole condensing 
activity. The assays were performed in triplicate on two separate protein preparations and 
activity was assessed by the scintillation counting method using AcpM and a palmitoyl-
CoA primer. (B) The extent of transacylation activity of Mt-FabH and its mutants was 
determined by quantifying the binding of [3H]-myristoyl-CoA to the protein after incubation 
by liquid scintillation counting of protein-bound radiolabelled acyl chains captured on Ni2+-
charged chelating Sepharose beads. Assays were performed in triplicate on two separate 
protein preparations. (C) The malonyl-AcpM decarboxylation activity was obtained from a 
direct densitometric reading from the autoradiogram normalised to the activity of Mt-
FabH(WT) with AcpM and expressed as a percentage, as described in section 3.2.10., and 
by Brown et al. (2005). WT, wild-type. 
 
When the transacylation reaction was examined, both Mt-FabH(WT) and Mt-FabH(T45A) 
behaved similarly (Figure 3-7 B). However, as for the condensing activity, the Mt-
FabH(T45D) mutant exhibited a significant reduced transacylase activity compared with Mt-
FabH(WT). As mentioned above, the presence of a negative charge affects part-reaction 
activity of Mt-FabH. These results are in favour of a model where the substitution of the 
neighbouring Arg-46 by Ala has a moderate effect on the transacylation activity of Mt-FabH 
(Brown et al. 2005). 
 
In the malonyl-AcpM decarboxylation assay, the activity of Mt-FabH(WT) was arbitrarily 
fixed at 100 %. The substitution of Thr-45 by Ala only slightly affects the decarboxylation 
activity (Figure 3-7 C). Remarkably, the decarboxylative activity of Mt-FabH(T45D) was 
severely inhibited and was found to represent about 10 % of the wild-type activity (Figure 3-
7 C). As mentioned above, mimicking the phosphorylation state of Thr-45 fits properly with 
the overall effects observed in the case of R46A mutant, in which the decarboxylation 
activity was almost completely abrogated (Brown et al. 2005). As with the R46A mutation, 
the condensation activity of the T45D mutant protein was less affected than observed in the 
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decarboxylation activity. This can be attributed to the enzymatic state of the protein during 
the decarboxylation assays, upon which no acyl chain is bound to the active site Cys, which 
may change the overall decarboxylation activity of the protein, since the two part-reaction 
assays are not true kinetic representations of the condensation activity. 
 
3.4. Discussion 
The !-ketoacyl-ACP synthase III of M. tuberculosis (Mt-FabH) links the FAS-I and FAS-II 
systems, catalysing the condensation of FAS-I-derived acyl-CoAs with malonyl-AcpM 
(Brown et al. 2005, Choi et al. 2000, Scarsdale et al. 2001). The first step of the reaction, 
catalysed by a Mt-FabH homodimer, involves transfer of an acyl group from acyl-CoA to the 
enzyme active site. This is followed by a two-carbon acyl chain extension through a Claisen-
type condensation with malonyl-AcpM. The resulting !-ketoacyl-AcpM product is then 
reduced to acyl-AcpM by the !-ketoacyl-AcpM reductase MabA (Banerjee et al. 1998, 
Cohen-Gonsaud et al. 2002, Marrakchi et al. 2002), followed by a dehydration step carried 
out by the newly identified !-hydroxyacyl-AcpM dehydratases Rv0635-7 (HadA, HadB and 
HadC, respectively), also known as FabZ", FabZ and FabZ"" (Brown et al. 2007a, Sacco et al. 
2007), and reduced by the enoyl-AcpM reductase InhA, the primary target of isoniazid 
(Banerjee et al. 1994, Vilchèze et al. 2006, Zhang et al. 1992). In this study, Mt-FabH has 
been identified as a substrate of STPKs in mycobacteria. Phosphorylation of this enzyme 
occurs both in vitro and in vivo on a single and identical residue, Thr-45. It is noteworthy 
that, similarly to other FAS-II enzymes, Mt-FabH interacts with several STPKs in vitro, 
suggesting that it may be regulated by multiple environmental signals. Table 3-1 reviews the 
current evidence of Mt-FAS-II enzyme phosphorylation and highlights the fact that STPKs 
are selective with regard to which enzymes they phosphorylate. Identification of the Thr-45 
phosphoacceptor allowed for the assessment of the role of phosphorylation on the different 
activities characterising Mt-FabH (condensation, transacylation, and malonyl-AcpM 
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decarboxylation). The comparative analysis of enzymatic activities in Mt-FabH and Thr-45 
point mutants clearly demonstrates that phosphorylation on residue 45 is able to exert a 
marked influence on the activity of this enzyme and thus supports the hypothesis of 
regulation through STPK-mediated phosphorylation. Based on structural constraints, a direct 
effect on catalysis can be ruled out. However, the structural parameters are compatible with 
the assumption that Thr-45 phosphorylation regulates transacylation, decarboxylation, and 
condensing activities through affecting substrate binding. Precisely how this regulatory effect 
comes to bear remains to be elucidated. Interactions of a phosphorylated Thr-45 with 
adjacent residues Arg-46 and Trp-42 are likely to affect binding of CoA. Nonetheless, the 
enzymatic data suggest that the latter effect is less important than the interference with 
binding of AcpM, demonstrated by the 90 % reduction of decarboxylation activity in Mt-
FabH(T45D) compared with wild-type. Indeed, the parallel effects on decarboxylation of the 
Arg-46-Ala mutation in Brown et al. (2005) and that of the Thr-45-Asp mutation observed 
here hint that the Thr-45–Arg-46 surface patch constitutes a critical element of the interaction 
with AcpM. Together, these data suggest that phosphorylation may fine-tune the interactions 
of Mt-FabH with the components of the FAS-II system. 
 
Previously, it has been shown that Mt-FabD, KasA, and KasB are substrates of M. 
tuberculosis STPKs (Molle et al. 2006). There is now a strong body of evidence to suggest 
that several FAS-II components are phosphorylated and that STPK-dependent 
phosphorylation can induce either positive or negative signalling to the different 
interconnected FAS-II complexes. Indeed, a model based on co-existence of multiple 
interconnected FAS-II systems has been proposed (Veyron-Churlet et al. 2004). It predicts 
the occurrence of four FAS-II systems responsible for the initiation, elongation, and 
termination steps of the mycolic acid pathway, each system characterised by a common 
enzyme core along with a specific condensase (Figure 3-8). 
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TABLE 3-1. Phosphorylation of the Mt-FAS-II enzymes by the known serine / threonine 
protein kinases. ! no phosphorylation; " moderate phosphorylation; "" efficient 
phosphorylation; ? unknown, not tested. Assembled from Molle et al. (2006, 2007), Slama 
et al. (2011), Veyron-Churlet et al. (2009, 2010). 
 
Ser/Thr protein kinase (Pkn) Mt-FAS-II 
enzyme A B D E F G H I J K L 
AcpM ! ! ! ! ! ! ! ! ! ! ! 
FabD "" " " " " ! "" ! ! ! " 
FabH "" ? " " "" ? " ? ? ! ! 
KasA "" "" " "" "" ! "" ! ! ! ! 
KasB "" "" "" "" "" ! "" ! ! ! " 
MabA " "" "" "" ! ? ! ? ! ! " 
HadAB/BC " " " " " ? " ? ? ? ! 
InhA "" "" ! "" ! ? ! ? ? ! " 
 
The “initiation FAS-II” (I-FAS-II) is characterised by the condensase Mt-FabH, which 
converts an acyl-CoA from FAS-I to form !-ketoacyl-AcpM. Upon completion of the FAS-II 
reductive cycle, this acyl-AcpM derived product primes the “elongation-1 FAS-II” (E1-FAS-
II) characterised by the condensase KasA. E1-FAS-II elongates the acyl-AcpM to longer 
chain acyl-AcpM products, which are then channelled into the “elongation-2 FAS-II” (E2-
FAS-II), comprising KasB that completes the meromycolate precursor synthesis (Bhatt et al. 
2007a, 2007b). Various enzymes modify this acyl product further to form the mature 
meromycolate (Takayama et al. 2005) before lastly, the polyketide synthase Pks13 (Portevin 
et al. 2004) of the “termination FAS-II” system catalyses the condensation of the 
meromycolate (C56) with the !-branch (C26) (produced by FAS-I) to generate the oxo-
mycolic acid. The Rv2509 enzyme reduces this product to yield mature mycolates (Bhatt et 
al. 2008). The results here support a model in which STPK-dependent phosphorylation of the 
condensases can induce either positive or negative signalling to the I-FAS-II and E-FAS-II 
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complexes. To support this further, preliminary experiments performed by Veyron-Churlet 
and co-workers have demonstrated that, in addition to KasA, KasB, and Mt-FabH, the 
remaining mycobacterial condensase, Pks13, is also phosphorylated by M. tuberculosis 
STPKs (Veyron-Churlet et al. 2009). Thus, the differential expression of the mycobacterial 
STPKs in response to stress /environmental conditions may directly influence the 
phosphorylation profile of all four condensases, which in turn may modulate the different 
interconnected FAS-II systems. It is, therefore, tempting to hypothesise that phosphorylation 
controls critical enzymatic steps of the FAS-II pathway and, subsequently, regulation of 
mycolic acid biosynthesis in order to promote adaptation to environmental changes and 
survival within the infected host. 
 
It is noteworthy that over-expression of Mt-FabH in M. bovis BCG leads to an unusual 
smooth texture of the colony morphology and is accompanied by alterations in complex lipid 
composition, including a decrease in phthiocerol dimycocerosate (PDIM) synthesis (Choi et 
al. 2000). These methyl-branched fatty acids are formed by unique enzymes, which utilise 
acyl-CoA primers rather than ACP-bound primers (Kolattukudy et al. 1997). Since Mt-FabH 
uses long chain acyl-CoA primers and not acyl-ACP primers (Choi et al. 2000), over-
expression of this enzyme in mycobacteria may decrease the pool of acyl-CoA primers 
available for PDIM and other related complex lipid biosynthetic pathways. In addition, 
complex lipids, such as PDIMs, have been shown to interact with host cells and participate in 
the virulence and pathogenesis of M. tuberculosis (Camacho et al. 1999, Cox et al. 1999). 
This suggests that the expression level of Mt-FabH or regulation of its activity by 
phosphorylation may also be a determinant for M. tuberculosis virulence by controlling the 
pool of acyl-CoAs available for complex lipid synthesis. Supporting the view of a connection 
between FAS-II and PDIM biosynthetic pathways, a recent study conducted by Kruh et al. 
(2008) described a novel interaction between KasA and polyketide modules involved in the 
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biosynthesis of PDIM. These observations suggest that regulation of the activity of 
condensing enzymes, such as Mt-FabH (and KasA), by phosphorylation may directly 
participate in the control of both the FAS-II and the PDIM pathways. Further studies are 
needed to ascertain this hypothesis. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3-8. Proposed regulatory role of condensase phosphorylation in mycolic acid 
initiation, elongation and termination. Mycolic acid biosynthesis is initiated via de novo 
biosynthesis of C16-26-CoA by the mycobacterial FAS-I and further extended to the 
meromycolate precursor by FAS-II. FAS-I provides both the initiation primer (C16-CoA) for 
FAS-II and the C24-26 fatty acid utilised by the Claisen-type condensing enzyme Pks13 
(belonging to the T-FAS-II system) during the formation of the non-reduced mycolic acid. 
The initiation primer is utilised by Mt-FabH (a feature of the I-FAS-II system), forming a !-
ketoacyl-AcpM product, which is further modified via the reductive cycle of FAS-II 
performed by MabA, HadA, HadB, HadC and InhA. The derived aliphatic acyl-AcpM is 
then used as the substrate of the condensing enzymes KasA and KasB of the E-FAS-II 
systems. KasA is involved in the elongation of the meromycolate precursors that are further 
extended to their full lengths by KasB. The condensing enzymes are shown in pink. 
Experimental evidence has demonstrated phosphorylation of all four condensases. 
Phosphorylation can either activate (+) or inhibit (–) the condensing activity. A question 
mark indicates that the effect of phosphorylation on the enzyme activity has not yet been 
investigated. Based on Veyron-Churlet et al. (2009) and Slama et al. (2011). 
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Although this work here provides evidence for the first time that phosphorylation of Mt-FabH 
occurs in vivo in mycobacteria, more work is required to address whether it influences the 
production of mycolic acids (and PDIM synthesis) during in vivo growth and, eventually, if it 
participates in mycobacterial survival /virulence within the infected host. Using specialised 
transduction, it is now feasible to isolate isogenic strains of M. tuberculosis differing by 
single point mutations in the genome (Vilchèze et al. 2006). This technology would be 
particularly useful to transfer T45A or T45D point mutations that will either prevent or 
mimic constitutive phosphorylation of Mt-FabH in M. tuberculosis and investigate whether 
phosphorylation of Mt-FabH represents an important physiological event in vivo. 
  CHAPTER 4 
Insights into mycobacterial FadB2, 
FadB3, FadB4 and FadB5 
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4.1. Introduction 
4.1.1. Mt-FadB2 and Mt-FadB3. 
Despite lipid biosynthesis having been well studied in mycobacteria (Bhatt et al. 2007a, 
Heath & Rock 2004, Takayama et al. 1972, Takayama et al. 2005), the extensive field of 
lipid degradation has not yet been investigated with equal intensity. The chemistry of the !-
oxidation pathway is similar to the reverse of lipid biosynthesis. Saturated long-chain fatty 
acids are first activated by CoA attachment and subsequently undergo oxidation by an acyl-
CoA dehydrogenase. This is followed by hydration catalysed by an enoyl-CoA hydratase to 
produce !-hydroxyacyl-CoA. The hydroxy group is further oxidised to form a !-ketoacyl-
CoA, which is then finally cleaved by a !-ketoacyl-CoA thiolase releasing acetyl-CoA and a 
saturated fatty acid that is two carbons shorter (Black & DiRusso 1994). While playing a 
general role in fatty acid turnover, in mycobacteria fatty acid !-oxidation may have a specific 
relevance for the physiology of the bacterium during survival within the hypoxic niche of a 
granuloma, a critical site of chronic infection. The glyoxylate cycle, which utilises acetyl-
CoA (produced by !-oxidation) to generate glucose by conserving the two carbon atoms lost 
as 2 CO2 in the TCA cycle, is crucial for the persistence of M. tuberculosis in the mouse 
model of infection (McKinney et al. 2000). Additionally, several studies have indicated that 
host-derived fatty acids could be a key source of carbon to the bacteria (Bishai 2000, Bloch 
& Segal 1956,  Sassetti & Rubin 2003) suggesting that infecting mycobacteria favour 
exploiting the lipid-rich environment of host tissues over synthesising their own lipids de 
novo (Wheeler et al. 1990, Wheeler & Ratledge 1994). 
 
The third step in !-oxidation is catalysed by a !-hydroxyacyl-CoA dehydrogenase [EC 
1.1.1.35], which converts the !-hydroxy group to a !-keto using NAD(P)+ as a co-factor 
(Figure 4-1). There are many genes annotated as acyl-CoA dehydrogenases in the M. 
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tuberculosis genome, including fadE1-36. There are two fadB genes, however, described 
specifically as !-hydroxybutyryl-CoA dehydrogenases, fadB2 and fadB3. In E. coli, the fadA 
and fadB genes form a single operon encoding the two proteins of the !-oxidation multi-
enzyme complex (DiRusso 1990). In M. tuberculosis there are five discrete fadB genes and 
six fadA genes. Recently, the function of Mt-FadA5 has been shown to catalyse the thiolysis 
of cholesterol, although the function(s) of the other five fadA genes are yet to be elucidated 
(Nesbitt et al. 2010). FadB1 is thought to perform the second step in the pathway, involving 
conversion of the trans-2-enoyl to the !-hydroxy, but despite having putative functions 
assigned, the actual function(s) of FadB2, B3, B4 and B5 remain unknown. The number of 
fadB genes may suggest a certain degree of redundancy amongst the FadB enzymes, 
especially as only FadB3 has been described as essential (Sassetti et al. 2003), but there is no 
evidence yet to show this. It is possible that the FadB enzymes are chain length-specific, like 
the short-, medium- and long-chain !-hydroxyacyl-CoA dehydrogenases found in 
mammalian mitochondria (El-Fakhri & Middleton 1982, McGuire et al. 1990). 
 
 
 
 
 
 
FIGURE 4-1. The proposed Mt-FadB2 and Mt-FadB3 reaction scheme. Mycobacterial !-
hydroxyacyl-CoA dehydrogenase catalyses the NAD(P)+-dependent reduction of !-
hydroxyacyl-CoA to !-oxoacyl-CoA. 
 
The Mt-FadB2 (Rv0468) sequence is homologous to the products of the M. smegmatis gene 
MSMEG0912 (91.6 % sequence similarity), the M. leprae gene Ml_2461 (94.4 % sequence 
similarity) and sections of the E. coli and Psuedomonas fragi FadB enzymes (Figure 4-2 A, 
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B). The fadB2 gene is interesting because it is conserved across mycobacteria, and also is 
located in the genome adjacent to icl1 (Figure 4-2 B). This gene encodes the glyoxylate shunt 
enzyme, isocitrate lyase, which has been shown to promote persistence of M. tuberculosis 
cells in an infected host (McKinney et al. 2000). Unlike fadB2, fadB3 is not conserved across 
mycobacteria. There is much less homology between Mt-FadB3 (Rv1715) and the closest M. 
smegmatis protein, MSMEG6791, sharing only 45.6 % sequence similarity (Labarga et al. 
2007). A similar homology is found between Mt-FadB2 and Mt-FadB3 (44.8 %). 
Interestingly, there is no homologue for Mt-FadB3 in M. leprae, which could suggest that the 
gene is not essential at all, given the vastly reduced genome of M. leprae (Cole et al. 2001). 
The M. bovis fadB3 gene is identical to that of M. tuberculosis, apart from a single point 
mutation (g!a) that has split the gene into two parts, Mb1742 and Mb1743, annotated as 
fadB3a and fadB3b respectively (Tuberculist). 
 
Prior to sequencing the first M. tuberculosis genome, a !-hydroxyacyl-CoA dehydrogenase 
enzyme from M. smegmatis had been characterised using a purified protein fraction 
containing !-hydroxyacyl-CoA dehydrogenase activity (Shimakata et al. 1979). This, and a 
previous study by the same group, found that the enzyme was involved in the acetyl-CoA-
dependent elongation of fatty acids, but failed to provide evidence for its involvement in fatty 
acid !-oxidation (Shimakata et al. 1977). 
 
4.1.2. Mt-FadB4 and Mt-FadB5. 
Two further M. tuberculosis fadB genes, fadB4 and fadB5, are also investigated here, albeit 
in not so much detail. The functions of mycobacterial FadB4 and FadB5 are unknown, 
although both are described as NADPH:quinone oxidoreductases (NQOs) [EC 1.6.5.5], 
enzymes that essentially catalyse the one-electron reduction of quinones (Lechat et al. 2008). 
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FIGURE 4-2. Sequence alignments. (A) Multiple sequence alignment of M. tuberculosis FadB2 
with mycobacterial homologues and other M. tuberculosis Fad proteins. The amino acid 
sequences of M. tuberculosis FadB2 (Mt_FadB2, accession number CAA17423) and FadB3 
(Mt_FadB3, accession number CAE55415) are compared with the amino acid sequence of 
homologues in M. smegmatis (Ms_0912, accession number ABK71785), M. leprae (Ml_2461, 
accession number CAC31978), E. coli (Ec_FadB, accession number AAC76849 residues 297–
624) and Psuedomonas fragi (Pf_FadB accession number 2D3T_A residues 297–624). The 
figure was generated using Clustal W and ESPript (available from http://expasy.ch/) and data for 
the corresponding secondary structure for Psudomonas fragi FadB (residues 297–624) was 
obtained from the Protein Data Bank. Red-filled boxes indicate residues conserved across all the 
species aligned and blue-boxed residues are those of high similarity. The triangles indicate the 
putative NAD+-binding site and the stars highlight residues of the hypothetical catalytic triad. 
(B) Maps of the genomic regions of M. tuberculosis H37Rv fadB2, M. smegmatis mc2155 
MSMEG0912 and M. leprae TN fadB2. 
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There is much evidence from other bacterial species and eukaryotes that these NQOs have an 
antioxidant or detoxifying function (Itoh et al. 1997, Shimada 2006, Triccas et al. 1999, 
Tumminia et al. 1993). Oxidative molecules are not only a bi-product of aerobic respiration 
but are also produced by macrophages and other lymphocytes to aid the killing of 
phagocytosed bacteria. It is therefore interesting to note that fadB4 is known to be up-
regulated during intracellular growth, which could be one of the many defence mechanisms 
mycobacteria have evolved in order to allow them to reside and multiply within the 
macrophage (Triccas et al. 1999). As such, FadB4 is a virulence factor and therefore 
demands attention. 
 
E. coli NQO enzymes 1 and 2 are membrane-bound. Membrane-bound quinone 
oxidoreductases are well studied in bacteria and are essential constituents of the respiratory 
chain. These insoluble proteins are NADH-dependent, require either FMN or FAD for 
activity, and some have iron-sulfur clusters as co-factors. Mycobacterial FadB4 and FadB5 
are, however, annotated as members of a distinct group of soluble NQOs, of which there are 
far fewer examples. There is one example of a soluble NQO in E. coli encoded by the gene 
qor. FadB4 and Qor share 44.5 % sequence similarity and FadB5 and Qor share 45.3 % 
sequence similarity. Thorn and co-workers (1995) determined the structure of this protein 
complexed with NADPH but were unable to elucidate a function. Later, Søballe & Poole 
(1999) found that Qor maintains ubiquinone in its reduced state thereby promoting its 
antioxidant function. Streptococcus gordonii has an oxidative stress response operon 
comprising three genes nosX, qor1 and qor2, the latter two being quinone oxidoreductases. 
The operon responds to environmental oxygen levels and oxidative stress and is important in 
biofilm formation (Loo et al. 2004). A similar finding was made in Staphylococcus aureus by 
Maruyama et al. (2003). The team identified that gene SA1989 encoded a protein with NQO-
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activity that was capable of the one-electron reduction of quinone to semiquinone and was 
more highly expressed when under oxidative stress conditions (Figure 4-3). 
 
 
 
 
 
 
 
FIGURE 4-3. Quinone metabolism. (A) The one-electron reduction of quinone to the 
semiquinone radical. (B) Oxidation of the semiquinone radical and generation of a 
superoxide anion (O2–). (C) Conversion of accumulated semiquinone radical to 
hydroquinone and (D) the two-electron reduction of quinone. Adapted from Maruyama et 
al. (2003). 
 
In eukaryotes, there are two types of soluble NQOs, DT-diaphorase and zeta-crystallin 
(Maruyama et al. 2003). The former, a flavoenzyme, detoxifies quinone by catalysing the 
NAD(P)H-dependent reduction of quinone with two electrons to produce hydroquinone. The 
latter, zeta-crystallin, does not require FMN or FAD and catalyses the NADPH-dependent 
one-electron reduction of quinone to produce the semiquinone radical. The radical is highly 
unstable and is thus readily oxidised back to quinone in the presence of oxygen to produce 
superoxide anions (Figure 4-3). Zeta-crystallin is a highly conserved protein, found in 
bacteria, plants and animals (Shimomura et al. 2003). There are three zeta-crystallin 
homologues in Arabidopsis thaliana of which P1-zeta-crystallin has been very well studied 
(Mano et al. 2000a, 2000b, 2002). P1 is oxidative stress-induced, it catalyses the NADPH-
dependent reduction of quinones, diamides and 2-alkenals of carbon chain C3-C9. The protein 
has highest specificity for 4-hydroxy-(2E)-nonenal, a major toxic product from lipid 
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peroxides. The P1 enzyme catalyses the hydrogenation of ",!-unsaturated bonds (but not the 
reduction of the aldehyde moiety) to give saturated aldehydes (Mano et al. 2002). Giving the 
importance of lipids to M. tuberculosis and the annotation of fadB4 and fadB5 as being 
involved in fatty acid degradation, the genes may have a role in lipid peroxide detoxification. 
 
The location of fadB4 in the genome may also suggest a role in detoxification. The gene is 
downstream of fadE23 and fadE24, both of which encode putative acyl-CoA 
dehydrogenases. These two genes were found to be induced upon isoniazid treatment. It was 
concluded that, rather than being directly linked to the isoniazid response, FadE23 and 
FadE24 may be involved in mechanisms related to the toxic effects of the drug (Wilson et al. 
1999). Speculatively, fadE24, fadE23 and fadB4 could form a detoxification operon that is 
induced during periods of toxic stress. 
 
The function of M. tuberculosis FadB4 was explored in a single study in 2008 (Scandurra et 
al. 2008). A "Mt-fadB4 deletion mutant was created and the effects were observed in a 
mouse model of infection. The mutant was found to be hypervirulent: cells replicated faster 
in the host than the wild-type strain and induced less TNF-" secretion in macrophages. As a 
result, mice infected with the mutant died sooner than those infected with wild-type M. 
tuberculosis. Several hypervirulent deletion mutants have been described in M. tuberculosis 
(Rousseau et al. 2003, Shimono et al. 2003) and other pathogens such as Cryptococcus 
(Nelson et al. 2001) and Shigella (Hachani et al. 2008). One reason for this is that the 
deletions are removing toxic protein products, thereby giving an advantage in the host, but 
confer reduced growth outside the host, therefore are not retained (Scandurra et al. 2008). An 
alternative explanation for mutations involving the pathogen’s cell wall, cell surface proteins 
or secreted factors, is that the disruption alters the interaction with the host immune cells 
(Rousseau et al. 2003, Saint-Joanis et al. 2006). 
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FadB5 (Rv1912c) is non-essential according to Sassetti et al. (2003) and has been found 
wholly or partially deleted in some clinical isolates of M. tuberculosis (TubercuList; Lechat 
et al. 2008). The protein shares a 44.1 % sequence similarity with FadB4 and it too is 
annotated as a putative oxidoreductase containing a zeta-crystallin signature. Bacillus cereus 
has a fadB5 gene described as a zinc-binding oxidoreductase and, although a homologue has 
been identified in M. leprae, there is no close match to FadB5 in M. smegmatis. The closest 
‘homologue’ is MSMEG6362, which is annotated as a putative quinone oxidoreductase but 
only shares 45.3 % sequence similarity.  
 
This works describes the cloning of M. tuberculosis !-hydroxyacyl-CoA dehydrogenases, 
Mt-FadB2 and Mt-FadB3, and the putative NQO Mt-FadB4, their over-expression in E. coli 
and purification, which in the case of FadB2, has allowed for detailed protein characterisation 
and kinetic studies. In parallel, mutants of the fadB2, fadB3 and fadB4 homologues in the 
surrogate species M. smegmatis, and M. bovis BCG "fadB3 and "fadB5 strains, were 
generated, in order to explore the functional role of these genes in vivo. 
 
4.2. Materials and Methods 
4.2.1. In silico analysis of the FadB proteins. 
The Rv0468 (Mt-FadB2), Rv1715 (Mt-FadB3), Rv3141 (Mt-FadB4) and Rv1912c (Mt-
FadB5) nucleotide and protein sequences were obtained from TubercuList (Lechat et al. 
2008; http://genolist.pasteur.fr/TubercuList/). Homologous genes in M. bovis BCG and M. 
smegmatis were identified using the BLAST feature on the xBASE server (Chaudhuri et al. 
2008). EMBOSS-Needle and ClustalW from the EMBL-EBI server (Labarga et al. 2007) and 
ESPript (Gouet et al. 1999) were used to produce the pair-wise and multiple sequence 
alignments of !-hydroxyacyl-CoA dehydrogenase from various species respectively. The 
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ProtParam tool from the Swiss Institute of Bioinformatics ExPASy Server was used for 
primary sequence analysis (Gasteiger et al. 2005), and GOR IV and TMHMM were used to 
predict the secondary protein structure (Garnier et al. 1996). 
 
4.2.2. Plasmids and DNA manipulation. 
The E. coli compatible vector pET28b (Novagen) containing a T7 promoter and encoding 
both 6-histidine N- and C-terminal tags was used for the over-expression of Mt-FadB2 and 
Mt-FadB3, and the pET28a plasmid for Mt-FadB4. The Mt-FadB2 PCR amplifications were 
executed using VentR® DNA polymerase (New England Biolabs) and the Mt-FadB3 and Mt-
FadB4 PCR reactions executed using Phusion® DNA polymerase (Finnzymes). 
Chromosomal DNA from M. tuberculosis strain H37Rv was used as the template. Mt-FadB2 
PCR amplification was performed using the upstream primer 5#-
gatcgatccatatggtgagcgatgcgatccagcgg-3# and the downstream primer 3#-
gatcgatcaagcttgtacgtgtagaaacctcgacc-5#, which contain NdeI and HindIII restriction sites 
respectively (underlined). The 858 bp PCR product was then doubly digested with 
NdeI/HindIII and ligated into a similarly cut pET28b plasmid, yielding pET28b-Mt-fadB2. 
Mt-FadB3 PCR amplification was performed using the upstream primer 5#-
gatcgatccatatgctgacctcgcacgggttctcc-3# and the downstream primer 3#-
gatcgatcaagctttgtcccccttcctttttcgtt-5#, which also contain NdeI and HindIII restriction sites 
respectively (underlined). The 912 bp PCR product was then doubly digested with 
NdeI/HindIII and ligated into a similarly cut pET28b plasmid to give pET28b-Mt-fadB3. Mt-
FadB4 PCR amplification was performed using the upstream primer 5#-
gatcgatccatatgcgcgcggtacgggtgactgcc-3# and downstream 3#-
gatcgatcaagcttgtcgcgcacgcgtagtacgac-5#, which contain NdeI and HindIII restriction sites 
respectively (underlined). The 969 bp PCR product was then doubly digested with 
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NdeI/HindIII and ligated into a similarly cut pET28a plasmid, yielding pET28a-Mt-fadB4. 
DNA sequencing was used to verify the recombinant genes. 
 
4.2.3. Construction of the Mt-FadB2 S122A mutant. 
The Stratagene QuikChange® Multi Site-Directed Mutagenesis Kit was used to create a 
pET28b-Mt-fadB2(S122A) plasmid. The following primers were used to introduce the 
mutation into the pET28b-Mt-fadB2 plasmid template: 5#-tggcgtcgaataccgccagcatcccgatc-3# 
and 5#-gatcgggatgctggcggtattcgacgcca-3#. The ensuing PCR and transformation were 
performed as per the kit manual. Sequencing was used to confirm that the mutation had been 
made. 
 
4.2.4. Over-expression of wild-type and S122A Mt-FadB2, Mt-FadB3 and Mt-
FadB4. 
The wild-type and S122A-mutated proteins were over-expressed using the same protocol. 
pET28b-Mt-fadB2 and pET28b-Mt-fadB2(S122A) plasmids were independently transformed 
into E. coli C43 (DE3) cells and incubated on LB agar containing 25 µg/ml kanamycin 
overnight at 37 °C. One colony of each was used to inoculate LB broth (5 ml) containing 
kanamycin (25 µg/ml) and cultures were incubated in a rotary incubator at 37 °C overnight. 
These mini-cultures were used separately to inoculate Terrific Broth (1 l) containing 
kanamycin (25 µg/ml) and incubated in a rotary incubator (180 rpm) at 37 °C until the OD600 
had reached 0.6. At this point, the cultures were induced by the addition of 1 mM IPTG and 
incubated with shaking for 16 h at 16 °C. The cells were harvested by centrifugation at 4,500 
$ g for 12 min and stored at -20 °C for purification. Over-expression of the his-tagged Mt-
FadB2 was confirmed by Western blot analysis using mouse monoclonal Penta-His™ 
Antibody (Qiagen). 
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The pET28b-Mt-fadB3 plasmid was similarly transformed into E. coli C43 (DE3) cells and 
incubated on LB agar containing 25 µg/ml kanamycin overnight at 37 °C. One colony was 
used to inoculate LB broth (5 ml) containing 25 µg/ml kanamycin and 1 % glucose and 
cultures were incubated in a rotary incubator at 37 °C overnight. This mini-culture was used 
to inoculate 1 l Terrific Broth containing kanamycin (25 µg/ml) and was incubated in a rotary 
incubator (180 rpm) at 37 °C until the OD600 had reached 0.6. At this point, the culture was 
induced by the addition of 0.25 mM IPTG and incubated with shaking at 37 °C for 3.5 h. The 
cells were harvested by centrifugation at 4,500 $ g for 12 min and stored at -20 °C for 
purification. Over-expression of the His-tagged Mt-FadB3 was visualised by Western blot 
analysis using mouse monoclonal Penta-His™ Antibody. 
 
The pET28a-Mt-fadB4 plasmid was co-transformed into E. coli BL21 (DE3) cells along with 
plasmids harbouring the GroES and CPN 60.2 chaperones (kindly donated by Dr S. Batt, 
University of Birmingham). Cells were incubated on selective LB agar containing 25 µg/ml 
kanamycin and 100 µg/ml ampicillin overnight at 37 °C. One colony was used to inoculate 
LB broth (5 ml) containing the same antibiotics and 1 % glucose, and the culture was 
incubated in a rotary incubator at 37 °C overnight. This mini-culture was used to inoculate 1 l 
Terrific Broth containing the same selective antibiotics and incubated at 37 °C with shaking 
until the OD600 had reached 0.6. At this point, the culture was induced by the addition of 0.25 
mM IPTG and incubated similarly at 16 °C for 16 h. The cells were harvested by 
centrifugation at 4,500 $ g for 12 min and stored at -20 °C for purification. Over-expression 
of the His-tagged protein was confirmed by Western blot analysis using mouse monoclonal 
Penta-His™ Antibody. 
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4.2.5. Purification of wild-type and S122A Mt-FadB2 proteins, Mt-FadB3 and Mt-
FadB4. 
The same purification method was applied to both wild-type and S122A-mutated Mt-FadB2 
proteins. Pelleted cells were resuspended in buffer A (0.02 M sodium phosphate, pH 7.9, 0.5 
M NaCl) and lysed by probe sonication (10 cycles of 30 second pulses followed by 30 
second cooling intervals). The crude lysate was centrifuged at 27,000 $ g for 40 min at 4 °C 
to remove the insoluble components and the resulting clarified lysate was applied to a Ni2+-
charged 5 ml HisTrap™ HP affinity column (GE Healthcare). The column was washed with 
10 column volumes of buffer A and the protein was eluted with a step-wise gradient of 50 
mM (50 ml), 130 mM (10 ml) and 1 M (10 ml) imidazole. The fractions were analysed by 12 
% SDS-PAGE followed by Coomassie staining. A large single band at 30 kDa on the gel 
demonstrated the purity of the protein and Mt-FadB2 was correctly identified by a trypsin 
digest and mass spectrometry. The fractions containing pure Mt-FadB2 protein were 
dialysed, first against 50 mM potassium phosphate (pH 7.9), 50 mM NaF, with 1 mM EDTA 
added to remove any leached Ni2+, and then twice against 50 mM potassium phosphate (pH 
7.9), 50 mM NaF at 4 °C. The potassium phosphate/NaF buffer was chosen because it 
provided optimal conditions for circular dichroism experiments. The purified protein 
concentration was estimated using the BCA Protein Assay kit and protein aliquots were 
stored at -80 °C both with and without the addition of 10 % glycerol. 
 
Mt-FadB3-containing pelleted cells were resuspended in buffer A containing one EDTA-free 
complete protease inhibitor-cocktail tablet (Roche) and a few grains of DNase I (New 
England Biolabs) and lysed by probe sonication as for Mt-FadB2. The crude lysate was 
centrifuged at 27,000 $ g for 45 min at 4 °C to remove the insoluble components and the 
resulting clarified lysate was applied to a Ni2+-charged 5 ml HisTrap™ HP affinity column. 
The column was washed with 5 column volumes of buffer A and the protein was eluted with 
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a step-wise imidazole gradient: thrice each of 25 mM and 50 mM (all 10 ml fractions), twice 
each of 75 mM, 100 mM and 150 mM (all 10 ml) and once each of 250 mM, 500 mM and 1 
M (all 10 ml). The fractions were analysed by 12 % SDS-PAGE followed by Coomassie 
staining. A large single band at 30 kDa was visible demonstrating the purity of the protein. 
The second 150 mM and 250 mM fractions containing pure Mt-FadB3 were dialysed, first 
against 50 mM Tris%HCl (pH 7.9), 50 mM NaCl, with 1 mM EDTA added to remove any 
leached Ni2+, and then twice against 50 mM Tris!HCl (pH 7.9), 50 mM NaCl at 4 °C. After 
determining the concentration (as before), the purified protein was stored in aliquots at -80 
°C or -20 °C both with and without the addition of 10 % glycerol. 
 
The E. coli cells containing Mt-FadB4 were resuspended in buffer A containing an EDTA-
free complete protease inhibitor-cocktail tablet and a few grains of DNaseI and lysed by 
probe sonication as above. The crude lysate was centrifuged at 27,000 $ g for 45 min at 4 °C 
to remove the insoluble components and the resulting clarified lysate was applied to a Ni2+-
charged 1 ml HisTrap™ HP affinity column. The column was washed with 5 column 
volumes of buffer A and the protein was eluted with a step-wise imidazole gradient: twice 
each of 25 mM, 50 mM, 75 mM, 100 mM, 150 mM and 250 mM (all 10 ml fractions) and 
once each of 500 mM and 1 M (both 10 ml). The fractions were analysed by 12 % SDS-
PAGE followed by Coomassie staining. The strongest bands at around 35 kDa on the gel 
corresponding to Mt-FadB4 were visible in the 75 mM imidazole fractions, much weaker 
bands were visible in the 100 mM and 150 mM fractions. All six fractions containing protein 
were pooled and dialysed three times against 20 mM Tris!HCl (pH 7.5), 10 mM NaCl, 0.1 
mM DTT and 10 % glycerol, with 1 mM EDTA added to remove any leached Ni2+ in the first 
buffer, at 4 °C. Attempts were made to remove the contaminants by loading the dialysed 
protein onto a QHP anion-exchange column (GE Healthcare) equilibrated with dialysis 
buffer. The protein was eluted with an increasing salt (Cl-) concentration from 50 mM to 400 
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mM NaCl in 1.5 ml fractions. Those containing the purest protein were pooled and dialysed 
as before. The protein concentration was estimated using the BCA Protein Assay kit as 0.23 
mg/ml and the protein was stored at -20 °C. 
 
4.2.6. Enzyme assay for wild-type and S122A Mt-FadB2. 
The activity assay for Mt-FadB2 was based on that previously described (Nemeria et al. 
2001). The forward Mt-FadB2-dependent reduction of NAD+ to NADH was monitored 
spectrophotometrically at 340 nm using a Jenway 6710 UV/Vis spectrophotometer. The 
standardised 1 ml reaction contained 100 mM N-cyclohexyl-3-aminopropanesulfonic acid 
(CAPS) buffer (pH 9.5), 50 µM NAD+, 50 µM !-hydroxybutyryl-CoA and 7 µg purified Mt-
FadB2 protein. The reaction mixture minus the protein was incubated for 2 minutes at 30 °C 
before adding the enzyme to start the reaction. The reverse reaction was observed similarly. 
The standard 1 ml reaction contained 100 mM potassium phosphate buffer (pH 7.0), 50 µM 
NADH, 50 µM acetoacetyl-CoA and 7 µg pure Mt-FadB2 protein. All controls were 
performed to ensure neither the potassium phosphate/NaF buffer nor any of the assay buffers 
or substrates interfered with the assay results. The initial velocity of each reaction was 
measured and the kinetic parameters, KM, Vmax and kcat, for each substrate and co-factor were 
ascertained by varying their concentration and fitting the data to the Michaelis-Menten 
equation using SigmaPlot 8.0. Each reaction was performed in triplicate. 
 
4.2.7. Circular dichroism spectroscopy of wild-type and S122A Mt-FadB2. 
All circular dichroism (CD) far UV spectra were obtained at 25 °C using a JASCO J-715 
spectropolarimeter and a 0.01 cm pathlength cell. The wild-type and S122A-mutant Mt-
FadB2 proteins were made to 1.1 mg/ml as determined by the BCA Protein Assay kit. To 
compare the folding of the wild-type and mutant protein, 50 mM potassium phosphate (pH 
7.9), 50 mM NaF buffer was used. To assess protein folding at different pH values, 50 mM 
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potassium phosphate (pH 6, pH 7 or pH 8), 50 mM NaF or 50 mM CAPS (pH 9, pH 10 or pH 
11), 50 mM NaF was used. Each condition was scanned eight times over a wavelength of 
197–245 nm and a bandwidth of 2 nm. The results were normalised by subtracting the 
baseline buffer spectrum from each. 
 
4.2.8. Analytical ultracentrifugation of wild-type Mt-FadB2. 
Analytical ultracentrifuge (AUC) experiments were performed using an 8-piece An60Ti rotor 
in a Beckman-Optima XL-I using interference optics. The protein was analysed separately 
with substrate, product and co-factors as well as native. Sedimentation velocity was executed 
at 4 °C, 40,000 rpm and data were processed using the continuous c(s) distribution method in 
the SEDFIT program. 
 
4.2.9. Mt-FadB2 crystallisation trials. 
Mt-FadB2 was purified, dialysed and concentrated to 30 mg/ml. Native protein was 
incubated overnight at 4 °C with 8 mM NAD+, NADH, !-hydroxybutyryl-CoA or 
acetoacetyl-CoA prior to trials. The Molecular Dimensions optimised sparse matrix screens 
JCSG-plus™ and Structure Screen™ were used initially to identify conditions that were most 
permissible for crystal growth. The sitting drop vapour diffusion method was employed using 
a 96-well plate and a Mosquito nano-drop crystallisation robot. Conditions were optimised 
and the best crystals were cryoprotected, frozen and diffracted. 
 
 
 
 
Chapter 4 Mycobacterial FadB Enzymes 
!
 155 
4.2.10. Construction of the fadB2 (MSMEG0912), fadB3 (MSMEG6791) and fadB4 
(MSMEG2033) deletion mutants in M. smegmatis and the fadB3 (Mb1742-1743) and 
fadB5 (Mb1947c) deletion mutants in M. bovis BCG. 
All five mycobacterial deletion mutants were generated using the specialised transduction 
method previously described by Bardarov et al. (2002). All initial PCR amplifications for the 
M. smegmatis mutants were performed using M. smegmatis mc2155 genomic DNA and 
Phusion® DNA polymerase. For "Ms-fadB2, a 1000 bp sequence of the upstream region of 
Ms-fadB2 and an 800 bp sequence of the downstream region of the gene were PCR amplified 
using the following primers, each containing a DraIII restriction site at the 5# end 
(underlined): Ms-fadB2_LL (5#-ttttttttcacaaagtgctggagccctgcatcgcgcg-3#), Ms-fadB2_LR (5#-
ttttttttcacttcgtgcgggatgctcgacgtgttcg-3#), Ms-fadB2_RL (5#-
ttttttttcacagagtgctgctctcggcaatccgcat-3#) and Ms-fadB2_RR (5#-
ttttttttcaccttgtgcttcccaaccctgcaggcgg-3#). For the M. smegmatis fadB3 null-mutant, an 861 bp 
sequence of the upstream region of Ms-fadB3 and a 974 bp sequence of the downstream 
region of Ms-fadB3 were PCR amplified using the following primers, each containing a 
DraIII restriction site at the 5# end (underlined): Ms-fadB3_LL (5#-
ttttttttcacaaagtgggcttcatgcaggcgctaac-3#), Ms-fadB3_LR (5#-
ttttttttcacttcgtgacggcctccatcacgtagtc-3#), Ms-fadB3_RL (5#-
ttttttttcacagagtgtcgcataccgcaacaagg-3#) and Ms-fadB3_RR (5#-
ttttttttcaccttgtgaggcgtgaaagctggaag-3#). For the Ms-fadB4 deletion mutant, a 1000 bp 
sequence of the upstream region of Ms-fadB4 and a 900 bp sequence of the downstream 
region of the gene were amplified by PCR using the following primers, each containing a 
DraIII restriction site at the 5# end (underlined): Ms-fadB4_LL (5#-
ttttttttcacaaagtgcccaactcggtggccagcgc-3#), Ms-fadB4_LR (5#-
ttttttttcacttcgtgacaccggccacctcggcgcc-3#), Ms-fadB4_RL (5#-
ttttttttcacagagtgtcggcgcgggttggggtgcg-3#) and Ms-fadB4_RR (5#-
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ttttttttcaccttgtgccgtcaacacgcgaatcggc-3#). The PCR fragments for each gene were cloned 
independently into the appropriate p0004S vector to generate the allelic exchange plasmids 
p"Ms-fadB2, p"Ms-fadB3 and p"Ms-fadB4. The plasmids were then PacI-digested and 
packaged separately into the mycobacteriophage phAE159 to generate the knock-out phages, 
ph"Ms-fadB2, ph"Ms-fadB3 and ph"Ms-fadB4. High titre phage particles were produced for 
each knock-out and transduced into wild-type M. smegmatis mc2155 cells, as previously 
described (Bardarov et al. 2002). True hygromycin-resistant colonies obtained after 
transduction were confirmed as Ms-fadB2-, Ms-fadB3- and Ms-fadB4-deletion mutants by 
Southern blot. 
 
The initial PCR amplifications for the M. bovis BCG mutants were performed using M. bovis 
BCG genomic DNA as the template and Phusion® DNA polymerase. For the M. bovis BCG 
fadB3 null-mutant, an 802 bp sequence of the upstream region of Mb-fadB3 and an 853 bp 
sequence downstream of Mb-fadB3 were PCR amplified using the following primers, each 
containing a BstAPI restriction site at the 5# end (underlined): Mb-fadB3_LL (5#-
ttttttttgcataaattgcccgtttggacggagtgttg-3#), Mb-fadB3_LR (5#-
ttttttttgcatttcttgcgccgttcgaagagttcctg-3#), Mb-fadB3_RL (5#-
ttttttttgcatagattgcacatcgggttggacctcac-3#) and Mb-fadB3_RR (5#-
ttttttttgcatcttttgcgaagtcgtcgagcaccttg-3#). For the "Mb-fadB5 mutant, a 994 bp sequence 
upstream of Mb-fadB5 and an 821 bp sequence downstream of the gene were PCR amplified 
using the following primers: Mb-fadB5_LL (5#-ttttttttcacaaagtgatcgcaagtacccgatcaag-3#) and 
Mb-fadB5_LR (5#-ttttttttcacttcgtgtagccaccaaatcgtgtacc-3#) both containing a DraIII restriction 
site, underlined, and Mb-fadB5_RL (5#-ttttttttccatagattggcgaagctcctgaagcacatc-3#) and Mb-
fadB5_RR (5#-ttttttttccatcttttggttggagaagccagggtttcg-3#) both containing a Van91i restriction 
site, underlined. Allelic exchange substrates were generated as described for the M. 
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smegmatis mutants and packaged similarly. High titre phage particles were transduced into 
wild-type M. bovis BCG cells and genuine mutant colonies were verified by Southern blot. 
 
4.2.11. Construction of the complemented knock-out strains. 
The E. coli–Mycobacterium shuttle vector pMV261 was used for all complementation 
experiments (Stover et al. 1991). The M. tuberculosis genes Rv0468 (fadB2), Rv1715 
(fadB3), Rv3141 (fadB4) and Rv1912c (fadB5) were PCR amplified using H37Rv 
chromosomal DNA, and the homologous M. smegmatis genes MSMEG0912 (fadB2), 
MSMEG6791 (fadB3), MSMEG2033 (fadB4) and MSMEG6362 (fadB5) were amplified from 
M. smegmatis mc2155 chromosomal DNA, all using Phusion® DNA polymerase. The 
following primers were used, all restriction sites are underlined with the restriction 
endonuclease in parentheses: Mt-fadB2 upstream 5#-gatcgatcggatccagtgagcgatgcgatccagcgg-
3# (BamHI), Mt-fadB2 downstream 3#-gatcgatcaagcttatcagtacgtgtagaaacctcg-5# (HindIII), Mt-
fadB3 upstream 5#-gatcgatcggatccaatgctgacctcgcacgggttc-3# (BamHI), Mt-fadB3 downstream 
3#-gatcgatcaagcttctatgtcccccttcctttttcgtt-5# (HindIII), Mt-fadB4 upstream 5#-
gatcgatcggatccaatgcgcgcggtacgggtgact-3# (BamHI), Mt-fadB4 downstream 3#-
gatcgatcaagcttttagtcgcgcacgcgtagtac-5# (HindIII), Mt-fadB5 upstream 5#-
gatcgatcggatccatgcgagcagtggtcatcacc-3# (BamHI), Mt-fadB5 downstream 5#-
gatcgatcaagcttacacggtaccagcaccacctt-3# (HindIII), Ms-fadB2 upstream 5#-
gatcgatcggatccagtgagcaatgcaatcgaacga-3# (BamHI), Ms-fadB2 downstream 3#-
gatcgatcaagctttcagtaggtatagaagccctt-5# (HindIII), Ms-fadB3 upstream 5#-
gatcgatcggatccaatgctgacctcgcacgggttc-3# (BamHI), Ms-fadB3 downstream 3#-
gatcgatcaagcttctatgtcccccttcctttttcgtt-5# (HindIII), Ms-fadB4 upstream 5#-
gatcgatcggatccaatgcgcgctgcactgataac-3# (BamHI), Ms-fadB4 downstream 3#-
gatcgatcaagctttcagcgcagtttgagcacca-5# (HindIII), Ms-fadB5 upstream 5#-
gatcgatcggatccaatgtctcctgccgtgcgtcc-3# (BamHI), Ms-fadB5 downstream 5#-
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gatcgatcaagctttcattcggagacgcgcagca-3# (HindIII). The PCR products were then digested with 
BamHI and HindIII and each ligated into a similarly cut pMV261 plasmid, yielding 
pMV261-Mt-fadB2, pMV261-Mt-fadB3, pMV261-Mt-fadB4, pMV261-Mt-fadB5, pMV261-
Ms-fadB2, pMV261-Ms-fadB3, pMV261-Ms-fadB4 and pMV261-Ms-fadB5. DNA 
sequencing was used to verify the recombinant genes. Electrocompetent "Ms-fadB2 cells 
were electroporated with pMV261-Ms-fadB2, pMV261-Mt-fadB2 or pMV261 plasmid, 
electrocompetent "Ms-fadB3 and "Mb-fadB3 cells were electroporated with pMV261-Mt-
fadB3, pMV261-Ms-fadB3 or pMV261 plasmid. Electrocompetent "Ms-fadB4 cells were 
electroporated with pMV261-Ms-fadB4, pMV261-Mt-fadB4 or pMV261 plasmid, and 
electrocompetent "Mb-fadB5 cells were electroporated with pMV261-Mt-fadB5, pMV261-
Ms-fadB5 or pMV261 plasmid. Transformants were selected for using hygromycin- (100 
µg/ml for M. smegmatis mutants, 75 µg/ml for M. bovis BCG mutants) and kanamycin- (25 
µg/ml) containing agar plates. 
 
4.2.12. Growth analysis of the deletion mutants. 
4.2.12.1. Growth on different carbon sources. 
The fadB2 and fadB4 deletion mutants were analysed for growth on different carbon sources. 
Wild-type M. smegmatis, "Ms-fadB2, "Ms-fadB4, the complemented strains (pMV261-Ms-
fadB2, pMV261-Mt-fadB2, pMV261-Ms-fadB4 and pMV261-Mt-fadB4) and M. smegmatis 
containing an empty pMV261 plasmid were grown to saturation in minimal medium (MM) 
plus 0.1 % glucose. The MM used was based on that of Chang at al. (2009), containing (per 
litre) 1.5 g KH2PO4, 1.0 g NH4Cl, 0.2 g MgSO4!7H2O, 20.0 mg CaCl2!2H2O, 1.2 mg ferric 
ammonium citrate, 0.85 g NaCl and 8.99 g Na2HPO4!12H2O. The cultures were then washed 
and resuspended in PBS before streaking on MM agar plates supplemented with either 0.1 % 
glycerol, glucose, acetate or propionate, or 0.002 % caprylic acid, capric acid, lauric acid, 
myristic acid, palmitic acid, oleic acid or linoleic acid, and, in the case of "Ms-fadB2, 0.2 
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mM cholesterol. Growth of the "Ms-fadB2 strains was also monitored in liquid MM 
containing cholesterol (0.2 mM) as the sole carbon source: cells were grown in 7H9 to an 
OD600 of 0.6 before being washed and resuspended in MM+cholesterol. The OD600 was 
monitored over 90 h. Cholesterol was prepared for medium supplementation as described by 
Chang et al. (2009), where a 100 mM stock was made in a 1:1 (v/v) tyloxapol :ethanol 
solution and the cholesterol was dissolved by heating to 70 °C and with vortexing. 
 
4.2.12.2. Lipid analysis. 
See sections 2.2.6. and 2.2.7. for lipid, FAMEs and MAMEs extraction and analysis 
procedures. 
 
4.2.12.3. Sensitivity to oxidative and SDS stress. 
The Bauer-Kirby disc diffusion method was used to test the sensitivity of M. smegmatis 
"Ms-fadB2 cells to oxidative stress and "Ms-fadB3 and "Ms-fadB4 cells to oxidative and 
SDS stress (Bauer et al. 1966). Wild-type, mutant and complemented cells were grown to 
OD600 1.0 in 7H9 with 0.05 % Tween®-80 and the appropriate antibiotic(s). Cells were 
washed, resuspended in fresh medium and 200 µl was used to inoculate 4 ml 7H9 soft (0.75 
%) agar. Sterile filter paper discs (6 mm in diameter), saturated with 6 µl of 30 % H2O2, 10 % 
SDS or H2O (control), were applied to the overlaid plates in duplicate and incubated at 37 °C 
for 3 days. The diameters of the zones of inhibition surrounding the discs were then 
measured. 
 
4.2.12.4. Sensitivity to acid stress. 
The sensitivity of the "Ms-fadB2 mutant to acid stress was also tested by monitoring the 
survival of strains in 7H9 medium at pH 2, 3, 4, 5, 6 and 7 over 24 h. At 3 h intervals 50 µl 
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samples were taken, pelleted by centrifugation and washed with PBS before being stored at 4 
°C for viable count analysis. Briefly, the 50 µl samples were diluted to 10-7 and 10 µl aliquots 
were spotted onto 7H11 (+OADC) agar in triplicate. Following incubation at 37 °C for 2 
days, colonies were counted and converted to colony-forming units (CFU/ml). Growth was 
similarly monitored in SDS stress conditions in liquid medium. Strains were grown in 7H9 
medium to an OD600 of 0.4 before adding sterile 0.05 % SDS at t = 0 h. Samples were stored 
and cell viability was monitored as for acid stress. 
 
4.2.12.5. Sensitivity to isoniazid. 
Sensitivity to isoniazid of wild-type M. smegmatis mc2155 compared to the "Ms-fadB2 and 
"Ms-fadB3 mutants and the complemented strains was assessed using the agar dilution 
method. TSB agar plates were supplemented with isoniazid at concentrations ranging from 
0–20 µg/ml in duplicate. M. smegmatis strains were grown in TSB with 0.05 % Tween®-80 
and appropriate antibiotic(s) until OD600 ~0.6. The cells were then resuspended in fresh 
medium, serially diluted to 10-7 and spotted (10 µl) on the plates. After incubation at 37 °C 
for 3–4 days, the colonies were counted and converted to log(CFU/ml). 
 
4.2.12.6. Ability to utilise amino acids. 
The ability of the "Ms-fadB4 mutant to utilise amino acids was evaluated using MM agar 
supplemented with alanine, asparagine, lysine, leucine, valine or threonine (20 µg/ml and 100 
µg/ml) or 0.1 % glucose (control). Cells were initially grown to OD600 1.0 in 7H9 with 0.05 
% Tween®-80 and then washed and used to inoculate MM broth containing 0.1 % glucose. 
Cells were serially diluted to 10-7, spotted (10 µl) on the plates and incubated at 37 °C for one 
week. The colonies were counted and converted into units of log(CFU/ml). 
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4.3. Results 
4.3.1. In silico analysis of Mt-FadB2 and Mt-FadB3. 
Mt-FadB2 has a higher than average proportion of charged amino acids (24.1 %) compared to 
the entire M. tuberculosis proteome (20.0 %), the majority of which being negatively charged 
(Asp + Glu, 13.3 %) (Luthra et al. 2008). Similarly, there are more polar residues (42.3 %) 
than hydrophobic residues, which is also found for Mt-FadB3. The high percentage of 
charged and polar residues suggests that the protein is soluble and therefore not an integral 
cell membrane protein. The theoretical pI of native Mt-FadB2 protein is calculated as 5.2, 
whereas for the recombinant protein used here it is calculated as 6.1 (Gasteiger et al. 2005). 
 
Alignment of !-hydroxyacyl-CoA dehydrogenases from mycobacteria and other species 
highlights the conserved residues of the hypothetical catalytic triad as identified by Barycki 
et al. (1999) (Figure 4-2 A). The residues annotated with triangles are consistent with the 
sequence of a Rossmann fold, a structural motif known to bind nucleotides. This is supported 
by the computed GOR IV secondary structure (Garnier et al. 1996), which predicts a !-
sheet–"-helix–!-sheet motif at the C-terminus, a feature that is also seen in the overlaid 
secondary structure from the Pseudomonas fragi FadB protein. Mt-FadB2 has some sequence 
similarity to Mt-FadB3 and part of the Mt-FadB1 protein (scores of 44.8 % and 54.1 %, 
respectively). The identity between Mt-FadB2, -FadB4 and -FadB5 from M. tuberculosis, 
however, is much less (sequence similarity scores of 18.0 % and 16.1 % respectively) and 
Mt-FadB4 and -FadB5 do not share the same NAD+ binding-site or hypothetical catalytic 
triad residues. This may indicate redundancy between Mt-FadB1, -FadB2 and -FadB3 but 
alternative role(s) for Mt-FadB4 and -FadB5. 
 
 
Chapter 4 Mycobacterial FadB Enzymes 
!
 162 
4.3.2. Over-expression and purification of Mt-FadB2 and Mt-FadB3. 
Sequencing confirmed that there were no errors in the pET28b-Mt-fadB2 and pET28b-Mt-
fadB3 plasmids and that the PCR had added six histidine residues to both the N- and C-
termini. Mt-FadB2 expressed well in E. coli C43 (DE3) cells following induction with 1 mM 
IPTG at 16 °C overnight, producing a high yield of His6-tagged protein, as confirmed by 
Western blot (data not shown). Purification of Mt-FadB2 was a one-step process using a pre-
packed Ni2+-affinity column followed by dialysis against a 50 mM potassium phosphate (pH 
7.9), 50 mM NaF buffer at 4 °C (Figure 4-4 A). The purity of the protein was seen by a large 
single band at ~32 kDa on SDS-PAGE and was correctly identified as Mt-FadB2 by trypsin 
digestion and mass spectrometry. Mt-FadB2 concentration was determined using a BCA 
Protein Assay kit (ThermoScientific) and a total of 18 mg of protein could be obtained from a 
1-litre culture. A much lower yield of Mt-FadB3 was obtained, roughly 4 mg per litre of 
culture, but the one-step purification successfully removed all contaminants (Figure 4-4 B). 
 
 
 
 
 
 
 
 
FIGURE 4-4. Purification of Mt-FadB2 and Mt-FadB3. The proteins were produced by 
IPTG-induction of E. coli C41 (DE3) transformants containing pET28b-Mt-fadB2 or 
pET28b-Mt-fadB3. Following cell growth at 37 °C and after induction at 16 °C, the proteins 
were purified using a 5 ml Ni2+-charged His-trap column and eluted with an increasing 
imidazole concentration. Fractions were visualised by Coomassie Blue staining after 
separation by electrophoresis on 12 % SDS-PAGE. (A) Mt-FadB2, (B) Mt-FadB3. 
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4.3.3. Mt-FadB2 is an enzymatically active !-hydroyxybutyryl-CoA dehydrogenase. 
In an effort to demonstrate enzymatic activity of Mt-FadB2, a spectrophotometric assay was 
developed, which involved monitoring the reduction of the co-factor NAD+ at 340 nm 
(Figure 4-5 A). The His-tagged protein was found to be active both fresh and after being 
frozen without glycerol. The protein was highly stable, retaining its activity whilst being kept 
at 4 °C for over one week. The kinetic parameters calculated from the data using SigmaPlot 
8.0 are displayed in Table 4-1. 
 
TABLE 4-1. Kinetic parameters of Mt-FadB2 as determined by spectrophotometric 
assay and double-reciprocal plots. Values represent means ± standard error. 
 
 KM (µM) Vmax (nmol min-1 mg-1) kcat (min-1) 
!-Hydroxybuyryl-CoA 43.5 ± 5.82 188.3 ± 7.4 0.723 ± 0.0284 
Acetoactyl-CoA 65.6 ± 4.87 126.6 ± 8.6 0.677 ± 0.0330 
NAD+ 29.5 ± 2.78 63.1 ± 1.7 0.242 ± 0.00653 
NADH 50.0 ± 16.8 2,588.0 ± 200 11.36 ± 0.768 
 
Only short-chain C4 !-hydroxyacyl-CoA was tested as a substrate for FadB2, due to longer-
chain molecules not being available commercially. However, a series of substrates of varying 
chain length were chemically synthesised by Dr V. Bhowruth (University of Birmingham), 
whereby the CoA is substituted with an N-acetylcysteamine (N-AC) group. It has been shown 
previously that some acyl-CoA dehydrogenases are capable of turning over such a mimic, a 
useful finding since it is far easier to synthesise N-AC-attached fatty acids than CoA (Kass et 
al. 1967, Shimakata et al. 1979, Williamson & Engel 1984). In order to solubilise the longer-
chain fatty acids, tyloxpol (0.25 %) needed to be added to the reaction. Control assays were 
performed to ensure the detergent did not interfere with the spectrophotometric readings. 
Despite this, however, purified Mt-FadB2 did not appear to turn over C12-N-AC (Figure 4-6). 
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FIGURE 4-5. Mt-FadB2 enzyme kinetics. The reaction velocities were ascertained using 
increasing concentrations of substrate, !-hydroxybutyryl-CoA (A) and acetoacetyl-CoA (B). 
The data were fitted to the Michaelis-Menten equation using SigmaPlot 8.0 and by linear 
regression in the Lineweaver-Burke plot (insert). Points are the average of three replicates ± 
standard error. 
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FIGURE 4-6. Raw data showing Mt-FadB2 enzyme activity using !-hydroxylauryl-N-
acetylcysteamine (C12-N-AC) as the substrate and NAD+ as the co-factor. The reduction 
of NAD+ to NADH was monitored spectrophotometrically. The standard 1 ml reaction 
contained 100 mM CAPS buffer (pH 9.5), 50 µM NAD+, 1mM or 0.5 mM C12-N-AC and 7 
µg purified Mt-FadB2. The reaction mixture minus the protein was incubated at 30 °C 
before adding the enzyme to start the reaction. 
 
The activity for the NAD+-dependent dehydrogenase reaction was tested over a range of 
temperatures and pH values and the optima were found to be 37 °C and pH 10 (CAPS 
buffer), respectively (Figure 4-7 A, B). Not surprisingly, Mt-FadB2 was most active at the 
physiological temperature of the M. tuberculosis mammalian host, 37 °C. The pH data 
suggest that the enzyme appears to work best in alkaline conditions, the same as that obtained 
by Shimakata et al. (1979), who purified a protein fraction containing !-hydroxyacyl-CoA 
dehydrogenase activity from M. smegmatis. This, however, can be explained by the presence 
of protons in the enzyme reaction. Because of the release of H+ upon oxidation of !-
hydroxybutyryl-CoA and the fact that the reaction is reversible (Figure 4-1), the assay is very 
sensitive to changes in pH (He et al. 1989, Wakil et al. 1954). 
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FIGURE 4-7. Mt-FadB2 enzyme activity. The activity of the Mt-FadB2 forward, NAD+-
dependent reaction was tested at different temperatures (A) and both the NAD+- and 
NADH-dependent reactions were observed at different pHs (B and C respectively). Points 
are the average of three replicates ± standard error. 
 
Wakil et al. (1954) studied the activity of a !-hydroxyacyl-CoA dehydrogenase isolated from 
beef liver mitochondria. The group found that the inflection point corresponding to 50 % !-
hydroxybutyryl-CoA oxidation occurred at pH 8.2; at pH 9.0 or above oxidation is almost 
complete, and the equilibrium constant (Keq) for !-hydroxybutyryl-CoA was calculated as 6.3 
$ 10-11. By using this Keq for the reaction assayed here, the effect of pH on the equilibrium 
can be explained (Figure 4-8). 
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FIGURE 4-8. The effect of pH ([H+]) on the position of the !-hydroxybutyryl-CoA 
dehydrogenase equilibrium. The equilibrium constant equation for the reaction is stated in 
the centre box. The forward, !-hydroxybutyryl-CoA oxidation reaction calculations are at 
the top; the reverse, NADH-dependent reaction calculations are at the bottom. Reactions at 
pH 7 are on the left; reactions at pH 10 are on the right. All values are molar unless 
otherwise stated. See text for details. 
 
In the forward reaction, at pH 7, the proton concentration is such that equilibrium is pushed 
to the left (reactants) so very little acetoacetyl-CoA and NADH product is made. At pH 10, 
however, there are far fewer protons present and the reaction equilibrium is almost 
completely towards the product. This means that there is a higher yield of acetoacetyl-CoA 
and NADH product. The opposite is seen for the reverse NADH-dependent reaction (Figure 
4-8). 
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CD spectra revealed that the protein is more susceptible to unfolding when in acidic 
conditions than at high pH values; the tertiary structure is maintained even at pH 10 (Figure 
4-9 B). Nevertheless, it is likely that the optimal pH for in vivo activity may be different from 
those obtained with purified protein, especially knowing that the pI values of the native and 
recombinant protein are different. 
 
 
 
 
 
 
 
 
 
FIGURE 4-9. Circular dichroism (CD) spectra. (A) Superimposed CD spectra of wild-type 
Mt-FadB2 and S122A-mutated Mt-FadB2 in 50 mM potassium phosphate (pH 7.9), 50 mM 
NaF buffer. (B) Superimposed CD spectra of wild-type Mt-FadB2 in different pH buffers 
(50 mM potassium phosphate (pH 6, 7 or 8), 50 mM NaF or 50 mM CAPS (pH 9, 10 or 11), 
50 mM NaF). Protein samples (1.1 mg/ml) were scanned in a 0.01 cm pathlength cell using 
a Jasco-J-715 spectropolarimeter. Spectra are averages of eight scans over a wavelength 
range of 197 to 245 nm, with a bandwidth of 2 nm. The results were normalised by 
subtracting the baseline buffer spectrum from each. 
 
Furthermore, Mt-FadB2 NAD+-reducing activity was found to be non-metal dependent, 
however various uni- and divalent cations were tested to see if their presence inhibited or 
activated the protein. Mg2+ and Ca2+ enhanced the activity of the enzyme, whereas Zn2+, Ni2+ 
and Co2+ had an inhibitory effect (Figure 4-10). Wakil et al. (1954) found that the addition of 
Mg2+ to the forward !-hydroxybutyryl-CoA oxidation reaction also had the effect of 
increased activity. This could be explained by the di-cations forming a complex with the !-
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oxoacyl-CoA product, in effect removing it from the reaction, resulting in a shift of 
equilibrium to the right (Wakil et al. 1954). The enzyme was not active when NADP+ was 
used as a co-factor, even in the presence of CaCl2. 
 
 
 
 
 
 
 
 
 
 
FIGURE 4-10. The effect of different uni- and divalent cations on the rate of reaction. 
Using !-hydroxybutyryl-CoA and NAD+ as the substrate and co-factor respectively, 
different uni- and divalent cations were added to the reaction mix at a concentration of 1 
mM or 10 mM. Bars represent the average of three replicates ± standard error. 
 
Liu et al. (2004) found that, by substituting the Ser-137 residue with an alanine in rat 
mitochondrial !-hydroxyacyl-CoA dehydrogenase, the activity was greatly reduced, 
demonstrating that Ser-137 was a key catalytic residue. Generation of the equivalent 
mutation in Mt-FadB2 (Ser-122-Ala) abolished all activity, supporting the idea that Mt-
FadB2 is indeed a !-hydroxyacyl-CoA dehydrogenase (data not shown). CD far-UV (197–
245 nm) spectra of the wild-type and mutant protein were obtained to confirm the correct 
folding of both proteins (Figure 4-9 A). As well as showing that the mutation did not cause 
any changes to the secondary structure, this result strongly indicates that Ser-122 is a key 
active site residue of Mt-FadB2 that is directly involved in catalysis. 
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4.3.4. The NADH-dependent reverse reaction. 
The ability of Mt-FadB2 to catalyse the reverse reaction, converting acetoacetyl-CoA to !-
hydroxybutyryl-CoA, using NADH as the co-factor, was also investigated (Figure 4-5 B, 
Table 4-1). Shimakata et al. (1979) could not conclude that their protein with !-hydroxyacyl-
CoA dehydrogenase activity was involved in fatty acid  !-oxidation, but their results did 
show that the dehydrogenase was involved in the fatty acid elongation system. Wheeler et al. 
(1991) also implied the same conclusions in mycobacteria by showing that other enzymes of 
the !-oxidation pathway could catalyse both forward and reverse reactions. This reverse 
reaction was tested over a range of pH values and the optimum was found to be pH 5.5–6.5 
(potassium phosphate buffer) (Figure 4-7 C, 4-8), a result that has been previously described 
for !-hydroxyacyl-CoA dehydrogenase (Shimakata et al. 1979). The enzyme kinetics for Mt-
FadB2 indicate that the protein has a slightly greater affinity for !-hydroxybutyryl-CoA than 
acetoacetyl-CoA, i.e., the fatty acid catabolism direction. It was also found that, whereas the 
forward reaction could not use NADP+ as the co-factor, the reverse reaction was able to use 
NADPH as well as NADH. This therefore also indicates a role for Mt-FadB2 in lipid 
synthesis and fatty acid elongation. 
 
4.3.5. Analytical ultracentrifugation of Mt-FadB2. 
Analytical ultracentrifugation of Mt-FadB2 provided information about the state the protein 
adopts in buffered solution with NAD+ and NADH co-factors and the substrate !-
hydroxybutyryl-CoA. Absorbance data were not collected because the ligands absorb at the 
same wavelength as the protein, however, interference data of the native protein indicated 
that Mt-FadB2 exists in two forms, most likely as a monomer and dimer (Figure 4-11). 
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FIGURE 4-11. Analytical ultracentrifugation. The sedimentation mode indicates that Mt-
FadB2 exists as both a monomer and dimer in buffered solution. Samples were centrifuged 
at 40,000 rpm at 4 °C for 8 h. 
 
4.3.6. Mt-FadB2 crystallisation trials. 
Attempts were made to crystallise native Mt-FadB2 and protein bound to NAD+, NADH, !-
hydroxybutyryl-CoA or acetoacetyl-CoA. Several buffers produced crystals sufficient for 
diffraction. The precipitant solution that yielded the best cube-shaped crystals was 0.1 M 4-
(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; pH 7.5), 12 % polyethylene 
glycol (PEG) 6000, 6 % 2-methyl-2,4-pentanediol (MPD) using native protein. Crystals were 
cryoprotected with 0.1 M HEPES (pH 7.5), 15 % PEG 6000, 20 mM NAD+ and 15 % 
glycerol and soaked for 10 min before flash freezing in liquid nitrogen. The diffraction data 
were collected on the University of Birmingham X-ray diffractor. The best resolution 
obtained was 3.81 Å, which was not adequate to solve the structure of the protein (Figure 4-
12 A). 
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From this, efforts were made to optimise the conditions further, by increasing the precipitant 
(PEG 6000) or salt (HEPES) concentration. Other initially promising conditions were also 
trialled and modified. Isomorphous replacement of the methionine residues in the protein 
with selenomethionine was also tried, in an attempt to improve phase determination to aid 
structure resolution. However, problems arose with selenium labelling: it was thought this 
may have been due to the massive over-production of protein, so firstly the IPTG 
concentration used for induction was reduced. When this strategy proved unsuccessful, the 
bacterial strain used was changed from E. coli C43 to Tuner™ cells, in which induction by 
IPTG concentration can be more tightly controlled. Only a slight improvement was made, 
however, with a maximum of three out of nine methionine residues being replaced. Attempts 
to crystallise Mt-FadB2 halted at this point. A simulation of Mt-FadB2 was instead generated 
using the SWISS-MODEL server (<http://swissmodel.expasy.org/>; Arnold et al. 2006, 
Kiefer et al. 2009, Peitsch 1995), based on the protein structure of human heart short-chain L-
3-hydroxyacyl-CoA dehydrogenase (PBD entry, 3HAD; Barycki et al. 1999) (Figure 4-12 
B). 
 
 
 
 
 
 
 
 
 
FIGURE 4-12. Mt-FadB2 crystallisation. (A) Mt-FadB2 protein crystal (B) The simulated 
structure of Mt-FadB2 based on human heart short-chain L-3-hydroxyacyl-CoA 
dehydrogenase, PBD entry: 3HAD (Barycki et al. 1999). 
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4.3.7. M. smegmatis fadB2 and fadB3 deletion mutant analysis. 
The Ms-fadB2, Ms-fadB3 and Mb-fadB3 knock-out mutants were generated using specialised 
transduction (Bardarov et al. 2002) and confirmed by Southern blot (Figure 4-13). This 
verified that neither fadB2 nor the fadB3 homologue MSME6791 are essential in M. 
smegmatis, as suggested by transposon data reported for M. tuberculosis (Sassetti et al. 
2003). The same transposon data, however, reported that the fadB3 gene in M. tuberculosis 
(Mb1742-1743) is essential. For this reason the generation of a mutant lacking the fadB3 
homologue in M. bovis BCG, a close relation to M. tuberculosis, is surprising. The best way 
of proving this, however, would be to attempt to generate the Mt-fadB3 knock-out in M. 
tuberculosis. 
 
There were no obvious differences were observed either in colony morphology or lipid 
profiles between the "Ms-fadB2 and wild-type M. smegmatis strains (Figures 4-14, 4-15 and 
4-16), except for a second species in the phopspholipid region visible in the "Ms-fadB2-
pMV261-Ms-fadB2 complemented strain (Figure 4-15 B). It would be interesting to identify 
what this potential phospholipid is. Also, better separation of the M. smegmatis MAMEs 
would provide more accurate information regarding the biosynthesis of "-, "#-and epoxy-
mycolates (Figure 4-16 B). 
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FIGURE 4-13. Generation of the M. smegmatis fadB2 (MSMEG0912), fadB3 
(MSMEG6791) and M. bovis BCG fadB3 (Mb1742-1743) knock-out mutants. Left-hand 
panels map the regions of the genes of interest in the M. smegmatis or M. bovis BCG 
genome and the corresponding regions in the mutant. Right-hand panels show Southern blot 
analyses of the PCR products obtained from genomic DNA isolated from wild-type M. 
smegmatis mc2155 or mutant strains. (A) M. smegmatis "fadB2, (B) M. smegmatis "fadB3 
and (C) M. bovis BCG "fadB3. Regions where the right-hand PCR primer probe binds to 
the gDNA fragments are indicated by solid lines and expected sizes of the hybridised bands 
are indicated with dashed lines. Hyg, hygromycin resistance gene from S. hygroscopicus. 
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FIGURE 4-14. TLC autoradiography of [14C]-labelled apolar lipid extracts from M. 
smegmatis "fadB2 and complementing strains. Legend over page. 
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FIGURE 4-14. TLC autoradiography of [14C]-labelled apolar lipid extracts from M. 
smegmatis "fadB2 and complementing strains. Apolar lipids were extracted twice with 1 
ml petroleum ether (60–80 °C) for 15 min. Extracts were pooled, dried and resuspended in 
200 µl dichloromethane prior to TLC. Plates were developed using the following systems: 
(A) direction 1, petroleum ether / ethyl acetate (98 :2, v/v) and direction 2, petroleum 
ether / acetone  (98 :2, v/v), (B) direction 1, petroleum ether / acetone (92 :8, v/v) and 
direction 2, toluene / acetone (95 :5, v/v), (C) direction 1, choroform / methanol  (96 :4, v/v) 
and direction 2, toluene / acetone  (80 :20, v/v), (D) direction 1, choroform / methanol / water 
(100 :14 :0.8, v/v/v) and direction 2, chloroform / acetone / methanol / water (50 :60 :2.5 :3, 
v/v/v/v). Lipids were visualised by autoradiography (overnight exposure of Kodak X-Omat 
AR film to the TLC plates). TAG, triacyl glycerol; DAG, diacyl glycerol; GMM, glucose 
monomycolate; SL, sulfolipid; TMM, trehalose monomycolate, TDM, trehalose dimycolate. 
 
 
 
 
 
 
 
 
 
 
FIGURE 4-15. TLC autoradiography of [14C]-labelled polar lipid extracts from M. 
smegmatis "fadB2 and complementing strains. Polar lipids were extracted twice with 750 
µl chloroform / methanol / 0.3 % NaCl (5 :10 :4, v/v/v) for 30 min, then again with 1.3 ml 
chloroform and 1.3 ml 0.3 % NaCl. Extracts were pooled, dried and resuspended in 200 µl 
chloroform / methanol (2 :1, v/v) prior to TLC. Plates were developed using the following 
systems: (A) direction 1, chloroform / methanol / water (100 :14 :0.8, v/v/v) and direction 2, 
chloroform / acetone / methanol / water (50 :60 :2.5 :3, v/v/v/v), (B) direction 1, 
chloroform / methanol / water (60 :30 :6, v/v/v) and direction 2, chloroform / acetic 
acid / methanol / water (40 :25 :3 :6, v/v/v/v). DAT, diacyl trehalose; GMM, glucose 
monomycolate; TDM, trehalose dimycolate; PL, phospholipid; PI, phosphatidylinositol; 
AcxPIMx, acylacted PIM(s). 
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FIGURE 4-16. TLC autoradiography of [14C]-labelled fatty acid methyl esters (FAMEs) 
and mycolic acid methyl esters (MAMEs) from M. smegmatis "fadB2 and 
complementing strains. Cell wall-bound FAMEs and MAMEs were extracted from 
delipidated cells with TBAH, iodomethane and dichloromethane and washed three times 
with 2 ml deionised water. Extracts were pooled, dried and resuspended in 200 µl 
dichloromethane prior to TLC. Plates were developed using the following systems: (A) 
petroleum ether / acetone (95 :5, v/v), (B) 2D aqueous silver nitrate (10 % w/v) direction 1, 
hexane / ethyl acetate (19 :1, v/v) and direction 2, petroleum ether / diethyl ether (17 :1, v/v). 
SF, solvent front; FAMEs, fatty acid methyl esters; MAMEs, mycolic acid methyl esters. 
 
Growth of the "Ms-fadB2 mutant on minimal medium containing a variety of carbon sources 
was compared to that of the wild-type and complemented strains. There was no difference in 
growth observed between any of the strains when grown on agar media containing glycerol, 
glucose, acetate, propionate, caprylic acid, capric acid, lauric acid, myristic acid, palmitic 
acid, oleic acid or linoleic acid as the sole carbon source (data not shown). Following the 
recent report on a mycobacterial FadA enzyme, which acts as a thiolase in cholesterol 
metabolism (Nesbitt et al. 2010), the growth of the Ms-fadB2 deletion mutant on minimal 
medium containing cholesterol as the sole carbon source was also tested. However, in this 
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case too, no differences were observed in the growth of the wild-type and mutant strains 
(Figure 4-17). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4-17. M. smegmatis "fadB2 mutant growth analysis in cholesterol. Growth 
curves of M. smegmatis wild-type, "fadB2, and the Mt- and Ms-fadB2 complemented 
strains in minimal medium (MM) with 0.2 % glycerol (MM+G), 0.1 % tyloxapol :ethanol 
(1 :1 v/v) or 0.2 mM cholesterol (MM+C). 
 
Previously, it has been shown that Mt-fadB2 is up-regulated upon acid shock and SDS stress 
(Fisher et al. 2002, Manganelli et al. 2001). To test whether FadB2 conferred tolerance to 
these stresses, the "Ms-fadB2 mutant was grown in media of various pH values or containing 
different concentrations of SDS. The findings, however, indicate that the deletion had no 
effect on cell growth rate and survival at physiological pH, acidic pH or under SDS stress 
(Figure 4-18). 
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FIGURE 4-18. M. smegmatis "fadB2 mutant growth analysis in acid and SDS. (A) Acid 
stress killing curve. (B) SDS stress killing curve. Cultures were grown to an OD600 of 0.4, 
washed and resuspended in 7H9 medium at pH 7 or pH 3 or containing 0.05 % SDS. 
Samples were taken over 24 h and viable counts were calculated as described in section 
4.2.12.3. Bars represent the average of three replicates ± standard error. 
 
The Bauer-Kirby disc diffusion method was also used to test how the M. smegmatis mutants 
responded to oxidative (30 % H2O2) and SDS (10 %) stress (Bauer et al. 1966). The zones of 
inhibition around the filter paper discs were measured and compared between the strains. 
Similarly, however, no statistically significant differences were observed between wild-type 
M. smegmatis and the "Ms-fadB2 or "Ms-fadB3 mutants (Figure 4-19). 
 
The growth of the "Ms-fadB2 and "Ms-fadB3 mutants on isoniazid was also tested, by 
diluting increasing concentrations of the drug in TSB agar. Isoniazid blocks the FAS-II 
biosynthetic pathway, thus creating an excess of fatty acids. Without either FadB2 or FadB3, 
it is reasonable to suggest that the surplus lipids cannot be metabolised and therefore 
potentially have a toxic effect on top of that produced by the drug. This did not appear to be 
the case, however, with results showing that both the mutant strains and the wild-type 
behaved in the same way under this stress (Figure 4-19 C). 
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FIGURE 4-19. Toleration of M. smegmatis "fadB2 and "fadB3 mutants to stresses. (A) 
30 % H2O2 ("Ms-fadB2, left panel; "Ms-fadB3, right panel) and (B) 10 % SDS. Sterile 
filter paper discs saturated with 6 µl of 30 % H2O2 or 10 % SDS were applied to the 
overlaid plates and incubated at 37 °C for 3 days. The diameters of the zones of inhibition 
surrounding the discs were then measured. Bars represent means of three replicates ± 
standard error. (C) Isoniazid. TSB agar plates supplemented with isoniazid (0–20 µg/ml or 
0–0.8 µg/ml) were spotted with 10 µl of each mutant ("Ms-fadB2, left panel; "Ms-fadB3, 
right panel) and wild-type (WT) culture, serially diluted to 10-7, in duplicate. After 
incubation at 37 °C for 3–4 days, the colonies were counted and converted to log (CFU/ml). 
Points represent the means of duplicates ± standard error. 
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4.3.8. In silico analysis of Mt-FadB4 and Mt-FadB5. 
The in silico data, generated using the GOR IV and TMHMM protein secondary structure 
prediction servers (Garnier et al. 1996), indicate that both Mt-FadB4 and Mt-FadB5 are 
soluble proteins, with no evidence for any transmembrane-spanning helices. The lack of 
cysteine residues in both FadB4 and FadB5, and therefore no iron-sulfur cluster [4Fe-4S]-
binding motifs (C-X-X-C-X-X-C), suggest that neither protein is an NDH-1 ion pump (Yagi et 
al. 2004). One study by Maruyama et al. (2003) identified two NQOs in Staphylococcus 
aureus, SA_1989 and SA_1988. SA_1989 contains an NAD(P)H-binding motif (A-X-X-G-X-
X-G), whereas the second downstream gene, SA_1988, encodes a protein with an alcohol 
dehydrogenase-type NAD(P)H-binding motif (G-X-G-X-X-G), as found in horse liver alcohol 
dehydrogenase. A similar finding was made in Streptococcus gordonii, where Qor1 
(SGO_1169) has the nuclotide-binding site and Qor2 (SGO_1170) has the alcohol 
dehydrogenase-type NAD(P)H-binding motif. Upon alignment of this section of both of 
these enzymes with the homologous portions from E. coli QorA, A. thaliana P1-zeta-
crystallin, horse liver alcohol dehydrogenase, FadB4 and FadB5, it becomes apparent that all 
enzymes share the same conserved motifs (Figure 4-20). Both FadB4 and FadB5 have the 
same NAD(P)H-binding motifs, A-X-X-G-X-X-G, which is highly conserved across different 
quinone oxidoreductases in bacteria, plants and mammals. 
 
4.3.9. Over-expression and purification of Mt-FadB4. 
Initial expression studies in E. coli C43 (DE3) cells harbouring the pET28a-Mt-fadB4 
plasmid showed a very small amount of soluble protein when induced with 1 mM IPTG. A 
one-step purification protocol with increasing concentrations of imidazole failed to remove 
many contaminants and very little FadB4 protein remained. Over-expression was improved 
greatly by the use of E. coli Tuner™ cells, however the majority of the protein was insoluble. 
Purification was attempted with the addition of 0.1 % Triton-X 100 in the elution buffers, the 
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rationale for this being that the detergent would break down any inclusion bodies trapping the 
protein. More FadB4 protein was obtained but was found to degrade during the second step 
of purification with an anion exchange QHP column (GE Healthcare). 
 
 
 
 
 
 
 
FIGURE 4-20. Sequence alignments. Multiple sequence alignment of NAD(P)H-binding 
motifs for Qor proteins. The amino acid sequences of M. tuberculosis FadB4 residues 132–
174 (Mt_FadB4) and FadB5 residues 135–176 (Mt_FadB5) are compared with 
Streptococcus gordonii Qor1 96–138 (Sg_Qor1), S. gordonii Qor2 386–415 (Sg_Qor2), 
Staphylococcus aureus SA_1988 143–184 (Sa_1988), S. aureus SA_1989 139–180 
(Sa_1989), Escherichia coli QorA 137–179 (Ec_QorA), Arabidopsis thaliana P1-&-
crystallin 150–192 (At_P1) and horse liver alcohol dehydrogenase 186–228 (Ef_LADH). 
Asterisks indicate the NAD(P)H-binding motifs, red boxes indicate highly conserved 
residues and yellow boxes indicate conserved residues. Based on Maruyama et al. (2003). 
 
The use of chaperones to improve soluble recombinant protein yield is well documented (de 
Marco et al. 2007, 2011a, 2011b, Gupta et al. 2006). Protein over-expression in E. coli cells 
often leads to mis-folding and aggregation, which can be due to a lack of endogenous 
chaperones or inadequate folding machinery in the cell. In certain cases if the recombinant 
protein is too alien to E. coli this species cannot be used, and a different over-expression 
species is chosen. Trigger factor, DnaK and the GroEL/ES systems are examples of enzymes 
used by E. coli to help fold newly synthesised proteins, re-fold those that have become 
denatured due to intrinsic instability or heat and solubilise aggregated proteins (de Marco et 
al. 2007). Therefore, E. coli BL21 (DE3) cells containing machinery for the expression of 
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GroES and CPN 60.2 chaperones were then used. Subsequently, soluble protein was 
produced that did not degrade during anion exchange chromatography and an estimated 0.7 
mg of Mt-FadB4 could be obtained from 1 l of culture using this method (Figure 4-21). 
 
 
 
 
 
 
 
 
FIGURE 4-21. Purification of Mt-FadB4. The protein was produced by IPTG-induction of 
E. coli BL21 (DE3) transformants containing pET28a-Mt-fadB4. Following cell growth at 
37 °C and after induction at 16 °C, the protein was purified using a 1 ml Ni2+-charged His-
trap column and eluted with an increasing imidazole concentration (A). After dialysis, the 
protein was further purified using a QHP anion exchange column (B). In both cases, 
fractions were visualised by Coomassie Blue staining after separation by electrophoresis on 
12 % SDS-PAGE. 
 
4.3.10. Growth analysis of the Ms-fadB4 deletion mutant. 
The Ms-fadB4 (MSMEG2033) knock-out was generated using specialised transduction 
(Bardarov et al. 2002) and confirmed by Southern blot (Figure 4-22). This confirmed that the 
gene is not essential in M. smegmatis, as suggested by Himar1-based transposon mutagenesis 
reported for M. tuberculosis (Sassetti et al. 2003). 
 
There were no obvious differences observed either in colony morphology or lipid profiles 
between the mutant and wild-type M. smegmatis strain mc2155 (Figures 4-23, 4-24 and 4-
25). 
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FIGURE 4-22. Generation of the M. smegmatis fadB4 (MSMEG2033) knock-out mutant. 
(A) Map of the fadB4 region in the M. smegmatis genome and its corresponding region in 
the mutant "fadB4. Hyg, hygromycin resistance gene from S. hygroscopicus. (B) Southern 
blot analysis of the PCR products obtained from genomic DNA isolated from wild-type M. 
smegmatis mc2155 or "fadB4. Regions where the right-hand PCR primer probe binds to the 
gDNA fragments are indicated by solid lines and expected sizes of the hybridised bands are 
indicated with dashed lines. 
 
Growth of the "Ms-fadB4 mutant on minimal medium containing a variety of carbon sources 
was compared to that of the wild-type and complemented strains. There was no difference in 
growth observed between any of the strains when grown on agar media containing glycerol, 
glucose, acetate, propionate, caprylic acid, capric acid, lauric acid, myristic acid, palmitic 
acid, oleic acid or linoleic acid as the sole carbon source (data not shown). The Bauer-Kirby 
disc diffusion experiment was used to investigate any altered sensitivity of the mutant to 
oxidative and SDS stress (Bauer et al. 1966). Results revealed that there was no difference 
between wild-type M. smegmatis and the "Ms-fadB4 strain (Figure 4-26 A, B). 
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FIGURE 4-23. TLC autoradiography of [14C]-labelled apolar lipid extracts from M. 
smegmatis "fadB4 and complementing strains. Apolar lipids were extracted twice with 1 
ml petroleum ether (60–80 °C) for 15 min. Extracts were pooled, dried and resuspended in 
200 µl dichloromethane prior to TLC. Plates were developed using the following systems: 
(A) direction 1, petroleum ether / ethyl acetate (98 :2, v/v) and direction 2, petroleum 
ether / acetone  (98 :2, v/v), (B) direction 1, petroleum ether / acetone (92 :8, v/v) and 
direction 2, toluene / acetone (95 :5, v/v), (C) direction 1, choroform / methanol  (96 :4, v/v) 
and direction 2, toluene / acetone  (80 :20, v/v), (D) direction 1, choroform / methanol / water 
(100 :14 :0.8, v/v/v) and direction 2, chloroform / acetone / methanol / water (50 :60 :2.5 :3, 
v/v/v/v). Lipids were visualised by autoradiography (overnight exposure of Kodak X-Omat 
AR film to the TLC plates). TAG, triacyl glycerol; DAG, diacyl glycerol; GMM, glucose 
monomycolate; SL, sulfolipid; TMM, trehalose monomycolate, TDM, trehalose dimycolate. 
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FIGURE 4-24. TLC autoradiography of [14C]-labelled polar lipid extracts from M. 
smegmatis "fadB4 and complementing strains. Polar lipids were extracted twice with 750 
µl chloroform / methanol / 0.3 % NaCl (5 :10 :4, v/v/v) for 30 min, then again with 1.3 ml 
chloroform and 1.3 ml 0.3 % NaCl. Extracts were pooled, dried and resuspended in 200 µl 
chloroform / methanol (2:1, v/v) prior to TLC. Plates were developed using the following 
systems: (A) direction 1, chloroform / methanol / water (100 :14 :0.8, v/v/v) and direction 2, 
chloroform / acetone / methanol / water (50 :60 :2.5 :3, v/v/v/v), (B) direction 1, 
chloroform / methanol / water (60 :30 :6, v/v/v) and direction 2, chloroform / acetic 
acid / methanol / water (40 :25 :3 :6, v/v/v/v). DAT, diacyl trehalose; GMM, glucose 
monomycolate; TDM, trehalose dimycolate; PL, phospholipid; PI, phosphatidylinositol; 
AcxPIMx, acylacted PIM(s). 
 
A report by Prüß et al. (1994) showed how E. coli cells that are devoid of either of the two 
NQO genes are less able to metabolise the amino acids glutamate, glycine, threonine and 
alanine. In order to test if this is also the case for M. smegmatis lacking the putative NQO 
fadB4, cells were plated on minimal medium agar containing the amino acids (20 µg/ml and 
100 µg/ml) alanine, asparagine, lysine, leucine, valine and threonine. No difference was 
observed, however, between the growth of the strains on glucose and on agar containing the 
amino acids (Figure 4-26 C). 
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FIGURE 4-25. TLC autoradiography of [14C]-labelled fatty acid methyl esters (FAMEs) 
and mycolic acid methyl esters (MAMEs) from M. smegmatis "fadB4 and 
complementing strains. Cell wall-bound FAMEs and MAMEs were extracted from 
delipidated cells with TBAH, iodomethane and dichloromethane and washed three times 
with 2 ml deionised water. Extracts were pooled, dried and resuspended in 200 µl 
dichloromethane prior to TLC. Plates were developed using the following systems: (A) 
petroleum ether / acetone (95 :5, v/v), (B) 2D aqueous silver nitrate (10 % w/v) direction 1, 
hexane / ethyl acetate (19 :1, v/v) and direction 2, petroleum ether / diethyl ether (17 :1, v/v). 
SF, solvent front; FAMEs, fatty acid methyl esters; MAMEs, mycolic acid methyl esters. 
Chapter 4 Mycobacterial FadB Enzymes 
!
 188 
4.3.11. Construction of the Mb-fadB5 deletion mutant. 
As with the other deletion mutants, "Mb-fadB5 (Mb1947c) was generated using specialised 
transduction (Bardarov et al. 2002) and the knock-out was confirmed by Southern blot 
(Figure 4-27). The successful deletion of the gene shows that fadB5 is not required for cell 
growth or survival in vitro, as predicted by Sassetti and co-workers (2003). 
 
4.4. Discussion 
The work described here provides a detailed study of Mt-FadB2 and preliminary insights into 
three of the other mycobacterial fadB genes, fadB3, fadB4 and fadB5. Investigation of the 
mycobacterial fatty acid !-oxidation pathway has been somewhat neglected, perhaps due to 
the assumed redundancy between the abundant fad-annotated genes. There is, however, an 
immense need to find new drug targets within M. tuberculosis in order to halt the spread of 
disease. By exploring novel genes, it is possible to isolate those essential to the bacillus, thus 
highlighting a potentially different pathway or system that can be inhibited by new drugs. 
 
Here, evidence for the function of Mt-FadB2 (Rv0468) in converting both !-hydroxyacyl-
CoA to acetoacetyl-CoA and acetoacetyl-CoA to !-hydroxyacyl-CoA has been provided. The 
NADH-oxidation ‘reverse’ reaction was found to be optimum at the pH inside the 
macrophage vacuole (pH 6–7), which could suggest that this reaction is favoured in vivo and 
that the dehydrogenase is utilised by the bacteria to synthesise, or elongate, fatty acids rather 
than degrade them, although this feature can also be explained by reaction equilibria. It was 
also shown, by gene deletion, that Ms-FadB2 is not essential in M. smegmatis. No differences 
could be found between the wild-type and deletion mutant strain in the lipid profile, although 
the presence of an extra phospholipid spot in the Ms-fadB2-complemented strain is of 
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potential interest. There were similarly no differences between strains in reaction to cellular 
stresses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 4-26. M. smegmatis "fadB4 growth analysis. Survival of mutant cells on (A) 30 
% H2O2 and (B) 10 % SDS. Sterile filter paper discs saturated with 6 µl of 30 % H2O2 or 10 
% SDS were applied to the overlaid plates and incubated at 37 °C for 3 days. The diameters 
of the zones of inhibition surrounding the discs were then measured. Values are means of 
three replicates ± standard error. (C) The growth of M. smegmatis "fadB4 on individual 
amino acids as the sole carbon source compared with wild-type and complementing strains. 
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FIGURE 4-27. Generation of the M. bovis BCG fadB5 (Mb1947c) knock-out mutant. (A) 
Map of the fadB5 region in the M. bovis BCG genome and its corresponding region in the 
mutant "fadB5. Hyg, hygromycin resistance gene from S. hygroscopicus. (B) Southern blot 
analysis of the PCR products obtained from genomic DNA isolated from wild-type M. bovis 
BCG or "fadB5. Regions where the right-hand PCR primer probe binds to the gDNA 
fragments are indicated by solid lines and expected sizes of the hybridised bands are 
indicated with dashed lines. 
 
Despite being unable to allocate a function to Mt-FadB3, the predicted role is the same as that 
of Mt-FadB2, a !-hydroxyacyl-CoA dehydrogenase. The spectrophotometric assay developed 
for Mt-FadB2 was tested with purified Mt-FadB3. The protein was unable to catalyse the 
NAD+-dependent reduction of !-hydroxybutyryl-CoA to acetoacetyl-CoA, in the presence or 
absence of CaCl2 or MgCl2 (the cations found to increase the activity of Mt-FadB2), in acidic 
or basic conditions, nor with NADP+ as the co-factor. The reverse reaction was also tested 
with the same acetoacetyl-CoA substrate in various conditions, with NADH or NADPH, but 
Mt-FadB3 was also unable to catalyse these reactions (data not shown). It could be 
hypothesised that Mt-FadB2 accepts short-chain molecules, such as !-hydroxybutyryl-CoA, 
and Mt-FadB3 takes longer chain CoAs. To test this, N-acetylcysteamine (N-AC) molecules 
that mimic CoA-attached molecules (synthesised by Dr. V. Bhowruth, University of 
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Birmingham) were tested as a substrate for both Mt-FadB2 and Mt-FadB3. Neither protein 
could turn over !-hydroxylauryl-N-AC (C12) at physiological pH, nor in alkaline conditions 
as found to be favoured for the Mt-FadB2 !-hydroxybutyryl-CoA reaction, with NAD+ as the 
co-factor. The addition of bovine serum albumin (50 µg) to the Mt-FadB3 reaction was also 
examined, to see if stabilising the enzyme would help activity. None of the conditions tested, 
however, resulted in NAD+-reduction, indicating that the protein was either not active or it is 
not able to catalyse the reaction. The role of Mt-FadB3 was investigated in vivo, also by 
means of gene deletion, and was similarly found to be non-essential in both M. smegmatis 
and M. bovis BCG. This could potentially be of interest, since a previous genome-wide study 
suggested the gene is essential in M. tuberculosis (Sassetti et al. 2003). The deletion would 
have to be performed in this species, however, in order to identify the importance, be it for 
survival or virulence or not at all. 
 
Mt-FadB4 and Mt-FadB5 are annotated as having NADH:quinone oxidoreductase activity. 
Despite this, and in order to test for functional redundancy, purified Mt-FadB4 was 
substituted into the Mt-FadB2 assay, but as predicted no activity was found. The in silico 
analysis of the proteins strongly indicates NQO function, since both have the highly 
conserved NAD(P)H-binding motifs A-X-X-G-X-X-G found in quinone oxidoreductases of 
bacteria, plants and mammals. 
 
In this study, a viable fadB4 gene deletion in M. smegmatis was generated, although no 
differences could be found when compared to the wild-type in the experiments completed. 
The homologous deletion in M. tuberculosis is also viable but was found to be hypervirulent 
during the initial two weeks of infection (Scandurra et al. 2008). The group proposed that this 
was due to changes in the composition of the M. tuberculosis "fadB4 cell wall, whereby the 
ability to enter and infect macrophages was significantly increased. The M. smegmatis fadB4 
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mutant generated here, however, did not appear to have any alterations to cell wall 
composition. The antioxidant function of the mutants was also tested, since evidence 
suggests that NQO enzymes may act as antioxidants (Itoh et al. 1997, Shimada 2006, Triccas 
et al. 1999, Tumminia et al. 1993). No differences were observed between the mutant, wild-
type and complemented strains when challenged with oxidative (H2O2) or SDS stress on agar 
(Bauer et al. 1966), although it would be interesting to repeat the experiment in liquid 
medium and in acidic conditions. It is, however, possible that Mt-FadB5 shares the same 
function, providing a back-up mechanism should FadB4 be lost. Genes important for survival 
are often duplicated, as found for mycobacterial resuscitation promotion factor (rpf) genes 
(Kana et al. 2008). 
 
Under these circumstances, the generation of double or multiple fadB knock-out strains in 
surrogate species, but most valuably in M. tuberculosis, would be ideal for studying the roles 
of these genes in the biology of mycobacteria. This would provide an excellent tool for 
studying how the mutant(s) interact with the host and a plethora of further information, such 
as altered virulence, could be obtained. 
  
 
 
 CHAPTER 5 
General Conclusions 
Chapter 5 General Conclusions 
!
 194 
With an estimated one third of the world’s population infected with tuberculosis, it is 
imperative that progress is made to halt the spread of disease. The emergence of drug 
resistant strains of M. tuberculosis and the synergistic effects of HIV-1 co-infection has 
complicated the battle further. Bearing in mind that the majority of cases are found in poorer 
countries, it is also important to create therapeutics that are cheap to produce and distribute in 
order to reach those most at need. This project has aimed to address these issues, taking a 
two-pronged approach to (a) identify novel compounds based on both known 
chemotherapeutics and new scaffolds inhibiting enzymes previously determined as essential, 
and (b) characterise formerly unstudied genes and their protein products with the view of 
isolating new drug targets. 
 
In chapter 2 the first of these project aims was explored. The objective was inhibition of 
FAS-II cycle enzymes, i.e. those not found in mammals and that are known to be effective 
targets through the use of known drugs such as isoniazid and ethionamide. Three different 
groups of novel compounds were tested: platensimycin, thiolactomycin analogues and indole 
derivatives. Platensimycin is an excellent example of a natural product being discovered as a 
new scaffold with therapeutic potential. Here, the compound was established as an inhibitor 
of mycobacterial growth, specifically of Mt-KasA and Mt-KasB, the !-ketoacyl-AcpM 
synthase enzymes that repeatedly elongate the meromycolate chain, with in vitro IC50 values 
of 2.0 ± 0.1 and 4.2 ± 0.1 µg/ml, respectively. Platensimycin was also found to be active 
against the whole cell, both slow-growing M. tuberculosis CDC1551 and fast-growing M. 
smegmatis mc2155, with MIC99 values of 12 and 14 µg/ml, respectively. Platencin is a 
congener of platensimycin that has activity against both FabF and FabH of Gram-positive 
bacteria (homologous to mycobacterial KasB and FabH, respectively) (Wang et al. 2007b). 
Given that platensimycin was found to be not active against Mt-FabH, it would be interesting 
to test platencin against this enzyme. Indeed, since this work, several analogues of both 
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compounds have been produced either naturally using Streptomyces platensis (Zhang et al. 
2011) or synthesised chemically (Jang et al. 2010, Wang & Sintim 2011). Some preliminary 
work was undertaken at the end of this project, testing three of these latter compounds 
against mycobacterial FAS-II enzymes in vitro in collaboration with J. Wang and Prof. H. 
Sintim (University of Maryland). Although the structures of these compounds are currently 
undisclosed and biological testing is just beginning, initial results have revealed some 
promising IC50 values of 144.0–165.5 µg/ml against Mt-FabH, 35.5–186.7 µg/ml against Mt-
KasA and 40.8–172.0 µg/ml against Mt-KasB. 
 
The thiolactomycin analogues tested were designed to competitively inhibit the Mt-FabH 
active site. Three were found to be active against the enzyme, two of which showed better 
IC50 values than the parent compound itself: 1.04 ± 0.2 µg/ml (QAB-62) and 1.1 ± 0.1 µg/ml 
(QAB-62a) compared to 16.0 µg/ml of thiolactomycin (Kim et al. 2006). Disappointingly, 
however, these compounds were also active against Ms-FAS-I crude cell extracts, a system 
also found in mammals, and collaborative work by Dr. Al-Balas (University of Strathclyde) 
demonstrated that QAB-61 and QAB-62 were not active against M. tuberculosis in vivo. 
Interestingly, four of the compounds did inhibit the whole cell, albeit not through FAS-I/II, 
with QAB-4a being most potent, showing an MIC99 of 0.06 µg/ml (compared to 13.0 µg/ml 
for thiolactomycin). Having such a low MIC99 value, QAB-4a should be examined further 
and better understood. By acquired QAB-4a resistance experiments and genome sequencing, 
the target could be discerned and a completely new way of inhibiting M. tuberculosis could 
be identified. 
 
Finally, work looking at derivatives of indole-containing compounds revealed four structures 
that displayed activity against Ms-FAS-II but not FAS-I. The compound showing most 
potential was WIUAKP-045, with an IC50 of 3.64 ± 0.02 µg/ml. It would be interesting to 
Chapter 5 General Conclusions 
!
 196 
assay this and the other four compounds against individual FAS-II enzymes in order to 
identify the precise target(s). Similarly, it would be worthwhile to generate molecules based 
on WIUAKP-045 to distinguish the active functional groups and potentially increase potency 
further. Another important additional experiment would be whole cell testing against M. 
tuberculosis. The lipid-rich cell wall often proves to be a highly impervious barrier, and, 
whilst the compounds may be active against FAS-II in vitro, they are generally useless unless 
they are able to enter the cell. 
 
Overall, chapter 2 has demonstrated that work finding new anti-tubercular chemotherapeutics 
is very much underway and all three of the structural scaffolds examined hold promise. The 
undertaking, however, is very challenging, expensive with regard to time and money and the 
ever-evolving target bacillus ensures resistance to any new drug. For this reason, groups are 
starting to apply new therapeutic strategies in the fight against TB. One example is the use of 
synergistic drug combinations. Although combined drug regimens are currently used as part 
of the DOTS treatment, a new approach uses spectinomycin as a ‘sensitiser’ (Ramón-García 
et al. 2011). Alone, the antibiotic has little effect on M. tuberculosis but can be employed 
with other antibiotics to increase potency. The advantages are that all the compounds are 
already approved so therapy could be mobilised quickly, and that this could be an efficient 
way of treating XDR strains. The disadvantage is that adding another antibiotic to the 
regimen increases cost. In a similar vein, a recent report identified thiophen-2-yl-1,2,4-
oxadiazoles as effective ethionamide boosters by not only increasing activity but also 
enhancing solubility and metabolic stability (Flipo et al. 2011). A second alternative mode of 
treatment is through augmenting and complementing the host’s immune cells i.e. directing 
drugs at macrophages rather than the internalised bacilli (Martins 2011). One particular 
mechanism is the use of phenothiazines, organic compounds already used in some anti-
psychotics and anti-histamines (Booth 2007). Phenothiazines act on both prokaryotic and 
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eukaryotic efflux pumps, ATPases and genes affecting cell permeability, thereby facilitating 
the killing by inactivated macrophages of both intracellular MDR and XDR M. tuberculosis 
(Amaral et al. 2010, Viveiros et al. 2010). As well as targeting XDR strains, by using this 
strategy the problem of developing drug resistance could be avoided. Betaglycan 
(transforming growth factor, beta receptor III; TGF!R3) has also been trialled in TB 
immunotherapy (Hernández-Pando et al. 2006). It is known that monocytes infected with M. 
tuberculosis express TGF-!I, which boosts the growth of ingested bacilli and inhibits the 
bacteristatic effects of TNF-! and IFN-" (Hirsch et al. 1994). A potent TGF-! antagonist, 
betaglycan, has been shown to rapidly reduce bacillary load from the infected lungs of mice 
when administered in combination with niflumic acid, a peptidoglycan synthesis inhibitor 
(Hernández-Pando et al. 2006). 
 
Chapter 3 turned attention to the regulation of FAS-II enzymes and the biosynthesis of 
mycolic acids. Understanding how these enzymes are switched on and off could provide 
another valuable tool in fighting tuberculosis. Previous reports have shown how InhA, the 
primary target of the highly successful drug isoniazid, is down-regulated by phosphorylation 
(Molle et al. 2010). The authors noted the importance of discerning how M. tuberculosis 
regulates mycolic acid content with regard to new anti-TB therapies. 
 
Work here looked at the regulation of Mt-FabH by phosphorylation and revealed, not only 
that the enzyme is a substrate for mycobacterial serine/ threonine protein kinases, but also is 
actually inhibited by phosphorylation of Thr-45. PknA and PknF were the most efficient 
kinases, with less phosphorylation by PknD, PknE and PknH. PknB, PknK and PknL failed 
to phosphorylate Mt-FabH, an interesting finding knowing that PknB phosphorylates the 
other KAS enzymes in M. tuberculosis, KasA and KasB (Molle et al. 2006). Using Mt-
FabH(T45D) as a mimic of constitutive phosphorylation, activity was assessed and compared 
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to the wild-type enzyme and T45A, T45E, T45S and T45/47A point mutants. The enzyme 
reaction was broken down into three parts: (i) condensation, (ii) transacylation and (iii) 
decarboxylation. The ‘phosphorylated’ version of the enzyme (T45D) displayed reduced 
activity in all three part-reactions: 42 % of wild-type condensing activity, 62 % of wild-type 
transacylation activity and 10 % of wild-type decarboxylation activity. Since some activity is 
seen in all experiments, it may be reasonable to suggest that Mt-FabH is modulated by 
phosphorylation, rather than simply switched on or off. 
 
Using the crystal structure of Mt-FabH (Alhamadsheh et al. 2007, Brown et al. 2005, 
Musayev et al. 2005, Scarsdale et al. 2001) and the mechanism of action proposed by 
Sachdeva et al. (2008a, 2008b), it was possible to locate the position of the phosphorylated 
residue and identify other residues that may be involved, and suggest how phosphorylation is 
used to tweak activity. Firstly, Thr-45 is close to the AcpM interaction site and, as such, 
addition of a phosphate group may be enough to prevent docking in the narrow binding 
channel. Secondly, the residue is #6 Å from Arg-46 and Trp-42, both of which are important 
in the binding of coenzyme A (work by Brown and co-workers (2005) found that mutations 
of Trp-42 significantly reduce KAS activity). In Ec-FabH, Arg-46 is the residue that co-
ordinates the pyrophosphate of CoA and Trp-42 stacks on top of the adenine base (Qiu et al. 
2001). By introducing a negatively charged group to this region, CoA substrate binding is 
directly hampered. The [PO4]3– would present an alternative salt bridge to CoA for Arg-46 
and may also impede the ability of Trp-42 to stack with the nucleobase. 
 
The work described here provides the first report on regulation of Mt-FabH, the critical linker 
enzyme between FAS-I and FAS-II in mycobacteria. Several further experiments could 
provide more information, such as at what stage of cell growth FabH is phosphorylated and 
how the enzyme is phosphorylated under different growth conditions. Khan et al. (2010) 
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generated a conditional inhA knockout in M. smegmatis and tested whether a constitutively 
phosphorylated InhA could rescue the deletion. A similar experiment could be done using an 
Ms-FabH knockout to see how FabH phosphorylation affects the whole cell. Additional work 
could look at how the synthesis of complex lipids and thus virulence are affected by 
constitutive FabH phosphorylation. 
 
The final section, Chapter 4, tackled the second project aim, to characterise new 
mycobacterial genes and identify potential drug targets. The focus was on the FadB enzymes, 
those involved in the fatty acid !-oxidation pathway. M. tuberculosis is able to survive 
intracellularly for very long periods of time and the importance of using host lipids to 
maintain this is well appreciated. There is, therefore, potential to produce new drugs that aim 
to halt this process, which could kill infecting bacilli essentially by starving them. Detailed 
research into the Fad enzymes has only taken hold within the last decade or so. Publication of 
the genome sequence in 1998 has helped the identification of these genes enormously (Cole 
et al. 1998). During this time, attention has mainly focussed on the thirty-six FadD genes, 
those annotated as fatty acyl-CoA synthetases, which activate fatty acids for metabolism. A 
wealth of data provides evidence for these genes being involved in a variety of important 
processes such as mycobactin (FadD33; LaMarca et al. 2004), phenolic glycolipid (FadD22; 
Ferreras et al. 2008, Siméone et al. 2010), PDIM (FadD26, FadD29 and FadD10; Hotter et 
al. 2005, Siméone et al. 2010) and sulfolipid (FadD23; Lynett & Stokes 2007) biosynthesis, 
mycolate recycling (FadD5; Dunphy et al. 2005), sterol metabolism (FadD19; Wilbrink et al. 
2011), M. avium invasion of mucosal epithelial cells (FadD2; Dam et al. 2006) and 
intracellular survival (FadD13; Khare et al. 2009, Singh et al. 2005, and FadD33; Rindi et al. 
2002, 2004). This shows how annotations made purely from the genome sequence and 
locations within the genome can be misleading. In contrast to FadD, of the five Mt-fadA 
genes only fadA5 has so far been characterised (Nesbitt et al. 2010). Similarly, there is one 
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paper reporting on the affects of deleting fadB4 in M. tuberculosis (Scandurra et al. 2008) 
and a very recent publication confirming the non-essentiality of Mt-FadB3 (Williams et al. 
2011). 
 
The gene explored in the most detail here was fadB2. Through the expression and 
purification of recombinant Mt-FadB2 the function of the enzyme was confirmed as a !-
hydroxybutyryl-CoA dehydrogenase, which uses NAD+ as the co-factor. Two reports from 
the 1970s describe a protein fraction from M. smegmatis containing a !-hydroxybutyryl-CoA 
dehydrogenase as being involved in fatty acid elongation, rather than !-oxidation (Shimakata 
et al. 1977, 1979). Although it is not known whether this group had isolated Ms-FadB2, the 
‘reverse’ reaction was also tested here, i.e. whether Mt-FadB2 would convert acetoacetyl-
CoA to !-hydroxybutyryl-CoA. Interestingly, not only did the enzyme catalyse the reaction, 
consistent with the reversible nature of mammalian mitochondrial !-hydroxybutyryl-CoA 
dehydrogenase, but it was also found that the pH-dependent activity was the same as that 
found over thirty years ago (Shimakata et al. 1979): the NAD+ reaction was optimal at pH 10 
and the NADH reaction optimal at pH 6. This is noteworthy knowing the acidic conditions 
bacilli are exposed to in macrophages. Perhaps, in vivo, the enzyme uses its dual functionality 
when the cell adapts and switches from lipid metabolism to biosynthesis. Despite being 
annotated as non-essential (Sassetti et al. 2003), it would be interesting to delete fadB2 from 
the M. tuberculosis genome and monitor cell growth and survival in different conditions and 
within macrophages, especially since Mt-FadB2 is up-regulated in macrophage and mouse 
infection models (Manganelli et al. 2001, Schnappinger et al. 2003, Talaat et al. 2004), as 
well as in low pH and acid shock conditions (Fisher et al. 2002). Some progress was made in 
investigating this by generating an M. smegmatis $fadB2 mutant. The cells were viable, 
confirming non-essentiality of the gene in this species, and no differences could be observed 
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between the knock-out and wild-type strains when treated with SDS, acid stress or isoniazid, 
nor were there any changes in lipid profile. 
 
Mycobacterial FadB3 is predicted to have the same function as FadB2. This hypothesis was 
tested with purified Mt-FadB3 but it was found that the enzyme was unable to turn over 
either !-hydroxybutyryl-CoA or acetoacetyl-CoA. In an effort to probe this further, longer 
hydroxyacyl-CoA mimics were synthesised, with an N-acetylcysteamine group (N-AC) 
replacing the CoA. The paper by Shimakata et al. (1979) showed how their enzyme would 
accept this substrate as well as an alternative artificial thioester, acetoacetyl-pantetheine, 
albeit with higher KM and lower Vmax values. Neither Mt-FadB2 nor Mt-FadB3, however, 
showed any activity with C12-N-AC, although in the case of recombinant FadB3 the purified 
protein might not have been active. Further experiments could be done to look into this, such 
as removing the His6-tag to see if it was obstructing the active site, and using CD analysis to 
ensure the protein was correctly folded. By way of investigating the role of FadB3 in vivo, 
$fadB3 mutants in both M. smegmatis and M. bovis BCG were generated. Both knock-outs 
were viable despite being one of only two fad genes annotated as being essential for in vitro 
growth in M. tuberculosis (Lamichhane et al. 2003, Sassetti et al. 2003). A recent report has 
further corroborated this finding, by producing a viable fadB3 deletion mutant in M. 
tuberculosis (Williams et al. 2011). The group could find no altered phenotype in the mutant 
strain with regard to growth on different carbon sources, a similar finding to the research 
here, nor with respect to growth and survival in the mouse model of infection. 
 
Preliminary results for two further deletion mutants were also produced, $Ms-fadB4 and 
$Mb-fadB5. With regard to the former, no differences were observed between the mutant, 
wild-type and complemented strains with respect to growth on sole carbon sources, or media 
containing SDS or H2O2, nor regarding amino acid metabolism or lipid profile. The deletion 
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of fadB5 in M. bovis BCG showed that the gene is not essential for in vitro growth, but 
unfortunately the strain was not explored further. It is clear from the literature that deleting 
single fad genes can have a big effect on the cell in vivo, such as the hypervirulent $Mt-
fadB4 mutant (Scandurra et al. 2008) and the seemingly attenuated $Mt-fadD5 (Dunphy et 
al. 2010). It is therefore vital to see how deleting each of these fadB genes would affect M. 
tuberculosis growth and survival in macrophages and whole animal models. 
 
Overall, this last chapter has given a significant indication that redundancy plays an 
enormous role in mycobacterial !-oxidation, signifying the importance of the pathway to the 
bacilli. It is evident that, in order for this essential process to be exploited as a drug target, 
much more biochemical analysis needs to be done and the effects of double and multiple 
deletion mutants need to be discerned. Allocating functions to the remaining FadB proteins 
would also be valuable, as has been done with many of the FadD enzymes. 
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6.1. Media 
6.1.1. Luria-Bertani (LB) broth and agar. 
To make 1 l of broth, dissolve 25 g Difco™ Middlebrook dehydrated LB in deionised H2O 
(dH2O) in a total volume of 1 litre. The medium contains peptone from casein, yeast extract 
and NaCl in the ratio 10:5:10 (v/v/v). For all the media described, solid agar versions can be 
made by adding 15 g agar (Oxoid Agar Technical; Agar No. 3) per 1 l liquid medium. 
Sterilisation is by autoclaving under high-pressure steam at approximately 123 °C for 15–20 
min. 
 
6.1.2. Terrific Broth. 
This is a rich medium devised by Tartoff & Hobbs (1987) to specifically produce a high yield 
of recombinant E. coli. To make 1 litre of broth, dissolve 12 g tryptone, 24 g yeast extract 
and 4 ml glycerol in dH2O in a total volume of 900 ml. In a separate flask, dissolve 2.31 g 
KH2PO4 and 12.54 g K2HPO4 in dH2O to a total volume of 100 ml. This is the 10! terrific 
broth salt. Sterilise both by autoclaving and, when at room temperature, aseptically add the 
100 ml 10! salts to the broth. 
 
6.1.3. Tryptic soy broth (TSB). 
TSB is a nutrient-rich medium used to grow M. smegmatis but not other mycobacteria. To 
make 1 litre of broth, dissolve 30 g Difco™ Middlebrook dehydrated TSB in dH2O to a total 
volume of 1 l. The medium contains 17 g pancreatic digest of casein, 5 g NaCl, 3 g papaic 
digest of soybean, 2.5 g dextrose and 2.5 g K2HPO4. 
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6.1.4. 7H9 broth. 
7H9 medium was developed by Middlebrook et al. (1954) and Middlebrook & Cohn (1958) 
for the growth of mycobacteria by including an essential high concentration of inorganic 
salts. When supplemented with glycerol or glycerol plus BBL™ Middlebrook ADC (100 ml 
per litre of 7H9 medium), growth is enhanced and suitable for supporting cultivation of M. 
bovis and M. tuberculosis. The medium contains (per 900 ml) 0.5 g ammonium sulfate, 0.5 g 
L-glutamic acid, 0.1 g sodium citrate, 1 mg pyridoxine, 0.5 mg biotin, 2.5 g Na2HPO4, 1 g 
KH2PO4, 40 mg ferric ammonium citrate, 50 mg MgSO4, 0.5 mg CaCl2, 1 mg ZnSO4 and 1 
mg CuSO4. Sterilise by autoclaving. BBL™ Middlebrook ADC can be added aseptically 
once the medium has cooled to 45 °C. It contains (per litre) 8.5 g NaCl, 50 g bovine albumin 
to bind potentially toxic free fatty acids, 20 g dextrose and 0.03 g catalase, which removes 
any peroxides. 
 
6.1.5. 7H11 agar. 
7H11 medium was formulated by Cohn et al. (1968) for culturing fastidious mycobacteria, 
including drug-resistant strains of M. tuberculosis. The addition of malachite green is 
intended to supply limited inhibition of contaminating bacteria, an important factor when 
culturing slow-growing bacteria. The medium contains (per 900 ml) 1 g pancreatic digest of 
casein, 0.5 g L-glutamic acid, 0.4 g sodium citrate, 1 mg pyridoxine, 0.5 mg biotin, 40 mg 
ferric ammonium citrate, 0.5 g ammonium sulfate, 1.5 g Na2HPO4, 1.5 g KH2PO4, 0.05 g 
MgSO4, 1 mg malachite green and 15 g agar. Similarly to 7H9, BBL™ Middlebrook ADC 
can be added aseptically to further enrich the medium. 
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6.1.6. Sauton’s medium. 
Sauton’s medium is a liquid broth used for the growth of fastidious cultures, specifically M. 
tuberculosis and M. bovis. The medium is not available commercially but can be prepared in-
house, containing (per litre) 0.5 g K2HPO4, 0.5 g MgSO4, 4 g L-asparagine, 0.05 g ferric 
ammonium citrate, 60 ml glycerol, 2 g citric acid, 0.1 ml ZnSO4 (1 % w/v), 5 ml Triton WR-
1339 (5 %), pH 7.2. 
 
6.1.7. Minimal media. 
Minimal media contain the minimal amount of nutrients to support cell growth. Usually these 
media consist of various salts that provide nitrogen for protein synthesis along with essential 
ions such as potassium, sodium, phosphate, chloride and calcium. 
 
6.1.7.1. Minimal medium for testing carbon sources in M. smegmatis. 
Individual carbon sources can be added to this medium to test for any metabolic deficiencies 
in mutant strains. The medium used contains (per litre) 1.5 g KH2PO4, 1.0 g NH4Cl, 0.2 g 
MgSO4"7H2O, 20.0 mg CaCl2"2H2O, 1.2 mg ferric ammonium citrate, 0.85 g NaCl and 8.99 
g Na2HPO4"12H2O. Additional carbon sources are independently sterilised and added to the 
autoclaved medium after it has cooled. 
 
6.1.7.2. Minimal medium for testing carbon sources in M. bovis BCG. 
A modified Sauton’s medium was used to test the growth of M. bovis BCG mutants on 
different carbon sources, as described by Keating et al. (2005). The medium contains (per 
litre) 4 g asparagine, 2 g citric acid, 0.5 g K2HPO4, 0.5 g MgSO4"7H2O and 0.05 g ferric 
ammonium citrate. 
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6.1.7.3. Minimal medium for seleno-methionine protein labelling. 
To aid structure determination of Mt-FadB2, attempts were made to label the protein with 
selenium by replacing methionine residues with seleno-methionine. The minimal medium 
used during this procedure contains (per litre) 200 ml 5! M9 salts, 2 mM MgSO4, 0.1 mM 
CaCl2 and 0.4 % glucose. The 5! M9 salts are made by dissolving the following in 1 l dH2O 
and sterilising by autoclaving: 83.9 g Na2HPO4"12H2O, 15 g KH2PO4, 2.5 g NaCl and 5.0 g 
NH4Cl. The MgSO4 and CaCl2 solutions are prepared and sterilised separately and added 
after the 5! M9 salts have been diluted (Sambrook & Russell 2001). 
 
6.2. Molecular biology protocols 
6.2.1. DNA sequences used in molecular biology protocols (TubercuList). 
6.2.1.1. M. tuberculosis fadB2 (Rv0468). 
gtgagcgatgcgatccagcgggtaggggttgtcggggccgggcagatggggtccggcatcgccgaggt
ctcggctcgcgccggcgtcgaagtgacggtgttcgagccggccgaggcgttgatcaccgcgggacgca
accgcatcgtgaagtcgctggagcgggccgtcagcgccggcaaggtaaccgagcgcgagcgtgaccgc
gccctcggcctgttgaccttcaccaccgacctcaacgacctatccgataggcaactggtgatcgaggc
cgttgtcgaggacgaggccgtcaagtccgagatcttcgccgagctcgaccgggtcgtcaccgatccgg
acgcggtgctggcgtcgaatacctccagcatcccgatcatgaaggtcgccgcggccaccaagcagccg
caacgggttcttggcctgcatttcttcaatccggtcccggtgctgccgctggtcgagttggtgcgcac
gctggtcaccgacgaagccgccgccgcgcgcacggaggagtttgccagtactgtgctgggcaaacagg
tcgtgcgttgctccgaccgctccggattcgtggtcaatgcgctcctggtgccgtatttgctgtcggcg
attcggatggtcgaggccgggtttgccaccgtcgaagatgtcgacaaggccgttgttgcggggttatc
gcacccgatgggtccgctgcggctttccgatcttgtcggcctagacaccctcaagctgatcgcggaca
agatgttcgaagaattcaaagaaccgcactacgggccccctccgctgttgctgcgtatggttgaggcg
ggccagttgggaaagaaatcgggtcgaggtttctacacgtactga 
 
6.2.1.2. M. smegmatis fadB2 (MSMEG0912). 
gtgagcaatgcaatcgaacgagtaggtgtcgtcggagccggccagatgggcagcggcatcgccgaggt
gtccgcccgcgcgggcgtcgacgtcctggtctacgacaccactgacgccttcgtgacggccgggcgca
accgcatcacgaagtcgctggagcgcgccgtgagcgcgggcaaggtcaccgagcgtgagaaggacgag
gcgctgggccggctgcgcttcaccacgagcctcgccgacatggccgaccgtcagctggtcatcgaggc
cgtgatcgaggacgagaacatcaagggcgagatcttcgccgaactcgaccgcgtgatcaccgaccccg
acgcggtgctggcgtcgaacacgtcgagcatcccgatcatgaagatcgcggcgtccaccgagaacccc
gagcgcgtgctgggcctgcacttcttcaacccggtgcccgtcctgccactcgtcgagttggtgtccac
actcgtcacctccgaggcggcggccgaccgggtcgagcagttcgccggatcggtgctgggcaagcagg
tcgtgcggtgctccgaccggtccggcttcgtggtgaacttcctgctcgtgccgtacctgctctcggca
atccgcatggtcgaaggtggcgtcgccaccatcgaggacgtcgacaaggccgtggtggccgggttgtc
gcacccgatggggccgctgcgcctgtccgatctggtagggctcgacacgctgaagctgatcgccgaca
agatgttcgacgagttcaaggagcccctgtacgcggcgccgccactgctgctgcgcatggtcgaggcc
ggccagctcggcaagaaaacgggcaagggcttctatacctactga 
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6.2.1.3. M. tuberculosis fadB3 (Rv1715). 
atgctgacctcgcacgggttctcccgtgccgccgtcgtgggtgccgggctgatgggccggcgcatcgc
cggcgtgctggcctcggcgggcctggatgtcgccatcaccgacaccaacgctgagattctccacgccg
cagcggtggaggccgcccgggtagccggtgctggccgtggctcggtggccgcggcagccgacctagcc
gcggcgataccagacgccgacctggtgattgaggccgtcgtcgaaaacctggccgtcaagcaggaact
cttcgaacggctggcgacactcgcgcccgacgcggtgctggccaccaacacctcggtgctgccgatcg
gcgctgtcaccgaacgggtcgaggacggcagccgagtgatcgggacacacttttggaaccgccggatc
ttatcccggtggtcgaggtggtgcccagcgcgcgcaccgccccagatacggcggatcgcgtcgtggcg
ctgctgacccaagtcggcaagctgccggtgcgggtcgggcgcacgtgccgggtttcatcggcaaccgg
ctgcagcacgcgctgtggcgcgaggcgatcgcgctggtcgccgagggtgtctgcgacccgaagacggt
agatctcgtggtacgcaacaccattgggctgcgactggccaccttggggccgctggaaaacgccgact
acatcgggttggacctcaccctggccatccacgacgcggtgatcccgagcctcaaccacgacccgcac
cccagcccgctgctgcgggaactggtcgccgccgggcaactcggggcgcgtaccggtcacggctttct
ggactggcccgcaggagcccgcgaggccaccaccgcccgacttgcccagcacatcgccgcgcaactcc
aagccaacgaaaaaggaagggggacatag 
 
6.2.1.4. M. bovis BCG fadB3 (Mb1742–1743). 
atgctgacctcgcacgggttctcccgtgccgccgtcgtgggtgccgggctgatgggccggcgcatcgc
cggcgtgctggcctcggcgggcctggatgtcgccatcaccgacaccaacgctgagattctccacgccg
cagcggtggaggccgcccgggtagccggtgctggccgtggctcggtggccgcggcagccgacctagcc
gcggcgataccagacgccgacctggtgattgaggccgtcgtcgaaaacctggccgtcaagcaggaact
cttcgaacggctggcgacactcgcgcccgacgcggtgctggccaccaacacctcggtgctgccgatcg
gcgctgtcaccgaacgggtcgaggacggcagccgagtgatcgggacacacttttggaacccgccggat
cttatcccggtggtcgaggtggtgcccagcgcgcgcaccgccccagatacggcggatcgcgtcgtggc
gctgctgacccaagtcggcaagctgccggtgcgggtcgggcgcgacgtgccgggtttcatcggcaacc
ggctgcagcacgcgctgtga|gtggtacgcaacaccattgggctgcgactggccaccttggggccgct
ggaaaacgccgactacatcgggttggacctcaccctggccatccacgacgcggtgatcccgagcctca
accacgacccgcaccccagcccgctgctgcgggaactggtcgccgccgggcaactcggggcgcgtacc
ggtcacggctttctggactggcccgcaggagcccgcgaggccaccaccgcccgacttgcccagcacat
cgccgcgcaactccaagccaacgaaaaaggaagggggacatag 
 
6.2.1.5. M. smegmatis fadB3 (MSMEG6791). 
atgcgcaagatcaacaccgtcacagtcgtcggcgccgggtacatgggcggcggcatcgcccaggtgct
ggccctcaacggattcaaggtccagatcgccgacgtcaacgccgaggccacccaggaggcgctcaagc
gcctcgaccgggaggcacgggaattcgagcagcagggcctgttcggccccggcagcgccgacaccatc
atgagcaacctcacggccagcgacagcctggacgacgccgtctccgacgtcgactacgtgatggaggc
cgttttcgaagacgtcgacgtcaagaaggaagtgctggcgcgcgtgtgtgcgagcgctcgccccgaca
cgatcatcggcaccaacacctccaccatcccggtcaaggtgctggtcgacgcggtaacccacccggag
cggttcctcaccgtgcacttctccaacccggcaccgttcatccccggtgtggaactcgtcgcgggcga
ggccacgacccaagaggtgatcgactccgtcaaggacctcctggcacgtgccggacgtgagggcgccc
aggtggccgacaccccgggtatggcgctgaaccgcctgcagtacgcgctgctcaaggaggcgacgctg
atcgtcgaagagggcgtggccaccaaggaggacgtcgacaccatcgtccgcaccacgttcggcttccg
gctcgggttcttcggcccgttcgccatcgccgatcaggccgggctcgacgtgtacgtcaagggctacc
acaccttggagaacgcattcggtgagcgcatggccacccccaagctgctcacggacaacgtcgacgcc
ggccgttacggcaccaagaacggcaagggctggaccggcgacttcgacgacgaaaccaaggctgcggt
catcgcataccgcaacaaggcctactcgcgcatgggcgaactgctgcgcgaactcggaccggccccca
agggcgcctga 
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6.2.1.6. M. tuberculosis fadB4 (Rv3141). 
atgcgcgcggtacgggtgactcggctggagggaccagatgcggtcgaggtggccgaggtcgaggaacc
cacgagcgccggtgtggtcatcgaggtgcacgctgccggcgtggccttcccggacgcactgctaaccc
gtggccgttaccagtaccgcccggagccgccattcgtgctcggcgccgagatcgccggagtggttcga
tcggcgccggataacagccaagtgcgttccggagacagggttgtcggcctcacgatgctcaccggcgg
catggccgaagtcgcggtattgtcgcccgagcgcgtgttcaagctgccggacaacatgactttcgagg
cgggcgcgggcgtgctgttcaacgacctgacggtgtacttcgcgctggcggtccggggccggctgcag
gccggtgagacggtgctggtgcacggggcggcaggcgggatcggcacatcgacgttgcgactagcgcc
ggcgctcggggcgtctcgcaccgtcgcggtggtcagcacgcaggagaaggccgagcttgcgacagtgg
ccggggcgacagatgtggtgttggccgaggggttcaaggacgcggtacaggagctgacgaacggccgt
ggtgtcgacatcgtcgtagacccggtcggcggcgaccggttcaccgattcgctgcgctcgcttgctgc
gggaggacggctgttggtcatcggcttcactggcggcgagattcccaccgtgaaggtaaaccgccttc
tgctcaacaacattgacgttgtcggggtaggctggggcgcctggtcgctgacccaccccgatgcgctg
gcccagcagtggtcacaactcgagcggctgctacgctcgggcaagctgcctcctcccgaaccagtggt
ctacccactggaccaagccgctgcggcgattgcatcgctggagaatcgcaccgccaaggggaaggtcg
tactacgcgtgcgcgactaa 
 
6.2.1.7. M. smegmatis fadB4 (MSMEG2033). 
atgcgcgctgcactgataacccgtctcgacggtcccgacgcggtggaagtggtcgaggtcgacgaacc
gtccggtgatgacgccgtcctgatcgacgtccacgccgcaggcgtggcgtttcccgacgcgctgctga
cgcgaggcctctaccagtacaagccggacctgccgttctcccccggcgccgaggtggccggtgtggtg
cgcagcgcaccggcaggcgcgtcggtcgcggcgggcgatcgtgtgctgggcctgacgatgctgtccgg
cggtatggcggaagtggttgcgctgcccgaggatcgcgtgttcaagctgcccgatgcggtgccgttcg
acgccggggcgggaatcctgttcaacgacatgaccgtgcacttcgtgctgcgcacccgcggcaggcta
tccggcggcgagacggttctggtgcacggcgccgctggcggaatcggttcgtcggtgctgcgcctggc
gcccgctttgggcgcggcccgcaccatcgcggtggtgtccaccgaggagaagggcgagatcgccaggg
ccgcaggcgcatccgatgtggtgctggccgacggtttccgtgacgcggtcaaggagttgaccgacggt
cgcggcgtcgacatggtggtcgaccccgtcggaggtgaccgcttcaccgattcgctgcgctcgctggc
ggtcggcgggcgcctgctggtggtcggcttcaccggcggcgagatcccccaggtgaaggtgaaccggt
tgctgctcaacaacatcgaggtgatcggcgcgggttggggtgcgtggactttcacgcacccgggttat
ctgcaggagcagtgggccgaactggagccgctgctggcctccggcgcggtcgccccgccgcaggtcga
ggtgtatccgttggagcaggccgcgcaggccatcgcgtcactggagaatcgcagcgccaagggcaagg
tggtgctcaaactgcgctga 
 
6.2.1.8. M. tuberculosis fadB5 (Rv1912c). 
atgcgagcagtggtcatcaccaaacatggcgacccatcggtcttgcaggtgcggcagcgaccggaccc
gccgccaccgggcccgggccagctgcgggtcgccgtccgcgcagcaggggtgaacttcgctgaccatc
tcgcccgcgtcggcctgtacccagacgcgccgaaacttccggcggtggtcggatacgaagtcgctggg
acggtcgaggctgtcggtgatggggtcgacccgaaccgggtcggcgaacgagtcctggccggtacacg
atttggtggctactgcgagatcgtcaacgttgcggccaccgactcggttgtgctccccgatgcgctga
gcttcgaacagggtgccgcggtcccggtgaattacgcgaccgcctgggcggcgctgcacggctacgga
tcgttgcgcgccggtgagcgggtgctgattcacgccgcggccggtggagtcggcatcgcggcggtcca
attcgcgaaagcagccaaggccgaagtgcacggcaccgcatcaccccaaaaacatcagaagctggccg
agttcggtgtggaccgcgcgatcgactaccgccgggacggctggtggcagggattgggcccgtatgac
gtcgtgcttgacgcgctcggcggcacctcgctgcggcggtcctacactctgctgcgcccgggtggaag
gctggttggctacgggatttcgaatatgcagcacggcgagaaacgatcgatgcgcagggtggcgcccc
acgcgttgtcaatgctgcgcggctttaacctgatgaaacaactcgaggagtcgaaaaccgtgatcggt
cttaacatgctgcggttgtgggacgatcgccgcacccttgaaccctggatcgcgccgctgaccaaggc
gctcaacgacggaacgatcctgccgatcgttcatgcaatcgtgccgttcgccgaagctcctgaagcac
atcggattctggccgcacgggagaacgtcgacaaggtggtgctggtaccgtga 
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6.2.1.9. M. bovis BCG fadB5 (Mb1947c). 
atgcgagcagtggtcatcaccaaacatggcgacccatcggtcttgcaggtgcggcagcgaccggaccc
gccgccaccgggcccgggccagctgcgggtcgccgtccgcgcagcaggggtgaacttcgctgaccatc
tcgcccgcgtcggcctgtacccagacgcgccgaaacttccggcggtggtcggatacgaagtcgctggg
acggtcgaggctgtcggtgatggggtcgacccgaaccgggtcggcgaacgagtcctggccggtacacg
atttggtggctactgcgagatcgtcaacgttgcggccaccgactcggttgtgctccccgatgcgctga
gcttcgaacagggtgccgcggtcccggtgaattacgcgaccgcctgggcggcgctgcacggctacgga
tcgttgcgcgccggtgagcgggtgctgattcacgccgcggccggtggagtcggcatcgcggcggtcca
attcgcgaaagcagccaaggccgaagtgcacggcaccgcatcaccccaaaaacatcagaagctggccg
agttcggtgtggaccgcgcgatcgactaccgccgggacggctggtggcagggattgggcccgtatgac
gtcgtgcttgacgcgctcggcggcacctcgctgcggcggtcctacactctgctgcgcccgggtggaag
gctggttggctacgggatttcgaatatgcagcacggcgagaaacgatcgatgcgcagggtggcgcccc
acgcgttgtcaatgctgcgcggctttaacctgatgaaacaactcgaggagtcgaaaaccgtgatcggt
cttaacatgctgcggttgtgggacgatcgccgcacccttgaaccctggatcgcgccgctgaccaaggc
gctcaacgacggaacgatcctgccgatcgttcatgcaatcgtgccgttcgccgaagctcctgaagcac
atcggattctggccgcacgggagaacgtcggcaaggtggtgctggtaccgtga 
 
6.2.2. Polymerase chain reaction (PCR). 
6.2.2.1. The general PCR mix. 
Two different DNA polymerases have been employed, VentR® and Phusion® (both New 
England Biolabs). The latter was used the majority of the time because it was found to be 
more successful. Four different conditions have been used throughout this project to optimise 
DNA amplification, which are as follows: 
 
Volume 
Constituent Stock concentration 
1 ! " # 
5' primer 100 pmol/µl 1 µl 1 µl 1 µl 1 µl 
3' primer 100 pmol/µl 1 µl 1 µl 1 µl 1 µl 
gDNA template 10 ng/µl 1 µl 1 µl 1 µl 1 µl 
dNTP 25 mM 2 µl 2 µl 2 µl 2 µl 
10! buffer  10 µl 10 µl 10 µl 10 µl 
DNA polymerase  1 µl 1 µl 1 µl 1 µl 
MgSO4 100 mM 0 µl 1 µl 0 µl 1 µl 
DMSO 100 % 0 µl 0 µl 8 µl 8 µl 
H2O  84 µl 83 µl 76 µl 75 µl 
Total  100 µl 
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6.2.2.2. PCR reaction steps. 
A variety of conditions have been tested throughout this project to optimise PCR yield and 
reduce mis-priming. The following two-step PCR procedure (with no annealing step) has 
been the most successful and has therefore been used most routinely: 
 
Temperature (°C) Time 
98 30 s 
98 10 s 
60.9 – 75.6 90 s 
72 10 min 
4 !"
 
6.2.3. DNA electrophoresis and purification. 
In order to separate DNA fragments according to size, electrophoresis is employed. The 
DNA samples with added loading dye (New England Biolabs) are pipetted into wells in an 
agarose gel (Bioline). An electric field is applied that causes the negatively-charged DNA to 
migrate towards the positive anode. The viscous medium of the agarose provides resistance 
for the DNA of varying degrees depending on the concentration. Generally, 1 % agarose gels 
have been used in this project, except when analysing larger fragments of DNA such as 
cosmids, when 0.8 % gels are used. The agarose is dissolved in TAE buffer (Sambrook & 
Russell 2001) by heating until boiling and is left to set in a gel cast. Once solid, the gel is 
completely submerged in TAE buffer within a HE33 Mini Submarine gel tank (Hoefer) and 
the DNA is loaded. The tank is connected to a power pack and the gel is run at 120–140 V, 
400 mA for 40–50 min. At the end of the run, the gel is immersed for 10–20 min in ethidium 
bromide, a fluorescent tag that intercalates with double-stranded DNA. The DNA bands can 
then be analysed under a UV light. 
 
 
! 35 cycles 
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Individual bands can be excised from the gel and purified using the QIAquick Gel Extraction 
Kit (Qiagen). Essentially, the gel is dissolved and the DNA is released. The dissolved gel is 
applied to a spin column with a silica membrane to which the DNA binds. Impurities are 
removed during the washing stages and the DNA is eluted with dH2O or EB buffer (10 mM 
Tris"HCl, pH 8.5). 
 
6.2.4. DNA digestion. 
In order to sub-clone PCR products or plasmid DNA into vectors or to check the orientation 
of sub-cloned DNA, the DNA must be digested and analysed by agarose gel electrophoresis. 
Usually, a double digest is required, where a 20 µl cocktail is made containing 1 µl of each 
restriction enzyme, 2 µl of digest buffer suitable for both enzymes, 10 µl DNA and 6 µl 
dH2O. The mix is incubated at 37 °C for 2 h, although this is enzyme-dependent; Van91i 
FastDigest enzyme only requires a 5 min incubation at 37 °C. For some restriction enzymes, 
when performing a double digest, a sequential digest is needed. 
 
6.2.5. DNA ligation. 
Sub-cloning requires DNA fragments to be ligated into plasmids that have been digested by 
the same enzymes. The 20 µl ligation cocktail consists of 1µl T4 ligase (New England 
Biolabs), 2 µl ligase buffer, 1 µl plasmid DNA, 10 µl fragment DNA that is to be inserted 
into the plasmid and 6 µl dH2O. T4 ligase requires an incubation of 16 h at 16 °C. Generally 
1! DNA loading dye: 
•  2.5 % Ficoll 400 
•  11 mM EDTA 
•  3.3 mM Tris!HCl 
•  0.017 % SDS 
•  0.015 % Bromophenol Blue 
•  pH 8.0 at 25 °C 
1! TAE buffer: 
•  40 mM Tris!acetate 
•  1 mM EDTA 
•  pH 8.0 at 25 °C 
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the number of plasmids containing the insert will be quite low, so E. coli cells are employed 
to make large numbers of plasmid. For this, the plasmid first has to be transformed into 
competent cells. 
 
6.2.6. Preparation of competent cells for heat-shock transformation. 
A glycerol stock of heat-shock competent E. coli cells is thawed on ice and 10 µl used to 
inoculate 5 ml LB broth. The culture is incubated with shaking at 37 °C overnight. Of this 
mini-culture, 500 µl is then used to inoculate 50 ml LB broth, which is incubated with 
shaking at 37 °C until the OD600 reaches 0.4–0.6. The culture is then centrifuged at 3,000 ! g 
for 10 min at 4 °C and, having removed the supernatant, the resulting pellet is resuspended in 
10 ml ice-cold CaCl2 and left at 4 °C for 20 min. The cells are centrifuged again at 3,000 ! g 
for 10 min at 4 °C, the supernatant is discarded and the pellet is resuspended in 2.5 ml ice-
cold CaCl2 + 15 % glycerol. The cells are then aliquotted and flash frozen using liquid 
nitrogen before storing immediately at -80 °C. 
 
Heat shock transformation: Cells (50 µl) are thawed on ice, 1 µl of plasmid DNA is added, 
gently mixed and kept at 4 °C for 30 min. The tube is then submerged in a water bath at 42 
°C for 45 sec with gentle agitation to equally distribute the heat. After this time, the tube is 
immediately put back on ice for 2 min before 200 µl LB broth is added. The cells are then 
incubated for 1 h at 37 °C without shaking (recovery time) and plated onto LB agar 
supplemented with selective antibiotic(s) as required. 
 
6.2.7. Preparation of competent cells for electroporation. 
A 5 ml culture of wild-type cells (M. smegmatis or M. bovis BCG) is grown from a glycerol 
stock in 7H9 broth (supplemented with BBL™ Middlebrook ADC for M. bovis) until the 
OD600 has reached 0.6–0.7. The culture is centrifuged at 3,000 ! g for 10 min at 4 °C and the 
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supernatant is discarded. The cells are washed three times with 5 ml ice-cold 10 % glycerol, 
centrifuging and removing the supernatant between each wash. Finally, the cells are 
resuspended in 5 ml ice-cold 10 % glycerol and aseptically pipetted into 100 µl aliquots 
before flash freezing. 
 
Electroporation: Cells (100 µl) are thawed on ice, 5 µl plasmid DNA is added to the cells, 
gently mixed and kept on ice for 10 min. The mix is then transferred to an electroporation 
cuvette (1 mm gap) and electroporated at 1,800 V, 1000 #, 25 µF in an Eppendorf 
electroporator 2510. 7H9 media (1 ml) is added to the cells and they are incubated at 37 °C 
static for 6 h (M. smegmatis) or 12 h (M. bovis) to recover. Following this time, the cells are 
spread onto 7H9 agar plates containing the appropriate selective antibiotic(s). Plates are 
incubated at 37 °C for 4–5 days (M. smegmatis) or 3–4 weeks (M. bovis), or until colonies 
are visible. 
 
6.2.8. Plasmid extraction 
To check that the fragment of DNA has been correctly inserted into the vector, the plasmid 
DNA needs to be purified away from the cell. This is done using a mini-prep kit (Qiagen). 
Colonies of transformed E. coli are used to inoculate 5 ml LB broth containing selective 
antibiotic and incubated overnight at 37 °C with shaking. The next day, the mini-cultures are 
centrifuged at 3,500 ! g for 10 min to form a pellet. The cells are resuspended in 250 µl P1 
buffer and transferred to a 1.5 ml eppendorf. P2 buffer (250 µl) is then added and mixed by 
inversion, immediately followed by the addition and mixing of 300 µl N3 buffer. The P2 
buffer lyses the cells releasing the contents and the N3 buffer differentiates between the 
plasmid and genomic DNA. The insoluble components are pelleted by centrifugation (13,000 
! g, 15 min) and the supernatant containing the DNA is applied to a QIAprep spin column. 
The column has a membrane onto which the plasmid DNA binds. The DNA is first washed 
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using 500 µl PB and 750 µl ethanol-containing PE buffer before eluting the DNA with 50 µl 
dH2O or, for larger plasmids and cosmids, warm EB buffer. 
 
6.2.9. Site-directed mutagenesis. 
The Stratagene QuikChange® Multi Site-Directed Mutagenesis Kit has been used in this 
project to introduce mutations into genes of interest. The protocol is outlined below: 
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6.2.10. Genomic DNA extraction. 
Genomic DNA (gDNA) in this project has been extracted from whole cells in order to (i) use 
it as a template for PCR and cloning procedures in the case of WT species and (ii) in order to 
check if desired mutations have been made following specialised transduction. A 10 ml 
culture of the mycobacterium of interest is grown in 7H9 plus 0.05 % Tween®-80, plus any 
selective antibiotic, by incubation at 37 °C for 24 h with shaking (M. smegmatis) or 7–14 
days static (M. bovis BCG). The cells are pelleted by centrifugation at 3,000 ! g for 15 min 
and the supernatant is discarded. The pellet is washed with 500 µl PBS, transferred to a clean 
eppendorf and centrifuged again. The pellet is resuspended in 225 µl P1 buffer and 25 µl 
lysozyme (10 mg/ml) is added, mixed gently and incubated at 37 °C overnight. The next day, 
50 µl SDS (10 %) and 25 µl proteinase K (10 mg/ml) are added, mixed gently and incubated 
at 55 °C for $ 6 h. One hundred µl NaCl (5 M) is then added to block binding of DNA to 
cetrimide. Then 500 µl chloroform is added, mixed by gentle inversion and centrifuged at 
13,000 ! g for 15 min. The top (aqueous) layer is aspirated into a clean tube making sure 
none of the interface debris is removed. To this supernatant, 280 µl isopropanol is added and 
mixed by inversion until the DNA can be seen to precipitate out of solution. After incubation 
at room temperature for 5 min, the tube is centrifuged to harvest the DNA. The supernatant is 
removed and the DNA pellet is washed with 70 % ethanol (500 µl). Following further 
centrifugation, the supernatant is again removed. The ethanol is allowed to evaporate before 
covering the DNA with 25 µl EB buffer. The pellet dissolves in the buffer overnight at 4 °C. 
 
6.2.11. Southern blotting. 
This technique, summarised in Figure 6-1, is used to identify fragments of DNA and, in the 
case of this project, to confirm gene knock-out mutants and is performed as per the kit 
manual (Roche Applied Science). The extracted gDNA of the wild-type bacteria and the 
mutant is first cut using a restriction enzyme that will produce different sized fragments in 
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both strains. Gel electrophoresis is used to separate the fragments, which will produce a 
ladder pattern (Figure 6-1 A). The gel is submerged in 0.25 N HCl to depurinate the DNA – 
this breaks it into smaller fragments allowing for better transfer later (Figure 6-1 B). The gel 
is then covered with a solution that denatures the double-stranded DNA – this will aid 
binding of the negative DNA to the positive membrane (Figure 6-1 C). The gel is returned to 
pH 7.4 before transferring the DNA to a positively charged nitrocellulose membrane by 
capillary action (Figure 6-1 D). Once complete, the DNA is covalently bound to the 
membrane by UV radiation. The hybridisation probe is a single DNA fragment with a 
specific sequence whose presence in the target DNA is to be determined. This can be the 
PCR fragments used to knock the gene out in the specialised transduction protocol. The 
probe is prepared by boiling, snap freezing and labelling with digoxigenin-dUTP (Figure 6-1 
E). The membrane is exposed to the probe overnight at 65 °C. The next day the membrane is 
washed and the antibody is incubated with the membrane for 30 min at 25 °C (Figure 6-1 F). 
The antibody binds to the digoxigenin-dUTP on the probe and is conjugated to alkaline 
phosphatase. CSPD is then applied to the membrane (1 ml). The alkaline phosphatase on the 
antibody dephosphorylates the CSPD, which is a chemiluminescence reaction (Figure 6-1 G). 
The light emitted is visualised by exposing the membrane to film. 
 
6.2.12. Specialised transduction. 
Specialised transduction is a process used to create gene knock-out mutants in mycobacteria, 
first introduced by Bardarov et al. in 2002. Broadly, transduction is the transfer of genetic 
material from one bacterial cell to another via a viral vector. Specialised transduction is a 
result of the virus making a mistake when removing itself from the bacterial chromosome, 
i.e. when transitioning from the lysogenic to the lytic cycle. A small portion of bacterial 
DNA from either end of the viral DNA is mistakenly packaged into the capsid and injected 
into the next cell. There are several possible consequences of this, including recycling of the 
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DNA or insertion into the chromosome resulting in gene duplication. The outcome harnessed 
in genetic engineering, however, is homologous recombination. Regions shared by the 
transferred bacterial DNA and the host chromosome match up and the viral genetic material 
between the bacterial portions is exchanged. In essence, the gene of interest in replaced in the 
genome with a hygromycin-resistance cassette by homologous recombination. The 
transduced cells are then plated on hygromycin selective media to screen for mutant colonies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-1. Southern blot procedure. (A) The gDNA is digested and fragments separated 
by gel electrophoresis, (B) DNA depurination, (C) DNA denaturation and neutralisation, 
(D) The DNA is transferred to a nitrocellulose membrane by capillary action and covalently 
bound by UV radiation, (E) The probe is labelled with DIG-dUTP and is hybridised with 
the membrane (F). (G) Immunodetection – the alkaline phosphatase conjugated to the anti-
DIG-dUTP antibody catalyses the CSPD chemiluminescent reaction. 
 
Methods used prior to Bardarov et al. (2002) used electroporation to deliver the hygromycin-
resistant gene or allelic exchange substrate (AES). However, this was found to be inefficient 
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in slow-growing mycobacteria largely due to erroneous recombination events and the high 
tendency for cells to clump together, making it difficult to isolate successful transductants. A 
protocol was developed that employs mycobacteriophages to transfer the AES rather than 
electroporation (Figure 6-2).  
 
1. AES and cosmid construction: 
Fragments of DNA, roughly 800–900 bp in length, upstream (to the left) and downstream (to 
the right) of the gene of interest are first amplified by PCR. The primers used also include a 
restriction site for specific endonucleases, such as DraIII, AlwNI or BstAPI. It is these 
fragments that will match up with the mycobacterial chromosome to allow homologous 
recombination to occur. The DNA products are then cloned into the p0004S plasmid, which 
contains a PacI restriction site, a hygromycin resistance cassette and %& resolvase recognition 
sites, regions that are capable of mediating site-specific recombination. The complete vector 
is transformed into E. coli Top10 cells and selected for by plating on hygromycin (150 
µg/ml) agar. Following mini-prep, the plasmid is sequenced to check for errors. The p0004S 
vector is then linearised by PacI digestion. The phage DNA, phAE159, is cut similarly with 
PacI to remove the '-lactamase gene and provide a site in which to clone in the p0004S 
vector. Fragments are ligated using T4 ligase. The complete phAE159-p0004S phasmid is 
then packaged into phage particles, which are used to transfect E. coli HB101 cells. These 
cells are used because they have high transformation efficiency. Transfected cells are plated 
onto selective medium (150 µg/ml hygromycin) and transductant colonies are picked after 
overnight incubation and mini-prepped. A small sample is cut with PacI and run on a 0.7 % 
agarose gel. The inserted p0004S DNA should appear on the gel as a drop-out band from the 
large phage plasmid. 
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2. Propagation of phage particles 
The phasmid is electroporated into M. smegmatis mc2155 cells regardless of the species in 
which the knock-out is being made. TSB media (1 ml, devoid of Tween®-80) is added and 
the cells are incubated at 30 °C for 6 h. The phage particles are temperature-sensitive and are 
unable to replicate at 37 °C. The electroporated cells are mixed with wild-type M. smegmatis 
mc2155 and overlaid on 7H9 plates containing no Tween®-80 or antibiotic. Plates are 
incubated at 30 °C for 2–3 days. After this time phage plaques should be visible on the lawn 
of M. smegmatis cells, forming a lacy pattern. Sterile MP buffer (4 ml) is applied to the 
surface of the bacterial lawn and the plates are left at room temperature for 4–6 h to soak up 
the phage particles. The MP buffer is then pooled and filtered (0.2 µm) to remove any M. 
smegmatis cells. The concentration of phage particles is assessed by serially diluting the 
pooled buffer and spotting 10 µl on 7H9 plates (devoid of antibiotic) overlaid with wild-type 
M. smegmatis. Phage plaques at each dilution are totalled and the titre is calculated. A titre of 
~1010 particles is required for transduction. 
 
3. Transduction 
Wild-type cells in which the knock-out is being made (M. smegmatis, M. bovis BCG, M. 
marinum) are cultured to an OD600 of 0.8–1.0 in appropriate medium containing 0.05 % 
Tween®-80. The cells are then pelleted and washed with sterile MP buffer to remove the 
Tween®-80, as the surfactant can impede transduction. The cells are resuspended in MP 
buffer to give a concentration of 109 cells per ml. Roughly 108 phages are added to the cells 
and gently mixed. The transduction mixture is incubated at 37 °C overnight. The next day the 
cells are pelleted, resuspended in 2 ml fresh medium and the mixture is left to recover at 37 
°C for 6 h. Following this, the cells are resuspended again in fresh medium and plated on 
selective agar, 100 µg/ml hygromycin for M. smegmatis or 75 µg/ml hygromycin for M. 
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bovis BCG. Transductants should appear after 6–7 days for M. smegmatis or 3–4 weeks for 
M. bovis BCG. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-2. Specialised transduction. See text above (section 6.2.12.) for full 
description. 
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6.2.13. Bacterial strains. 
6.2.13.1. E. coli strains used for plasmid propagation. 
The following E. coli strains have been used to increase plasmid copy number. The strains 
have been developed to have very high transformation efficiency. 
 
Top10 
Source: Invitrogen 
Genotype: F– mcrA ((mrr-hsdRMS-mcrBC) )80lacZ(M15 (lacX74 nupG recA1 araD139 
((ara-leu)7697 galE15 galK16 rpsL(StrR) endA1 *– 
Characteristics: Has high transformation efficiency and allows the stable replication of high 
copy number plasmids. Deletion of hsdR and mrcA allow the transformation of both 
methylated and unmethylated DNA and (endA1 abolishes non-specific digestion of DNA by 
endonuclease I. 
 
HB101 
Source: Invitrogen 
Genotype: F– mcrB mrr hsdS20 (rB–, mB–) recA13 supE44 ara14 galK2 lacY1 proA2 
rpsL20(Smr) xy15 *– leu mtl1. 
Characteristics: Hybrid of E. coli K12 and E. coli B strains. Has very high transformation 
efficiency. The (recA phenotype helps to minimise recombination events. 
 
XL-10 Gold 
Source: Stratagene 
Genotype: endA1 glnV44 recA1 thi-1 gyrA96 relA1 lac The ((mcrA)183 ((mcrCB-hsdSMR-
mrr)173 tetR F+[proAB lacIqZ(M15 Tn10(TetR Amy CmR)] 
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Characteristics: (Hte phenotype allows cells to accept large or ligated plasmids much better. 
It dramatically increases transformation efficiency and cells grow faster producing larger 
colonies. 
 
6.2.13.2. E. coli strains used for protein over-expression. 
These E. coli strains differ from those above by having the IPTG inducible T7 RNA 
polymerase. This polymerase, from the T7 bacteriophage, synthesises RNA in the 5+!3+ 
direction in the presence of a DNA template, Mg2+ ions and, very specifically, the upstream 
T7 promoter. T7 promoter-driven expression is repressed until IPTG addition. This molecule 
acts as a mimic for lactose, which binds to the repressor inactivating it and initiating lac 
operon transcription. There are three genes in the lac operon, lacZ, lacY and lacA, which 
encode '-galactosidase, '-galactoside permease and '-galactoside transacetylase 
respectively. In protein over-expression systems, it is the lacZ gene that is replaced by the 
gene of interest. 
 
BL21 (DE3) 
Genotype: F– ompT gal dcm lon hsdSB(rB– mB–) *(DE3 [lacI lacUV5-T7 gene 1 ind1 sam7 
nin5]) 
Characteristics: E. coli B strain containing the lambda prophage DE3, which harbours a 
single copy of the T7 RNA polymerase gene under the control of the lacUV5 promoter. 
lacUV5 is a mutated lac operon that is less sensitive to cyclic AMP, a molecule known to 
derepress the lac promoter. Addition of 1 % glucose to the culture medium also reduces 
‘leaky’ expression by increasing repression at the promoter. In combination with the pET 
vector system as well, which also has a T7/ lac promoter, basal expression is minimal and 
target protein expression is greatly improved. BL21 cells are also protease deficient (lon–, 
ompT–), improving protein yield further. 
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C41 (DE3) 
Genotype: F– ompT gal dcm hsdSB(rB- mB-)(DE3) 
Characteristics: Derived from BL21, C41 cells have at least one mutation such that over-
expression of toxic proteins is tolerated and the cells remain viable. C41 are also used for 
over-expressing membrane proteins. Both transformation efficiency and protein expression 
are better than in BL21. 
 
C43 (DE3) 
Genotype: F– ompT gal dcm hsdSB(rB- mB-)(DE3) 
Characteristics: Derived from C41 cells, C43 cells are mutated so that a different set of toxic 
proteins from C41 can be expressed. 
 
Tuner™ 
Genotype: F– ompT hsdSB (rB– mB–) gal dcm lacY1(DE3) 
Characteristics: Also derived from BL21, Tuner™ cells are deficient in the lacY gene. This 
allows the level of expression to be regulated by altering IPTG concentration. The (lacY 
phenotype also provides uniform levels of target gene induction through consistent entry of 
IPTG into all cells. 
 
6.2.13.3. Mycobacterial strains. 
M. smegmatis mc2155 
M. smegmatis mc2155 is a mutant of M. smegmatis originally isolated in 1990 (Snapper et al. 
1990). Unlike the parental strain, mc2155 has very high electroporation transformation 
efficiency. The genome was sequenced by the J. Craig Venter Institute in 2004 and was 
found to have one circular chromosome of 6.98 Mb and high G+C content (67.4 %). 
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M. bovis BCG str. Pasteur 1173P2 
The avirulent BCG (Bacille Calmette-Guérin) strain was originally derived from M. bovis by 
serial passage on glycerol-ox bile-saturated potato slices from 1908 to 1921. The source of 
attenuation is due to the loss of the RD1 locus (Belley et al. 2004, Keller et al. 2008), a 9.5 
kb region found to regulate numerous loci (Mahairas et al. 1996). The Pasteur strain 1173P2 
was passaged a further 1,173 times at the Pasteur Institute in Paris (ExPasy HAMAP) and 
was sequenced by the Pasteur Institute in 2009. The genome is 4.37 Mb and also has a high 
G+C content (65.6 %). 
 
M. tuberculosis CDC1551 
Sequenced by the J. Craig Venter Institute in 2000, the CDC1551 strain was first identified in 
1995 in the USA (Manca et al. 1999). The strain had a very high transmission rate but a 
subsequent study showed that it is no more virulent than other M. tuberculosis strains but 
does induce a greater host response. Like all mycobacteria, CDC1551 has a high G+C 
content of 65.6 % and is 4.40 Mb. 
 
6.2.14. CellTiter-Blue® cell viability assay. 
The CellTiter-Blue® (Promega) assay kit has been used in this project for testing the efficacy 
of compounds against whole cell M. smegmatis and M. bovis BCG. The method was first 
used with mycobacteria by Franzblau et al. in 1998. The reagent contains resazurin, a 
compound that is reduced to resorufin in the mitochondria of viable cells. Resorufin is bright 
pink in colour and, unlike resazurin, is highly fluorescent (Figure 6-3). 
 
Cells are grown to an OD600 of 0.4 before being diluted 1:25 with fresh medium. The culture 
is aliquotted into a 96-well plate and the inhibitor is added at the desired concentration(s). 
The plate is sealed with parafilm to reduce evaporation and incubated at 37 °C without 
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shaking for 24 h. A 1:1 mixture of CellTiter-Blue® and Tween-80 (0.05 %) is made and 50 
µl is added to a control well containing culture with no drug. The plate is re-sealed and 
incubated at 37 °C until the well has turned pink indicating live metabolising cells. At this 
point, the same mixture of CellTiter-Blue® is added to the remaining wells and incubated 
similarly for a further 6–8 h. The fluorescence is then measured using a plate reader at 
560Ex /590Em. Because only the resorufin fluoresces, a high value indicates live cells and a 
low reading indicates non-viable cells. 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-3. The principal of CellTiter-Blue® for cell viability testing. See text above 
(section 6.2.14.) for full description. 
 
6.3. Protein biochemistry protocols 
6.3.1. SDS-PAGE. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis is used to separate proteins 
according to their molecular weight. Samples are initially diluted 1:1 with 2! Laemmli 
loading buffer and boiled for 10 min to denature the protein (leaving only the primary 
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structure) and to give all the proteins a negative charge (Figure 6-4). The gel consists of two 
parts, the lower resolving gel and the upper stacking gel in the approximate ratio 5:1: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Tetramethylethylenediamine, †ammonium persulfate: added to the mixture just before pouring into 
the gel cast. All volumes are sufficient for two gels. 
 
The gels are assembled in a SE200 Mighty Small vertical slab gel electrophoresis unit 
(Hoefer) and submerged in running buffer. The tank is connected to a power pack and the 
gels are run at 300 V, 20 mA per gel for 45 min to 1 h. 
2! Laemmli loading buffer: 
•  0.125 M Tris!HCl (pH 6.8) 
•  20 % Glycerol 
•  4 % SDS 
•  10 % !-mercaptoethanol 
Laemmli running buffer: 
•  3.03 % Tris 
•  1.44 % Glycine 
•  0.1 % SDS 
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When the run has finished, the gels are stained by immersion for 15–30 min in Coomassie 
Brilliant Blue, a dye that binds to arginine, histidine and aromatic residues of the proteins on 
the gel. To remove all the non-specific binding, the gel is gently washed with dH2O and 
immersed in destain solution until protein bands can be clearly seen. 
 
 
 
 
 
 
FIGURE 6-4. The effect of SDS and heating on proteins. 
 
6.3.2. Western blotting 
This technique, summarised in Figure 6-5, allows for the identification of His-tagged 
proteins. The protein sample is initially run on a SDS-PAGE gel of the appropriate 
acrylamide concentration. The proteins are then transferred electrophoretically onto a 
nitrocellulose membrane in a Transblot tank (Bio-Rad), submerged in transfer buffer. The 
tank is connected to a power pack and run at 10 V, 300 mA for 1 h. The membrane is 
removed to blocking buffer for 30 min to help prevent any non-specific binding before the 
mouse monoclonal Penta-His antibody (Qiagen), diluted 1:1,000 with 50 ml BSA-TBS-T 
buffer, is added for a further 30 min. The membrane is then washed with TBS-T buffer 
before adding the anti-mouse antibody. The membrane is washed again with TBS-T then 
TBS buffer before finally being immersed in BCIP reagent. This chemical reacts with the 
alkaline phosphatase on the anti-mouse antibody to produce an insoluble blue-black 
precipitate. 
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FIGURE 6-5. Western blot procedure. (A) The proteins are loaded and separated on an 
SDS-PAGE gel, (B) the proteins are transferred to a nitrocellulose membrane 
electrophoretically, (C) the membrane is covered with blocking buffer before the Penta-His 
antibody is added (D). (E) The membrane is washed before covering with anti-mouse 
antibody (F). (G) The membrane is washed again before immunodetection, where the 
alkaline phosphatase conjugated to the anti-mouse antibody catalyses the BCIP 
chemiluminescent reaction. 
 
1. Transfer buffer (2 l): 
•  6.06 g Tris 
•  28.8 g Glycine 
•  200 ml Methanol 
5. TBS buffer: 
•  20 mM Tris!HCl 
•  150 mM NaCl 
4. TBS-T buffer: 
•  TBS + 0.05 % Tween®-20 
3. BSA-TBS-T buffer: 
•  TBS-T + 0.1 % (w/v) BSA powder 
2. Blocking buffer: 
•  TBS-T + 5 % (w/v) BSA powder 
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6.3.3. Isomorphous replacement of methionine residues with seleno-methionine. 
The pET28b-Mt-fadB2 plasmid was transformed into E. coli Tuner™ cells and incubated on 
LB agar containing 25 µg/ml kanamycin overnight at 37 °C. One colony was used to 
inoculate LB broth (5 ml) containing kanamycin (25 µg/ml) and cultures were incubated on a 
rotary incubator at 37 °C overnight. This mini-culture was used to inoculate 1 l LB broth 
containing kanamycin (25 µg/ml) and incubated on a rotary incubator (180 rpm) at 37 °C 
until the OD600 had reached 0.4. At this point, the cells were pelleted by centrifugation at 
4,500 ! g for 12 min. The supernatant was removed and the cells were resuspended in 
minimal medium (see section 6.1.7.3.) before further centrifugation to wash the cells. The 
cells were resuspended in the same minimal medium (1 l) plus kanamycin (25 µg/ml). Cell 
growth was then continued at 37 °C with shaking until an OD600 of 0.5 where upon the 
following amino acids were added: lysine, phenylalanine and threonine (0.1 mg/ml), 
isoleucine, leucine and valine (0.05 mg/ml) and L-selenomethionine (0.06 mg/ml). Growth 
was continued for a further hour at 37 °C before lowering the incubation temperature to 20 
°C. At this point protein over-production was induced with 0.5 mM IPTG and the cells were 
incubated at 20 °C with shaking overnight until the OD600 had reached ~2.0. Cells were 
harvested and the protein was purified and dialysed as per the wild-type Mt-FadB2 protein 
(see section 4.2.5.). 
 
MALDI-TOF mass spectrometry was used to identify the number of methionine residues 
replaced. The protein was prepared for this analysis using a ZipTipC18™ (Millipore™), 
equilibrated firstly with 50 % acetonitrile and then 1 % acetic acid. The protein (10 µl, 1.0 
mg/ml) was aspirated and dispensed 10! allowing it to bind to the chromatography medium 
inside the tip. The protein is eluted with 50 % acetonitrile /1 % acetic acid (10 µl). 
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6.4. Biophysical techniques 
6.4.1. Circular dichroism. 
Circular dichroism (CD) is a means of investigating the secondary structure of proteins. The 
principal behind the technique is based on the difference in absorption of left and right 
circularly polarised light of the ultra-violet range. Proteins are chiral molecules, meaning that 
they do not have superimposable mirror images. It is because of this chirality that the protein 
interacts differently with left and right circularly polarised light. Whereas photons of linearly 
polarised light oscillate in the same plane, circularly polarised light beams trace out a helix 
(Figure 6-6). 
 
 
 
 
 
 
 
 
 
FIGURE 6-6. The principal of circular dichroism. (A) Right circularly polarised light 
traces out a vector field in an anti-clockwise circle (B). The magnetic field, B, is 
perpendicular to the electric field so that k, E and B form the right-handed system. Adapted 
from Rodger & Nordén (1997). 
 
There are several advantages of using CD as a structural probe, including the quickness and 
simplicity of performing the experiment, the relatively low concentration of sample protein 
required and the fact that any size molecule can be studied, unlike NMR and crystallography, 
which can only provide detailed information for smaller proteins. The UV light is divided 
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into two groups: ‘near’ UV is the 250–300 nm region, where the aromatic residues 
(phenylalanine, tryptophan, tyrosine) and cysteine-cysteine disulfide bonds absorb. The 
amide backbones of proteins absorb in the ‘far’ UV region (~190–250 nm). Standard spectra 
have been identified for the "-helix, '-sheet, '-turn and random coil conformations (Figure 
6-7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-7. The standard CD spectra identifying the different secondary 
conformations of proteins observable. Adapted from Rodger & Nordén (1997). 
 
6.4.2. Analytical ultracentrifugation. 
Analytical ultracentrifugation (AUC) is a technique that can reveal several pieces of 
information about a solubilised protein, including size and shape, oligomerisation and 
protein-protein interactions (Balbo et al. 2009). The basic principle is that a protein sample is 
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monitored digitally as it is spun using ultra-violet light absorption and/or interference optical 
scanning. Sedimentation velocity (SV) and sedimentation equilibrium (SE) experiments are 
both widely performed with an AUC machine, however only the former was used in this 
project. SV is a time-course experiment that monitors the protein sample as it sediments. 
Results can disclose the shape and molecular mass of the sample as well as the non-covalent 
complexes that proteins form. SE cannot report on molecular shape but can provide molar 
mass and information on chemical equilibrium constants for reacting samples. 
 
The protein sample needs to be around 99 % pure, however relatively low sample 
concentrations (0.1–5 mg/ml) and volumes (~500 µl) are required. The sample is loaded into 
a cell alongside a reference cell containing the buffer in which the protein is dissolved 
(Figure 6-8 A). When a strong centrifugal force is applied a moving boundary is formed. The 
distance moved by the boundary is recorded as a function of time (Figure 6-8 B). Computer 
data analysis programs, such as SEDFIT, are used to interpret the data obtained. For this 
project the analyses were kindly performed by Dr. T. Dafforn (University of Birmingham). 
 
6.4.3. Crystallography. 
6.4.3.1. Protein crystallisation. 
In specific conditions, proteins can be forced to crystallise, whereby the purified protein 
slowly precipitates out from an aqueous buffered solution whilst not becoming denatured. 
During the process, individual protein molecules form a crystalline lattice by aligning in 
repeating unit cells, held together by non-covalent bonds. The objective behind crystallisation 
is to produce adequate crystals for X-ray diffraction, so that the tertiary structure of the 
protein can be obtained. 
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FIGURE 6-8. Analytical ultracentrifugation. (A) Sedimentation velocity cell. The sample 
is loaded into the top and the reference buffer into the bottom section. When centrifuged, 
the centrifugal force pushes the boundary towards the bottom of the cell. (B) Example of 
sedimentation velocity data. Ten scans are shown, t1 being the first, t10 being the last. A 
larger volume of reference buffer is added than sample so the meniscuses can be 
distinguished. Adapted from Cole & Hansen (2000). 
 
The most common method of crystallisation is to dissolve the protein (of at least 97 % purity) 
in a buffer solution that contains a precipitant, such as ammonium sulfate or polyethylene 
glycol (PEG). Over a period of time the water is removed, increasing both the protein and 
precipitant concentrations until crystals start to grow (Figure 6-9 A). One of the most 
common methods of crystallisation is vapour diffusion. Here, the protein/precipitant solution 
equilibrates with the reservoir solution, a larger volume containing an optimal precipitant 
concentration for crystallisation. Two examples of this method, both of which have been used 
in this project, are hanging-drop and sitting-drop vapour diffusion (Figure 6-9 B). With the 
hanging-drop system, the protein/precipitant droplet is suspended on the underside of a 
siliconised cover slip, which is then sealed to the top of the well containing the reservoir 
solution with air-tight vacuum grease. In the sitting-drop vapour diffusion technique, the 
droplet is pipetted directly onto a small plinth within or to the side of the reservoir well. The 
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wells are then covered with air-tight sealing tape. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 6-9. Conditions promoting protein crystallisation. (A) Phase diagram for protein 
crystallisation. (B) Hanging-drop vapour diffusion (top) and sitting-drop vapour diffusion 
(bottom). Adapted from Rhodes (2006). 
 
The first stage of crystallisation is ‘nucleation’, where protein aggregates start to form. If this 
stage continues it is likely that many small crystals are made in a relatively short space of 
time, using up the source of soluble protein before large crystals form. The second stage is 
‘growth’, which should result in crystals large enough to diffract. It is possible to ‘streak 
seed’ small but good quality crystals into new droplets by stroking the crystals with a hair 
and passing the hair through the new droplet. This is a faster way of obtaining crystals and it 
is more likely that more soluble protein makes up fewer bigger crystals (Rhodes 2006). 
 
Before diffraction, the crystals are individually mounted in tiny loops (<1 mm diameter). 
Collecting X-ray data at very low temperatures is thought to improve diffraction by 
increasing molecular order, a process known as ‘cryocrystallisation’. However, to protect the 
crystals from the intense cold of flash freezing in liquid nitrogen (–196 °C) and to prevent the 
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formation of ice crystals, which can interfere with the diffraction pattern, a cryoprotectant 
needs to first be applied. Within the original droplet the crystals are soaked in the 
cryoprotectant solution. This is the same as the precipitant solution but containing a 
concentration of glycerol, xylitol, glucose or PEG. The crystal is then scooped up in the loop, 
where it remains suspended in the cryoprotectant solution. The loop is dipped into liquid 
nitrogen and is kept at this low temperature until loaded onto the X-ray diffractor. 
 
6.4.3.2. X-ray diffraction. 
The principal behind X-ray diffraction is detecting the X-rays that have scattered after hitting 
the protein crystal. By then analysing the position of dots and their intensities formed by the 
scattered rays, a three-dimensional structure of the protein can be constructed. The crystal is 
mounted under a continuous stream of nitrogen gas (-100 °C) between the source of X-rays 
producing a narrow beam of rays and the detector (Figure 6-10). The detector could be an X-
ray film, however in this project an optical scanner linked to a computer was used. All the 
analysis work for this project was kindly performed by Dr. K. Fütterer (University of 
Birmingham). 
 
 
 
 
 
 
 
FIGURE 6-10. Schematic of X-ray crystallography. The crystal is held in suspension in 
cryoprotectant under a stream of nitrogen gas. X-ray beams are scattered by the crystal and 
data is collected electronically. Adapted from Rhodes 2006. 
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